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Genomic studies on the impact of host/virus interaction in EBV infection using
massively parallel high throughput sequencing
by Fanny WEGNER
Epstein-Barr virus is one of the most common viral infections in humans and, once
acquired, persists within its host throughout their life. EBV therefore represents an ex-
tremely successful virus, having evolved complex strategies to evade the host’s innate
and adaptive immune response during both initial and persistent stages of infection.
While infection is mostly harmless in the majority of cases, EBV has the ability to be
oncogenic in some individuals, and is associated with a wide range of malignancies as
well as non-cancerous diseases.
To generate new and useful insights into the evolution of EBV interactions with its
host, a hybridization-based target enrichment methodology was optimised to enable
whole genome sequencing of EBV directly from clinical samples. This allowed the gen-
eration of whole genome sequences of EBV directly from blood for the first time.
This methodology was subsequently applied to a number of distinct EBV sample col-
lections and the resulting data used to investigate the intra- and inter-host variation in
various clinical settings, such as infectious mononucleosis and immunosuppression with
chronic EBV infection. Additionally, the number of available whole genomes from East
Asia is expanded by eleven (unique) novel genomes from primary infection from a NPC-
non-endemic area. These sequences were used for a comparative analysis between NPC-
and non-NPC-derived EBV genomes and a number of sites were determined differenti-
ating these two groups.
Finally, comparative genomic analyses of world-wide EBV strain diversity were per-
formed using genome sequences generated here in conjunction with a large number
of publicly available EBV genome sequences. The comprehensive data sets generated,
which included measures of diversity, selection, and linkage, were used to identify poten-
tial targets of T cell immunity. In addition, the population structure of EBV was analysed
to better understand the forces that have shaped the evolution of EBV.
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1Chapter 1
Introduction
1.1 A brief evolutionary history of Lymphocryptoviruses
Epstein-Barr virus (EBV) belongs to the family of Herpesviridae (Davison et al., 2009) and
is spread world wide in the vast majority of the human population. It further belongs to
the genus of Lymphocryptoviruses (LCV) of the sub-family of γ-herpesviruses (the other
sub-families being α- and β-herpesviruses).
The natural hosts of γ-herpesviruses are mammals. The separation into the three her-
pesvirus sub-families occurred probably 400 million years ago (MYA), which was long
before the mammalian radiation 60-80 MYA. But the divergence into the existing species
was estimated to have happened over the last 60 MY, showing the long period of coevo-
lution between herpesviruses and their mammalian hosts (McGeoch et al., 1995).
Within human and non-human primates (NHP), New World and Old World LCVs
form distinct sister clades (McGeoch, Gatherer, and Dolan, 2005). The New World LCV
phylogeny based on viral DNA polymerase sequences generally reflects the phylogeny of
their respective hosts; in Old World LCVs however, the branching pattern is not well re-
solved and even with extended sequence data sets, the phylogeny remained incomplete
due to multifurcations and low statistical support of nodes. This, however, also suggests
that these viruses evolve more slowly as sequence variability is lower and could be in-
dicative of a more complex evolutionary history than just a synchronous host and virus
coevolution (Ehlers et al., 2010; Lacoste et al., 2010).
Human and NHP LCVs share a similar biological lifestyle. They establish a lifelong
latent infection, in which the virus is maintained as an episomal DNA molecule with
only a very reduced protein expression profile. Replication of the virus and production
of virions occurs during a lytic cycle. Nuclear antigens responsible for the establishment
of latency are functionally conserved, but show a high degree of sequence divergence.
In consequence, simian nuclear antigens do not cross-react with human anti-EBV sera
(Gerber et al., 1977). Lytic genes, however, are more conserved across EBV and NHP
LCVs, and cross-reactivity of human and Old World NHP antibodies has been shown
(Cho et al., 1999).
Interestingly, comparison of genome content and organisation between a New World
LCV genome (derived from CalHV3, a common marmoset-derived cell line) and Old
World LCV genomes including EBV highlighted eleven genes that are specific to Old
World LCVs, i.e. they were most likely acquired after separation of New World and Old
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World primates (Rivailler, Cho, and Wang, 2002). These genes are not essential for trans-
formation or replication, but rather facilitate host invasion, explaining the higher preva-
lence of LCV infection in Old World primates compared to New world primates. The
highest degree of similarity within the Old World LCV group as well between EBV and
New World NHP LCV has been found in the Epstein Barr nuclear antigen 1 (EBNA1)
homologue, possibly due to its essential role in maintenance of the viral genome (Yates
et al., 1996; Blake et al., 1999; Lacoste et al., 2010).
1.2 Epstein-Barr virus
EBV was discovered in 1964 by Sir Anthony Epstein and Yvonne Barr in a Burkitt’s lym-
phoma (BL) cell line via electron micrographs, and was the first virus being associated
with the development of human tumours (Epstein, Achong, and Barr, 1964). Since its
discovery EBV has been associated with a variety of other cancerous diseases as well as
infectious mononucleosis (IM) (Henle, Henle, and Horwitz, 1974). It has been estimated
that 1.8 % of cancer related deaths are due to EBV-associated malignancies (Khan et al.,
2014).
Like all herpesviruses, it consists of a large double stranded DNA molecule, which is
enclosed by a capsid, tegument, and envelope (Davison et al., 2009). EBV is extremely
successful in infecting humans. It is the most common viral infection as more than 95 %
of the world population are persistent carriers for life (Young, Yap, and Murray, 2016).
1.3 The life cycle of EBV
1.3.1 Virus entry
EBV is transmitted via saliva into which infectious virus particles are shed from already
infected hosts. Infection occurs usually very early in life. In developing countries, the
peak of infection as measured by EBV seropositivity is usually seen in the early years of
life (3-4 years), while there are often two peaks in developed countries: one peak in early
age (below 5 years) and one during adolescence (after 10 years) (Hjalgrim, Friborg, and
Melbye, 2007).
The primary infection targets are B cells and epithelial cells, although under some cir-
cumstances EBV can also infect T cells, Natural Killer (NK) cells and others (Isobe, 2004).
The virus usually enters the body through the oropharynx and encounters B cells in the
tonsils. Whether or not replication in epithelial cells plays also a role during infection is
still not clear, but recent evidence points into this direction. However, replication in epi-
thelial cells is likely an early event and in IM patients, the only disease associated with
primary infection, EBV cannot be found in epithelial cells of the oropharynx.
Host cells are entered using a mechanism involving at least five envelope glycopro-
teins (gp). The core glycoproteins shared and conserved among all herpesviruses are
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gH/gL and gB, whereas the tropism is determined by gp350 and gp42. The primary tar-
gets of infection are B cells through interaction between viral gp350 and gp42 with host
CD21 and HLA class II on the cell surface (Nemerow et al., 1987; Spriggs et al., 1996),
which leads to fusion with the B cell membrane. Epithelial fusion, on the other hand, is
mediated through interaction of viral gH and host α-v integrins (Chesnokova and Hutt-
Fletcher, 2011) as well as viral BMRF2 protein with host β-1 integrins (Xiao et al., 2008).
Interestingly, the viral tropism seems to be dependent on virion origin. Virions pro-
duced in B cells have fewer gp42 molecules than virions produced in epithelial cells and
vice versa. This is due to HLA class II processing in B cells, which renders the interact-
ing complex more prone to degradation and HLA class II presentation (Borza and Hutt-
Fletcher, 2002). Epithelial cells, however, do not possess HLA class II on their surface
and virions produced here are therefore gp42-enriched. As a consequence, virions origi-
nating from epithelial cells are much more infectious for B cells than virions originating
from B cells (Jiang, Scott, and Hutt-Fletcher, 2006). Likewise, B cell-produced virions are
more infectious for epithelial cells than those produced in epithelial cells. This is because
the presence of gp42 in the glycoprotein complex hinders the interaction with integrins
(Hutt-Fletcher, 2016). These observations of a tropism switch have led to the hypothesis
that EBV naturally alternates replications in the two cell types.
1.3.2 EBV latency
The virus’ life cycle has two stages: latency and lytic replication.
During latency, the virus remains within host cells as a circular extrachromosomal
DNA molecule and displays a very restricted gene expression profile in order to avoid
immune detection. Latency is established in memory B cells (Babcock et al., 1998), but
there is still uncertainty about the route of how this happens. There are two, not mutually
exclusive, models of persistence: The germinal centre (GC) model and the direct infection
model.
The germinal centre model According to this model, EBV+ memory B cells are the
result of normal B cell differentiation (figure 1.1) (Thorley-Lawson and Gross, 2004; Bab-
cock, Hochberg, and Thorley-Lawson, 2000). B cell differentiation usually occurs after
naïve B cells become exposed to an antigen. They enter the germinal centre, a structure
within the lymph nodes, where they undergo the germinal centre reaction and prolif-
erate. Their immunoglobulin genes undergo class switching and somatic hypermuta-
tion (SHM). The positive selection of antigen-specific B cells is further assisted by T cells
through CD40 receptor and antigen activation of the B cell receptor (BCR). B cells exit
the germinal centre reaction differentiated to either (antibody producing) plasma cells or
memory B cells.
In the case of EBV infection, however, naïve B cells are infected with the virus in
the lymphoid tissue in the oropharynx. Instead of being antigen-exposed, the virus ex-
presses a program called latency III (or growth program), which drives the proliferation
and expansion of infected B cells (Thorley-Lawson and Gross, 2004). This program is
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FIGURE 1.1: Upper panel: Germinal centre model of virus persistence.
EBV infects naive B cells, which are driven to proliferation by the latency III
program. The lymphoblasts enter the GC, where they mature and receive
survival signals by the latency II program. EBV infected immortalised
B memory cells exit the GC and circulate in the blood of the host with-
out any viral gene expression except during cell division. EBV-infected
memory B cells can transform into plasma cells upon antigen recognition,
which also results in lytic virus replication. It might also be possible that
EBV-infected plasma cells directly exit from the GC.
Lower panel: The origin of EBV-associated lymphomas. The exact stages
are not really known and patterns of latency between progenitor and tu-
mour cell cannot be expected to correspond. Figure modified from Young,
Yap, and Murray, 2016
characterised by the expression of nine latency genes: six nuclear antigens (EBNA1, -2,
-3A, -3B, -3C, and -LP), three latent membrane proteins (LMP1, -2A, and -2B) as well as
EBV-encoded small RNA (EBER) and non-transcribed BART (BamHI-A region rightward
transcript) miRNAs.
These EBV+ cells enter the germinal centre reaction. Here, a program called latency II
(or default program) is expressed, which consists only of EBNA1, LMP1 and LMP2. The
CD40 and BCR signalling is mimicked through LMP1 and LMP2 which are functional
homologues of the respective receptors, thereby providing the necessary survival signal
in the GC (Gires et al., 1997; Caldwell et al., 1998).
The transformed EBV-infected memory B cells finally exit the GC and circulate in
the blood stream of the host. At this stage, in order to avoid immune detection, EBV
downregulates viral gene expression (latency 0), but expresses EBNA1 (latency I) during
cell division.
The direct infection model The germinal centre model is inconsistent with observa-
tions of B cells isolated from GCs of IM patients, which do not seem to undergo SHM,
which would be expected if they partook in the GC reaction. Moreover, they exhibited an
unusual expression pattern by expressing EBNA2 but not LMP1, thereby differing from
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EBV+ GC B cell-derived tumours (BL, HL, and PTLD). It has therefore been proposed
that EBV in IM directly infects GC and/or memory B cells which expand without SHM
(Kurth et al., 2003).
1.3.3 Latency proteins
EBNA1 is the only protein consistently expressed in all latency programs (in latency 0
only during cell division). It has several vital functions: initiating replication of the viral
genome, mitotic segregation and acting as a transcription factor for other latency pro-
teins. It is a homo-dimeric protein that initiates EBV genome replication by binding to
the EBV latent origin of replication (oriP). Furthermore, it assures the equal partition-
ing of viral genomes to the host daughter cells. The viral DNA EBNA1-binding site is
found in the family of repeats (FR) region of the EBV genome, where it functions as a
transcriptional transactivator and enhances the transcription of other latent genes (Gahn
and Sugden, 1995). It also binds to cellular promotors thereby regulating the expression
of host genes (Canaan et al., 2009). It is further involved in p53 degradation and oncoge-
nesis (Fries, Miller, and Raab-Traub, 1996).
EBNA-LP is essential for B cell transformation and interacts with EBNA2 and other
transcription factors to activate viral and host gene transcription. EBNA2 acts as the main
transcription factor essential for B cell transformation by upregulating both groups of
viral latent genes (EBNAs and LMPs) as well as host genes including the B cell activation
molecules CD21 and CD23, as well as MYC (Pan et al., 2009; Kaiser et al., 1999). Instead
of binding DNA directly, it interacts with other host DNA-binding proteins like RBP-Jκ
(Tzellos et al., 2014).
A coactivator of EBNA2 is EBNA3A, which also interacts with EBNA3C and inhibits
RBP-Jκ recruitment, downregulates MYC, leads to arrest of host cells G1 phase, and
blocks EBNA2 activation effects (Cooper et al., 2003). It is essential for B cell transfor-
mation. Similarly, EBNA2 is coactivated by EBNA3B. However, it has been shown not to
be essential for B cell transformation (Tomkinson, Robertson, and Kieff, 1993). Instead, it
was suggested to act as a tumour supressor (White et al., 2012). The third and most es-
sential EBNA2 coactivator is EBNA3C. Together they upregulate the chemokine CXCL12
and its receptor CXCR4 (Zhao et al., 2011), which have been shown to be essential for
lymphoblastoid cell lines (LCL) proliferation and cell survival in a mouse model (Piovan
et al., 2005). It is also involved in a wide array of regulatory functions influencing B cell
growth such as the repression of the tumour suppressor p16INK4a in cooperation with
EBNA3A (Skalska et al., 2013). Additionally, EBNA3C can block apoptosis by inhibiting
the EBV-infection-mediated DNA damage response (Saha et al., 2012).
The LMP1 gene encodes for a CD40 homolog (Gires et al., 1997). It activates NF-κB,
JNK and p38 pathways and is therefore a major oncogene (Young, Arrand, and Murray,
2007; Izumi and Kieff, 1997).
LMP2A promotes cell growth. By activating ERK/MAPK pathway constitutively, it
mimics BCR signalling (Caldwell et al., 1998; Anderson and Longnecker, 2008). Simulta-
neously, it inhibits antigen-dependent BCR signalling. It is involved in the inhibition of
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apoptosis and essential in rescuing germinal center B cells which lack a functional BCR.
Additionally, it promotes epithelial cell spreading. LMP2B, a splice variant, negatively
regulates LMP2A (Wasil et al., 2013).
1.3.4 Lytic cycle
During the lytic cycle, new EBV virions are produced and it is therefore a necessity for
host to host transmission. Infectious virus is commonly found in the saliva of immuno-
competent, asymptomatic hosts (Ling et al., 2003; Hadinoto et al., 2009), suggesting that
there are sites of lytic replication within or close to the oral cavity.
Lytic cycle is usually only entered after reactivation from latency, but could also be
initiated upon primary infection, e.g. in epithelial cells. However, due to the long incu-
bation period for IM, primary lytic replication has not been observed (Kenney, 2007). The
lytic cycle can be initiated by BCR stimulation of B cells and the consequent differentia-
tion into plasma cells (Laichalk and Thorley-Lawson, 2005).
The transcription hierarchy can be divided into immediate-early (IE), early (E) and
late (L) genes. The two IE genes encoding transactivators are BZLF1 and BRLF1 which en-
code the major transactivators ZEBRA/Zta and Rta, respectively. Both transcription fac-
tors are responsible for the switch from latent to lytic phase. They allow the subsequent
expression of E gene products, which include viral replication proteins such as the viral
Pol, a heterodimer comprised of two subunits encoded by BALF5 (catalytic) and BMRF1
(accessory). In total there are six core viral replication proteins: BALF5, BMRF1, BALF2
(binds single stranded DNA), BBLF4 (helicase), BSLF1 (primase), and BBLF2/3 (primase-
associated protein) (Fixman, Hayward, and Hayward, 1992). Other E gene products are
responsible for deoxynucleotide metabolism, whereas many L genes encode structural
proteins and glycoproteins, such as BcLF1 (major capsid protein), BLLF1 (gp350), BILF2
(glycoprotein) and others (Kenney, 2007).
In some cases, full EBV genome integration into the host genome has been reported
in cell lines (Matsuo et al., 1984). Despite evidence for expression of latency proteins (Luo
et al., 2004), reactivation does not seem to occur from these genomes. In nasopharyngeal
carcinoma (NPC) biopsies, integrated EBV genomes could also be found in some cases,
indicating it can occur in vivo as well as in vitro. Moreover, coexistence of integrated EBV
genomes and episomes has been found in B-derived cell lines (Anvret, Karlsson, and
Bjursell, 1984; Delecluse et al., 1993).
1.4 The anti-EBV immune response
The establishment of latency results in a life long infection in a peripheral pool of recircu-
lating memory B cells. Upon re-entering the tonsils, memory B cells either change their
expression program or enter lytic replication and produce new infectious viral particles,
which can infect new naïve B cells or be shed into the saliva (Thorley-Lawson, 2001).
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In asymptomatic, immunocompetent carriers, reactivation and expression of viral
proteins leads to a rapid adaptive immune response, which controls but does not elimi-
nate the infection. The main effectors of this response are T cells. More than 50 epitopes
for both HLA class I and II have been described (Hislop et al., 2007). CD4+ and CD8+
T cells differ in their EBV immune targets and there is a hierarchy in the strength of im-
mune responses these targets elicit. The strongest cytotoxic T cell responses have been
observed against epitopes derived from proteins of the EBNA3 family as well as IE and E
lytic cycle proteins (Mautner and Bornkamm, 2012). In contrast the CD4+ T cell response
has been found to be particularly strong against lytic cycle proteins, especially structural
antigens, followed by autoantigens and then latent proteins (Mautner and Bornkamm,
2012).
There is also an antibody-mediated response that is established during primary infec-
tion, which partly persists for life in form of immunologbolulin (Ig) G antibodies directed
against the viral capsid antigen and EBNA1 (see subsection 1.5.1, kinetics shown in fig-
ure 1.2) (Henle et al., 1987; Hinderer et al., 1999). These responses, in addition to IgM
against viral capsid antigen (VCA), appear at specific phases of acute primary infection
and are therefore of diagnostic value. Further targets of the humoral response are early
antigen diffuse (EA-D) and gp350 (Panikkar et al., 2015).
Additionally, the innate immune system acts against viral infections by recognition
of viral particles and nucleic acids through Toll-like receptors (TLRs) which activate an in-
terferon (IFN) response. For example, EBERs, which are released from EBV-infected cells
and are present in sera of patients with a variety of EBV-related pathologies (including
IM, chronic active EBV infection, and EBV-associated hemophagocytic lymphohistocy-
tosis), induce TLR3 signaling (Iwakiri et al., 2009). Other TLRs which have been shown
to activate an innate immune response against EBV are TLR9 and -7 (Quan et al., 2010),
TLR2 (Ariza et al., 2009) and TLR8 (Farina et al., 2017).
Conversely, EBV has evolved mechanism to evade both adaptive and innate immune
responses. For example, BPLF1, the large tegument protein, assists in innate immune
evasion by interfering with TLR signaling (van Gent et al., 2014); the late gene BCRF1
encodes a interleuking (IL)-10 homologue with 84 % sequence identity to human IL-10
on the amino acid level. IL-10 is a immunomodulatory cytokine that acts as a suppressor
of T cell proliferation and cytokine production and inhibits interferon (IFN)-γ production
(Mosser and Zhang, 2008); interestingly, it has even been suggested that anti-gp350 anti-
bodies enhance infection of epithelial cells, thereby providing an alternative reservoir for
EBV during a T cell response against EBV-infected B cells (Turk et al., 2006).
1.5 EBV-associated diseases
EBV is for the most part non-pathogenic and has evolved complex strategies to establish
a life-long infection but to remain undetected. However, due to the nature of the trans-
formations it induces in B cells, it is associated with a variety of diseases, most of them
cancerous.
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1.5.1 Infectious mononucleosis
Infectious mononucleosis (IM) is the only disease caused by EBV associated with primary
infection. It was first described in 1920 (Sprunt and Evans, 1920) and is characterised
by pharyngitis, cervical lymph node enlargement, fatigue, and fever. It further shows
atypical large cells in the blood that have been later identified as CD8+ T cells, which are
responding to EBV-infected B cells (Callan et al., 1998).
Children become EBV+ at a younger age in developing countries than in developed
countries, where IM is most often observed in adolescents and young adults and where
it is thought to be acquired due to kissing (hence IM’s nick name ’kissing disease’) (Bal-
four, Dunmire, and Hogquist, 2015). One reason why IM is less frequently diagnosed
in younger children is that intimate kissing probably transmits large amount of infec-
tious virus, whereas younger children most likely become infected through parents and
siblings who transmit smaller amounts of oral secretions and therefore virus. However,
IM in children younger than 12 years has been observed and is not uncommon (Hor-
witz et al., 1981), but heterophile antibody tests are often unreliable in this patient group
(Balfour, Dunmire, and Hogquist, 2015). It has also been proposed that IM arises due
to cross-reactive influenza-specific CD8+ T cell responses, which are more likely to have
been acquired in high numbers at later age (Clute et al., 2005), but this hypothesis is still
contentious.
EBV can also be transmitted via blood, which suggests that the virus found in (mem-
ory) B cells is or can become infectious (Alfieri et al., 1996). Additionally, transmission via
transplantation of stem cells or solid organs can lead to life-threatening complications, in
particular in EBV- recipients (see Post-transplant lymphoproliferative disorders).
The incubation period of IM is approximately six weeks (Hoagland, 1955). Due to
the long incubation period and the subtle onset of disease, little is known about the early
virus-host interactions of primary infection. There are three phases of infection: acute
infection (0-3 weeks after onset), sub-acute phase (4 weeks-3 months) and convalescence
(4-6 months). During these stages, a discrete set of antibodies is being produced. IgM
antibodies targeting the VCA are first produced by around 75 % of patients (Hinderer et
al., 1999; Balfour et al., 2013) and can be detected during acute and sub-acute phase but
not during convalescence. IgG antibodies against VCA (produced as early as two weeks
after onset) (Hinderer et al., 1999) and IgG against EBNA1 (only during convalescence)
are produced by nearly all patients and persist for life (figure 1.2) (Henle et al., 1987). The
late onset of an antibody response against EBNA1 correlates with a delayed CD4 T cell
response against EBNA1 (Long et al., 2013).
EBV viral loads in blood and oral compartments increase sharply during acute in-
fection and subsequently decrease over time, though specific kinetics can vary between
patients. However, the virus is cleared faster from blood than from the oral compartment
and oral shedding of infectious virus can continue for several months (and recur upon
reactivation).
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FIGURE 1.2: EBV kinetics of antibody titres and viral loads during IM.
The background colour relates to the phases of IM infection (yellow: acute
phase and sub-acute phase, white: convalescence). IgM antibodies target-
ing VCA are produced by the majority of patients during acute and sub-
acute phase but not during convalescence. Shortly after onset of disease,
IgG against VCA are produced by virtually all patients and remain high
for the rest of the life. EBNA1 IgG antibodies are being produced during
convalescence and also persist for life. Viral load increases sharply in all
compartments and is generally higher in oral compartments where it also
decreases at a slower rate during convalescence compared to blood. Graph
modified from Odumade, Hogquist, and Balfour, 2011.
1.5.2 Burkitt’s lymphoma
Burkitt’s lymphoma (BL) was first described by Denis Burkitt in 1958 occuring in children
in equatorial Africa (Burkitt, 1958) and was the source from which EBV was first isolated
(Epstein, Achong, and Barr, 1964). It is a rapidly proliferating tumour usually of B cell
origin. There are three forms of BL: the endemic, high incidence form (also called the
’African’ variant and the most common childhood malignancy in equatorial Africa), the
sporadic form (occurring throughout the world) and the HIV-associated form (Vockerodt
et al., 2015). Common to all forms is the overexpression of MYC, a transcription factor
involved in regulation of many growth and proliferation-related genes (Uniprot Database
accessed last April 2017). The overexpression occurs due to a reciprocal translocation of
the MYC oncogene and one of the Ig light or heavy chain loci, which brings MYC under
the transcriptional control of an Ig locus (Klein, 1983) and drives the proliferation of the
lymphoblasts at a high rate. This translocation is generally seen as the essential step in
BL formation while EBV plays a supportive role by providing rescue signals for aberrant
BL cells.
The EBV association varies between BL types. Endemic BL is almost always EBV+,
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whereas incidence rates in sporadic (≈ 10-15 %) and HIV-associated forms (≈ 40 %) are
lower (Vockerodt et al., 2015). Moreover, sporadic and endemic forms differ in break-
point location within the Ig locus (VDJ/VJ regions in endemic BL, switch region in spo-
radic BL). One the one hand, this suggests that BL cells in endemic and sporadic cases
may have acquired their MYC translocation during different phases of B cell differentia-
tion (pre-GC and GC, respectively). On the other hand, VDJ/VJ breakpoints could occur
in the GC as a result of abnormal activation-induced deaminase (AID) activity, which
is responsible for inducing SHM in immunoglobulins (Goossens, Klein, and Küppers,
1998). AID and SHM have been shown to be induced by LMP1 expression (Epeldegui
et al., 2007), and in fact, SHM occurs more frequently in endemic and HIV-associated
BL than in sporadic BL (Bellan et al., 2005). However, AID is in turn also inhibited by
EBNA2 (Tobollik et al., 2006). Moreover, BL usually display a latency I profile in which
only EBNA1 is expressed. In consequence, the role of SHM induction through EBV in
vivo is not completely clear.
However, EBV provides another key component for MYC-driven oncogenesis. Be-
sides inducing cell proliferation, MYC overexpression also induces apoptosis (Milner
et al., 1993), but a number of EBV proteins have anti-apoptotic functions, among them
EBNA1 which is critical for EBV+ BL (Kennedy, Komano, and Sugden, 2003).
Another factor playing into the development of endemic BL are coinfections. The
high-incidence area of endemic BL overlaps with areas of holoendemic Plasmodium falci-
parum infection, which causes malaria. Two mechanisms could explain this observation:
First, malaria can lead to loss of EBV specific T cell immunity due to functional exhaus-
tion of T cells (Wykes et al., 2014). Second, malaria antigens themselves activate the
immune system and thereby drive polyclonal B cell expansions as well as lytic EBV re-
activation which increases the pool of EBV+ B cells. In turn, this increases the chance of
acquiring a MYC translocation (Chêne et al., 2007).
1.5.3 Hodgkin’s lymphoma
This malignancy was first described by Thomas Hodgkin in 1832 and its cause is still un-
known, even though the involvement of an infectious agent had been discussed early on.
The malignant cell type characteristic of Hodgkin’s lymphoma (HL) is Hodgkin/Reed-
Sternberg (HRS) cells. The vast majority of them are derived from GC B cells, i.e. they
have undergone SHM but do not possess a functional BCR due to crippling mutations in
the Ig genes (Küppers et al., 1994). These tumour cells are also extremely rare, making up
only 1 % of the tumour mass, as they are surrounded by a massive inflammatory infiltrate
made up of T cells, histiocytes, eosinophilic granulocytes and plasma cells (Bräuninger
et al., 2006).
EBV is the most likely candidate of infectious agents to be responsible for the transfor-
mative events leading to tumourigenesis. In almost 40 % of cases of classical Hodgkin’s
lymphoma (cHL), HRS cells are EBV+ and express the latency II program. The virus
might provide anti-apoptotic signals for these cells, which under normal conditions would
have been selected against in the GC. EBV has been shown to be able to rescue GC B cells
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with "crippled" BCRs as well as B cells not expressing any BCR in vitro through BCR-like
signaling via LMP2A (Bechtel et al., 2005; Chaganti et al., 2005; Mancao et al., 2005).
Moreover, all cHL cases with crippling mutations that prevent BCR expression were
found to be EBV+ (Bräuninger et al., 2006). Additionally, a number of pathways in HRS
cells are aberrantly activated, such as NF-κB, JAK/STAT and PI3K/AKT, all of which can
be activated through LMP1.
The involvement of EBV in the development of cHL is further supported by the find-
ing that there is an increased risk of developing EBV+ HL (but not EBV-) after infectious
mononucleosis (IM), in particular in young adults (Hjalgrim et al., 2003).
1.5.4 Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is one of the few carcinomas – malignancies of epi-
thelial origin – associated with EBV. Globally it is a rather rare tumour, but prevalence
rates vary geographically. Areas with particularly high prevalence include North Africa,
Southern China, South East Asia, as well as the Inuit people in Alaska (Wei and Sham,
2005). Here, the incidence rate is 20-30 times higher in men and 8-15 times higher in
women than in Europe and the rest of America (WHO, 2014). Interestingly, the incidence
rate of NPC in Chinese people who have immigrated to North America remains high,
but is lower in Chinese people born in North America (Wei and Sham, 2005; Dickson and
Flores, 1985), even though it is still elevated compared to local Caucasians (Buell, 1974;
Bei et al., 2016). It has been proposed that carcinogenesis is dependent on several factors:
host genetics (as highlighted by the distribution among populations), EBV infection and
genetics, and environmental factors such as smoking and the consumption of salted fish
and preserved/cured meat (Chen et al., 1990; Jia et al., 2010).
NPC is classified into two categories based on the tumour’s microscopic appear-
ance: keratinising squamous cell carcinoma (type I) and non-keratinising squamous cell
carcinoma (types II and III, which are differentiated and undifferentiated, respectively)
(Young and Dawson, 2014). Type I is relatively rare in Southern China, whereas types II
and III are the NPC forms in which EBV is consistently found and which are of particular
interest in endemic NPC regions (Wei et al., 2011).
The typical latency program expressed in NPC tumours is latency II (i.e. LMP2A/B,
LMP1, EBNA1, EBER1 and -2, as well as BART miRNAs). LMP1 expression is variable
in NPC, with approximately 20-40 % of tumours expressing it at the protein level (Young
and Dawson, 2014). It acts as a major oncogene and has been shown to induce hyper-
proliferation, drive the production of proinflammatory cytokines, enhance cell motil-
ity, and provide anti-apoptotic function in epithelial cells (Dawson, Port, and Young,
2012). The expression pattern of LMP2B is similar. In contrast to that, LMP2A is con-
sistently detected. LMP2A has been shown to be essential for epithelial cell outgrowth
in vitro (Scholle, Bendt, and Raab-Traub, 2000) and enhance motility and cell adhesion
(Allen, Young, and Dawson, 2005; Lu et al., 2006). Moreover, it can induce epithelial-to-
mesenchymal transition (EMT), a process connected with the acquisition of stem cell-like
properties (Kong et al., 2010).
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EBV infection is thought to play a supportive role in NPC pathogenesis and not to be
the initiating event, as healthy individuals at high risk of NPC as well as IM patients lack
evidence of EBV+ epithelial cells in the oropharynx (Young and Dawson, 2014). Other
important factors are genetic and epigenetic changes found in NPC which possibly pre-
cede and are required for infection. According to current model of NPC tumourigenesis,
environmental factors lead to the loss of heterozygosity on chromosomes 3p and 9p. As
a consequence, low-grade, preinvasive lesions form, which are susceptible to stable EBV
infection, in particular after additional genetic changes (such as overexpression cyclin D1
and the creation of a undifferentiated cellular environment) (Young and Dawson, 2014).
However, EBV infection likely ocurs before clonal expansion of tumour cells, as it has
been found to be monoclonal in NPC tumours (Raab-Traub and Flynn, 1986).
1.5.5 Post-transplant lymphoproliferative disorders
EBV infection is controlled mainly through T cell immunity, but NK cells and antibody
responses also play a role. Immunosuppression is the standard treatment for recipients
of solid organ and haemopoeitic stem cells. As a consequence, T cell responses are weak-
ened which leads to loss of control over EBV replication. In serious cases, this can result
in post-transplant lymphoproliferative disorder (PTLD), a term for a heterogeneous col-
lection of diseases ranging from B cell proliferations to lymphoma (Gulley and Tang,
2010).
According to the WHO, there are four histopathologic subtypes of EBV: early lesions,
polymorphic PTLD, monomorphic PTLD, and cHL-type PTLD. Early lesions, compared
to the other types, are usually polyclonal, but if untreated, a single clone can potentially
outgrow to one of the other subtypes (Swerdlow et al., 2008). Polymorphic PTLD consists
of lymphocytes and lymphoblasts of varying size, containing B cells as well as CD4+
and CD8+ T cells, while monomorphic PTLD resembles conventional lymphoma, such as
DLBCL and immunoblastic lymphoma, and is usually of B cell origin (Gulley and Tang,
2010) and only rarely of T or NK cell origin (Swerdlow, 2007). Classical HL-type PTLD is
a rarer type of PTLD (Pitman et al., 2006).
PTLD usually develops during the first year after transplantation: For haematopoeitic
stem cell transplants (HSCT), the median onset is two months, for solid organ trans-
plants (SOT) it is six months (Gulley and Tang, 2010). Nearly all PTLD tumours are EBV+
(60-80 % of cases). While EBV infection is extremely prevalent in the patient popula-
tion, only a fraction of transplant recipients will develop PTLD. Risk factors are age,
EBV seronegativity at the time of transplantation, coinfection with other viruses such
as cytomegalovirus (CMV), active EBV disease during transplantation, the intensity of
immunosuppression, HLA type and HLA mismatch as well as having a combination of
several risk factors (Gulley and Tang, 2010). PTLD occurs more frequently in children,
most likely due to the higher rate of primary infections. Additionally, the organ type of
the transplant influences the incidence of PTLD (table 1.1).
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PTLD tumours usually express the latency III program (i.e. all latency proteins in-
cluding EBERs and BART miRNAs). Acquired mutations on the host side, however, are
not well characterised.
Organ Incidence (%)
in children
Kidney 1-10
Marrow and stem cell 13
Liver 4-15
Heart or lung 6-20
Intestinal 12
TABLE 1.1: Incidence of PTLD by organ type in children (Gulley and Tang,
2010).
To avoid lymphoma formation, reduction of immunosuppression is the first treat-
ment option, so that the host can generate their own adaptive immune responses against
EBV and retrieve control over B cell proliferation. This is especially true for early lesions,
while it is often but not always sufficient for mono- and polymorphic PTLD. Other treat-
ment options include Rituximab, an anti-CD20 antibody, antivirals such as acyclovir and
ganciclovir, and adoptive immunotherapy with EBV specific cytotoxic T cells (Green and
Michaels, 2013). Levels of EBV in the blood or plasma is the primary marker for deciding
upon treatment for PTLD, but this is not necessarily predictive, as some patients with
high viral loads do not develop PTLD (Gulley and Tang, 2010; Kerkar et al., 2010).
1.5.6 Other associated malignancies
Gastric carcinoma is the third leading cause of death related to cancer (Ferlay et al., 2015).
Around 10 % of gastric carcinoma tumour are EBV+ and are phenotypically as well as
clincally very distinct from EBV- gastric carcinoma. Characteristics include highly methy-
lated CpG islands, wild-type p53 expression, loss of p16 tumour surpressor protein, and
a distinct pattern of allelic loss (Lee et al., 2004; Schneider et al., 2000; van Rees et al.,
2002). Additionally, EBV-associated gastric carcinoma (EBVaGC) displays differences in
prevalence between sex, age and ethnicity: it is more common in Caucasian and His-
panics than in Asians, more common in young than in the elderly, and more common in
men than women (Lee et al., 2009). Similar to the other epithelial EBV-associated cancer,
NPC, EBVaGC tumours express EBNA1, LMP2A, but also BARF1 protein, the EBERs,
and BART miRNAs (zur Hausen et al., 2000; Imai et al., 1994). EBV is absent in premalig-
nant lesions, suggesting again that EBV infection is a late event in gastric carcinogenesis
(zur Hausen et al., 2004).
All malignancies described so far are associated with latent infection. The only dis-
ease caused by lytic EBV infection is oral hairy leukoplakia, an AIDS-associated epithe-
lial hyperplasia on the lateral tongue (Hutt-Fletcher, 2016; Greenspan et al., 1985). It can
be treated with antiviral drugs which inhibit lytic replication such as acyclovir.
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Multiple sclerosis (MS) is a EBV-associated, but non-cancerous disease. It is a chronic
demyelinating disease of the central nervous system (CNS), which causes severe progres-
sive disability especially in younger people. It affects more than 2.5 million people world-
wide and is more common in females than males (Pender and Burrows, 2014). While usu-
ally seen as an autoimmune disease, more and more evidence suggests that EBV plays an
important role in pathogenesis. A meta-analysis showed that 100 % of MS patients are
EBV+ with two independent methods of EBV detection (Pakpoor et al., 2013). Second,
a history of IM increases the risk of MS (Thacker, Mirzaei, and Ascherio, 2006). Most
studies suggest now that EBV infection is a prerequisite of developing MS, but not suffi-
cient on its own as only a small subset of EBV+ carriers develop the disease (Pender and
Burrows, 2014). There are four mechanistic hypotheses about the possible contribution
of EBV to MS:
1. The cross-reactivity hypothesis suggests that EBV-specific T cells cross-react with CNS
antigens (Wucherpfennig and Strominger, 1995). However, a substantial body of evi-
dence disproved cross-reactivity to be the main cause of MS development, even if it might
contribute to disease progression (Pender and Burrows, 2014).
2. The bystander-damage hypothesis proposes that the damage caused by the immune
system in the CNS is primarily a bystander-effect of the immune response against EBV
antigens and not due to an autoimmune reaction (Serafini et al., 2007).
3. The αB-crystallin or ’mistaken self’ hypothesis builds on the observation that infec-
tious agents such as EBV can cause the expression of αB-crystallin, a small heat-shock
protein and known immunodominant antigen in MS patients, in lymphocytes. The im-
mune system mistakes this protein as a microbial antigen and mounts a CD4-mediated
immune response. However, αB-crystallin is also produced naturally by oligodendro-
cytes in the CNS, and the wrongly directed immune response results in their demyelina-
tion (van Noort et al., 2000).
4. The EBV-infected autoreactive B cell hypothesis proposes that autoimmune diseases
including MS are caused by EBV infection of already autoreactive B cells. They accumu-
late in their respective target organ due to a genetically determined defect in the CD8
response against EBV+ B cells, where they produce autoantibodies and provide costimu-
latory survival signals for autoreactive T cells (Pender, 2003).
1.6 Prevention and treatment of EBV infection
1.6.1 EBV Vaccine development
Vaccines have been successfully developed against a number of herpesviruses. There
is a Varicella Zoster virus (VZV) vaccine, first developed in the 1970s in Japan, which
prevents the development of chickenpox and reduces the rate of zoster – the two main
diseases caused by this virus in humans – but does not prevent infection (Takahashi et
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al., 1974). Additionally, there are vaccines for two non-human herpesviruses: gallid her-
pesvirus 2, which causes Marek’s disease in chickens (Churchill, Chubb, and Baxendale,
1969; Witter et al., 1970), and herpesvirus saimiri, a γ-herpesvirus infecting monkeys
closely related to human Karposi’s sarcoma-associated virus (KSHV) (Ablashi and Eas-
ton, 1976).
For EBV, however, vaccine development has been rather slow. Most efforts target
gp350, the most abundant surface protein on virions and EBV-infected cells (Johannsen
et al., 2004), responsible for the endocytosis of virions during cell entry. However, to
date, only one phase II clinical trial has been reported (Sokal et al., 2007). It was based on
soluble gp350 and reduced the rate of IM by 78 %, but did not prevent infection.
Alternatively, peptides of EBV proteins could be used to induce T cell immunity.
For example, Elliott et al., 2008 administered EBNA3A peptides to seronegative HLA-
controlled subjects. While T cell responses were developed by eight of nine subjects, and
no adverse events were reported, infection could not be prevented.
Yet another strategy uses virus-like particles, where latency proteins and transacti-
vators like BZLF1 are either inactivated or deleted, and which lacked the TR packaging
element normally required for virion DNA packaging (Ruiss et al., 2011). In mice, both
neutralising antibodies as well as cellular immune responses could be shown, but manu-
facturing is arguably difficult especially for usage in humans (Cohen, 2015).
1.6.2 Therapeutic EBV-specific T cell infusions
Administration of EBV-specific CD8+ T cells is an alternative therapeutic option, which
has been demonstrated to show activity in different EBV-associated malignancies. The
administered cytotoxic T cells (CTLs) need to be HLA-matched to the recipients in order
to be effective and avoid rejection. Both, autologous CTLs and HLA-matched EBV-CTLs
from EBV-seropositive donors can be used (Nijland et al., 2016). This approach is investi-
gated and results have been promosing in the setting of for example post-transplant care
of HSCT as well as SOT (Doubrovina et al., 2012; Icheva et al., 2013; Comoli et al., 2002;
Haque et al., 2007), HL and non-HL (Roskrow et al., 1998; Bollard et al., 2014), and NPC
(Straathof et al., 2005; Smith and Khanna, 2012).
1.6.3 CRISPR/Cas9 system as a therapeutic strategy
The CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR–
associated) system has evolved in bacteria and archaea as a defense mechanism against
viruses. It enables the cells to degrade foreign nucleic acids of viruses and mobile genetic
elements. Recently, this system has been developed into a genetic engineering tool (Ran
et al., 2013). It consists of two components: Cas9, a bacterial endonuclease, and guide
RNA (gRNA) which contain guide sequence. By co-expressing Cas9 and gRNAs of in-
terest, it is possible to recruit Cas9 to almost any site of interest in the genome where it
cleaves the double stranded DNA. DNA double strand breaks are repaired by the non-
homologous end joining pathway, an error-prone DNA repair mechanism of mammalian
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cells. Insertions and deletions can therefore easily lead to a frameshift or premature stop
codons, which disrupt the ORF.
Wang and Quake, 2014 first applied the CRISPR/Cas9 system in Raji cells as a model
for BL. They were able to demonstrate the clearance of EBV in a subpopulation of cells.
They used seven guide RNAs, thereby effectively targeting three different categories of
sequences, i.e. repeats as genome structure targets (IR1, IR2, IR4), proteins involved in
transformation (LMP1, EBNA3C) and in maintenance of latency (EBNA1). Upon genome
destruction, they further noted proliferation arrest and apoptosis of EBV+ cells, but not
cytotoxicity. Yuen et al., 2015 performed targeted editing of the EBV genome in different
EBV-infected human cell lines using two gRNAs to create a virus not expressing BART
miRNA by excising a fragment of the BART promoter. The authors then expanded this
study to other EBV targets (EBNA1, IR1, oriP) in the NPC cell line C666-1 and could show
a decrease in EBV load, a progressive but incomplete EBV supression and that cells were
sensitised to chemotherapy (Yuen et al., 2017). A third team showed complete inhibition
of viral replication and in some cases elimination of the genome from infected cells in
three different herpesviruses (HSV-1, CMV, EBV) (van Diemen et al., 2016).
These studies have shown the applicability of this new technology of genome editing
to EBV. However, for therapeutic purposes, approaches for delivery need to be devel-
oped. Adenovirus as used in gene therapy has been suggested as a promising method.
Furthermore, engineering delivery viruses that mimic the cell-tropism of the target virus
could be an option (Wang and Quake, 2014).
1.7 EBV genome
1.7.1 Genome structure
The genome of EBV is a circular, double-standed DNA molecule of around 172 kb length
(figure 1.3). The GC content varies accross the genome, but is on average 57%. Compared
to Herpes simplex virus 1 (HSV-1), the GC content is lower. This is thought to be a
result of EBV establishing latency in a dividing cell population compared to non-dividing
neurons in the case of HSV-1. As EBV has to replicate when the host cell divides, 5-
methylcytosine residues are spontaneously deaminated to thymidine and fixed during
replication (Honess et al., 1989).
Repeat regions
The genome of EBV (and other herpesviruses) contains several repeat regions. In terms
of herpesvirus biology, the genome can be classified structurally as a class C genome: It
has a terminal repeat region of 500 bp segments. Additionally, there are four internal
direct repeats and a number of smaller repeats (for example the family of repeats (FR)
and direct repeats (DR)). The internal repeat 1 (IR1) divides the genome into two unique
regions (unique short, US and unique long, UL), while the other three (IR2, IR3 and IR4)
lie within the UL region. In contrast to other Gammaherpesvirinae such as cottontail
Chapter 1. Introduction 17
Cp
Wp
Qp
OriLyt
OriLyt
OriP
FR
IR1
IR
2
D
R
IR3
IR
4
TR
FIGURE 1.3: Circular map of the genome. Blue: Open reading frames
(outer track: forward, inner track: reverse); Grey: Repeat regions; Red:
promoters; Green: origins of replication; Pink: non-coding RNAs.
rabbit herpesvirus, segment inversion cannot occur as the internal and terminal repeats
are unrelated (Davison, 2007; Lacoste et al., 2010). The copy number of internal and
terminal repeats can vary between isolates, as a result genome length is variable.
The role of most of the repeats is probably related to replication (Davison, 2007). The
terminal repeats are part of the mechanism to circularise the EBV genome after infec-
tion of the host cell and are essential for the DNA packaging during virion production
(Zimmermann and Hammerschmidt, 1995).
IR1 has a particular functional role, as it contains the viral Wp promoter which is
used to transcribe the EBNA genes. It is made up of five to ten copies of a 3072 bp long W
segment (repeat unit). Additionally, every repeat unit contains two exons of EBNA-LP. It
is therefore important in EBV’s transforming abilities as its length determines the number
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of available Wp promoters as well as the size of the transforming latency protein EBNA-
LP. Most indviduals carry virus with five to eight repeat units and it has been shown that
at least five copies are required for optimal B cell transformation, while fewer copies lead
to a progressively decreasing ability to transform (Tierney et al., 2011).
Smaller repeats may also play in role in regulation of translation, for example via
self-inhibition of synthesis. Such a repeat, IR3, consisting of Gly-Ala residues (GAr) of
variable length lies between two Gly-Arg rich regions at the N-terminus of EBNA1. It
has been shown to alter MHC-I presentation of EBNA1-derived peptides to CD8+ T cells
by suppressing mRNA translation in cis (Yin, Manoury, and Fåhraeus, 2003). This mech-
anism is likely due to the purine-rich mRNA sequence, rather than the encoded GAr
polypeptide (Tellam et al., 2012).
The origin of replication used during latency, OriP, contains the family of repeats (FR)
region and the dyad symmetry (DS) element, which are binding sites for EBNA1 (Yates,
Camiolo, and Bashaw, 2000). FR is the plasmid maintenance element and is tethered
via bound EBNA1 to condensed mitotic chromosomes, thereby ensuring the segregation
of plasmids to both daughter cells (Hung, Kang, and Kieff, 2001). DS is the origin of
replication and is the site at which EBNA1-dependent bidirectional DNA synthesis starts
(Hammerschmidt and Sugden, 2013).
Open reading frames and promoters
Spliced genes are rather uncommon in EBV, and apart from a few exceptions (the EBNA
genes are spliced from one 5’-leader), every gene has its own promoter. Moreover, ORFs
are not particularly clustered according to function or expression kinetics (Davison, 2007).
Latent proteins are expressed under the control of three promoters: Wp, Qp, and Cp
(see figure 1.3). Wp and Cp are located in the BamHI W fragment, with Wp being the
first promoter to be activated during in vitro immortalisation. Very early during infec-
tion, a switch from Wp to Cp occurs due to transactivation from EBNA1 and -2 on Cp
(Woisetschlaeger et al., 1990). Another promoter, Qp, located in the BamHI Q fragment,
drives EBNA1 expression and has been shown to be constitutively active in various EBV+
cell lines and tumours (Tao et al., 1998). It was found to be consistently hypomethylated,
resulting in the expression of EBNA1 no matter the cell type, type of latency, or the activ-
ity of other promoters (Tao et al., 1998).
Non-coding RNAs
EBV-encoded small RNAs The most abundant non-coding (nc)RNAs in EBV are the
EBV-encoded small RNAs (EBERs) (Rymo, 1979). They are therefore an excellent target
to identify EBV-infected cells in tissue using in situ hybridisation (Ambinder and Mann,
1994). There are two transcripts, EBER1 and EBER2, which are 167 bp and 172 bp long,
respectively, and which are divided by a 161 bp spacer region. Even though they only
share 54 % sequence similarity, both EBERs form stable stem-loop structures very sim-
ilar to each other (Rosa et al., 1981). EBER expression seems to be restricted to latently
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infected cells, whereas tissue associated with lytic replication of EBV, such as oral hairy
leukoplakia, is EBER-free (Gilligan et al., 1990).
EBERs are not necessary for B cell transformation (Swaminathan, Tomkinson, and
Kieff, 1991), but contribute to it (Yajima, Kanda, and Takada, 2005). They are thought to
play a role in cancerogenesis, as they are necessary to maintain the malignant phenotype
of BL cells (Komano et al., 1999) and provide apoptotic resistance in BL (Nanbo et al.,
2002) as well as epithelial cells (Nanbo, Yoshiyama, and Takada, 2005). They induce a
number of cytokines that act as autocrine gowth factors, including IL-10 in BL cells, IGF-
1 in NPC and EBVaGC cells, and IL-9 in T cells (Iwakiri and Takada, 2010). Additionally,
they have been shown to interact with and activate the innate immune system (Iwakiri
et al., 2009).
BamHI A rightward transcripts The BamHI A rightward region also encodes a number
of transcripts (BARTs). The BART region contains seven exons named I to VII, including
some alternative variants, which are alternatively spliced. There are at least six BART
splicing forms – BARF0, RK-BARF0, RPMS1, RPMS1A A73, and RB3 – each of them con-
taining a putative ORF. Expression of native proteins, however, have rarely been shown
conclusively in vivo (Yamamoto and Iwatsuki, 2012). Their specific function remains un-
known.
BamHI A rightward transcript miRNAs The intronic regions of the BARTs encode clus-
ters of microRNAs (BART-miRNAs), small non-coding RNAs ranging in size from 20 to
25 bp. There are two BART-miRNA clusters, comprising of 44 verfied mature miRNAs
derived from 22 precursors (Young, Yap, and Murray, 2016). Viruses lacking this locus
are only moderately impaired in their transforming ability (Vereide et al., 2014; Kanda
et al., 2015). In fact, it is to a large extent deleted in the strain B95-8. However, BART-
miRNAs have been suggested to play a role in oncogenesis, as some of them provide an
anti-apoptotic effect (Kang and Kieff, 2015; Vereide et al., 2014) and have been shown to
promote tumour growth in vivo (Qiu et al., 2015). They further maintain latency by tar-
geting lytic genes (Pfeffer et al., 2004; Barth et al., 2008) and modulate LMP1 expression
for immune evasion (Lo et al., 2007). Interestingly, miRNA might not only target the EBV-
infected cell in which they are produced. The release of exosomes containing miRNAs as
well as LMP1 has been observed in NPC cells (Meckes et al., 2010; Gourzones et al., 2010),
and the miRNAs were able to affect neighbouring cells. As the exosomes were found in
the serum samples, they can likely even reach more distant cells (Gourzones et al., 2010).
BamHI H rightward transcript miRNAs The BamHI H rightward fragment is the sec-
ond region in the EBV genome encoding a cluster of three miRNAs (BHRF1-miRNAs)
(Pfeffer et al., 2004), which are highly expressed in latency III expressing LCLs (Cai et al.,
2006; Cosmopoulos et al., 2009). Viruses lacking the BHRF1-miRNA locus are 20 times
less efficient in B cell transformation than wild-type (Feederle et al., 2011a) showing that
it contributes largely to the transforming capacity of EBV (Feederle et al., 2011a; Feederle
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et al., 2011b; Vereide et al., 2014). However, in tumour samples of NPC, GC and DLBCL
patients, BHRF1-miRNAs are largely absent (Chen et al., 2010b; Marquitz et al., 2013;
Imig et al., 2011). In contrast to that, AIDS-related DLBCL and BL showed high BHRF1-
miRNA expression (Xia et al., 2008). They also contribute to immune evasion, e.g. by
targeting CXCL11, a T cell attracting chemokine (Xia et al., 2008).
1.7.2 Genetic diversity in EBV
There is a great interest in identifying variants that are associated with specific diseases,
especially since incidence rates of associated tumours vary across the world.
Types of EBV
Based on the sequence variation found in the EBNA2 and EBNA3A-C genes, there two
types defined (Sample et al., 1990). On the amino acid level, the two types differ at around
53 % of positions in EBNA2 and 16-28 % in EBNA3A, -B, and -C (Sample et al., 1990).
Type 1 and 2 are equally prevalent in Africa, but in the rest of the world, type 1 is
the predominant strain (Zimber et al., 1986; Young et al., 1987). Type 2 is less effective
in infecting B cells, and type 1-infected LCLs show a superior growth (Rickinson, Young,
and Rowe, 1987). A single amino acid substitution in EBNA2 has been found to be re-
sponsible for this difference (Tzellos et al., 2014).
In a number of patient cohorts, in particular HIV-positive and other immunosup-
pressed patients, type 1 and 2 superinfections have been demonstrated (Sculley et al.,
1990; Srivastava et al., 2000; Santón et al., 2011). This allows the possibility of recombi-
nation occuring between types, and indeed, naturally occurring intertypic recombinants
have been described (Midgley et al., 2000; Yao et al., 1996; Kim, Kang, and Lee, 2006;
Palser et al., 2015).
Gene polymorphisms
LMP1 LMP1 is an oncogene which funtionally mimics a constitutively active form of
CD40 and is responsible for phenotypic changes in both B cells and epithelial cells. The
protein is encoded within three exons. It consists of an N-terminal domain of 24 aa, six
transmembrane domains each 20 aa long, and a C-terminal domain from position 185 to
386, which contains two C-terminal activation regions (CTAR1 and -2) (Uniprot Database).
Given the functional importance of the C-terminus, many studies looking at LMP1
diversity have focused on this region. Comparisons of polymorphisms in the C-terminus
has led to the classification of eight LMP1 variants: the reference strain B95-8, China 1,
China 2, China 3, North Carolina (NC), Mediterranean+, Mediterranean-, and Alaskan
(Ai et al., 2012; Edwards, Seillier-Moiseiwitsch, and Raab-Traub, 1999; Mainou and Raab-
Traub, 2006).
A commonly reported variation observed in LMP1 is a 30 bp deletion in the C-terminus
(del-LMP1), which results in the loss of amino acids 343-352 (Miller et al., 1994). This vari-
ation can be found worldwide (Correa et al., 2004; da Costa, Marques-Silva, and Moreli,
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2015; Lorenzetti et al., 2012) and it has been shown to occur in various EBV-associated
malignancies, such as NPC (da Costa, Marques-Silva, and Moreli, 2015; Banko et al.,
2016), HL (Ai et al., 2012; Guiretti et al., 2007; Zhou et al., 2001; Lorenzetti et al., 2012),
EBVaGC (Chen et al., 2010a; Chen et al., 2011; BenAyed-Guerfali et al., 2011), as well as
IM (Ai et al., 2012; Lorenzetti et al., 2012; Berger et al., 1997). The variant is therefore
thought to increase oncogenicity (Ai et al., 2012; Tao et al., 1998; Zhang et al., 2002).
The ten deleted amino acids affect the transformation effector site 2 (TES2) as well
as the CTAR2 region which plays a role in NF-κB activation. The transformation po-
tential seems to be enhanced in del-LMP1 carrying viruses compared to restored wild
type (WT)-LMP1 (Li, Chang, and Liu, 1996). However, not all studies could confirm a
functional difference for this variant (Fielding et al., 2001; Yeh et al., 1997) and the issue
remains controversial.
Another frequent variant is the substitution of G169425T at the XhoI restriction site
at the N-terminus of LMP1, which results in its loss (Hu et al., 1991). The biological
significance and consequence is uncertain, but due to its high prevelance in the Asian
population where NPC is endemic, the association was made between XhoI-loss and the
development of NPC (da Costa, Marques-Silva, and Moreli, 2015). However, in NPC
cases in North Africa, this variant is not observed (Ayadi et al., 2007; Bouzid et al., 1994).
Similarly, EBVaGC cases in China often display the XhoI-loss (Chen et al., 2010a), while
studies from other geographic regions do not (Abdirad et al., 2007; Ordonez et al., 2011).
One study of Asian populations has also associated XhoI-loss with a number of other
malignancies such as IM, hemophagocytic lymphohistiocytosis, and HL (Ai et al., 2012).
As most studies are biased towards sampling Asian populations, some papers have sug-
gested this variant is likely only a geographic variation (Ai et al., 2012).
LMP2A Variation in LMP2A has been described, but polymorphisms have not been
associated with any specific diseases (Tanaka et al., 1999; Berger et al., 1999; Wang et al.,
2010b; Han et al., 2012).
EBNA1 EBNA1 variants have mostly been classified based on their amino acid poly-
morphism at the C-terminus. The prototype sequence is P-ala (which includes the WT
strain) and variant strains are V-val, V-leu, V-pro, P-thr (Bhatia et al., 1996).
Many authors have found that the V-val variant is most commonly found in Asia
(Gutiérrez et al., 1997; Mai et al., 2007; Zhang et al., 2004; Sandvej, Zhou, and Hamilton-
Dutoit, 2000). It was suggested that the V-val variant is associated with development of
NPC (Zhang et al., 2004; Mai et al., 2007), due to expression differences of viral and host
genes as well as itself in epithelial cells (Mai et al., 2007). V-val was also reported to have
a higher transcriptional activity than P-ala (WT), and a higher binding affinity for the FR
element, which among other roles is a transcription enhancer for the LMP promoter as
well as the Cp promoter (Mai et al., 2010; Zhang et al., 2004). Another study showed that
the V-val variant might have a stronger anti-apoptotic effect on cells deprived of serum
and therefore growth-signals, a hallmark for tumour cells (Chao et al., 2015).
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However, other studies have weakened the suggested strong association with NPC,
as it was found to be most common in both healthy carriers as well as NPC, EBVaGC, IM,
HL and Hemophagocytic lymphohistiocytosis patients in Asia (Do et al., 2008; Chang et
al., 2009; Ai et al., 2012; Wang et al., 2010d). A recent study analysed EBV gene variation
in NPC biopsies in Caucasians from Serbia, a non-endemic region. They found EBNA1
P-thr and P-ala to be the most prevalent types, confirming the geographic association of
V-val with Asia (Banko et al., 2016). Further, they found a particular subtype of P-thr to
be associated with NPC type III in their cohort and proposed a particular combination
of EBNA2, LMP1 and EBNA1 polymorphisms (type1/Med/P-thr) to be a risk factor for
developing advanced NPC stages.
EBNA1 plays an important role in oncogenesis but evidence for disease association is
not clear. Furthermore, there is a clear bias in the literature of studying populations from
Asia. As a consequence, disentangling the effect of geography and disease association is
difficult. It requires careful studies with large sample sizes in well defined subpopula-
tions and controls.
EBNA2 The type-specific variations found in EBNA2 have not been found to be associ-
ated with a specific disease (Tzellos and Farrell, 2012). However, type 2 has been found to
be less efficient in transformation due to a single amino acid change in the transactivation
domain, S442D (Tzellos et al., 2014).
EBNA3A, -3B, -3C Variations differentiating between type 1 and 2 in the EBNA2 gene
are linked to the polymorphisms in the EBNA3 genes (Rowe et al., 1989). Six EBNA3 vari-
ants, including the prototype WT (B95.8), were defined based on linked polymorphisms
in the EBNA3A, -B and -C genes. Recombination of variation patterns was also observed
and formed the most distinct type (Görzer et al., 2006). Evidence for disease associa-
tion of polymorphisms, however, is weak. In a study of EBNA3C variation in northern
China, no association between variation and EBVaGC, NPC, or asymptomatic carriers
could be found (Wu et al., 2012). However, it has been shown that EBNA3B, which acts
as a tumour suppressor, carrying loss of function mutants leads to increased transform-
ing ability and promotes formation of DLBCL-like tumours in humanised mice, partly
due to reduced T-cell mediated killing in vivo (White et al., 2012). Similar phenotypic
tumours in humans were also found to carry a truncated EBNA3B, and cell lines derived
from these lymphoma displayed a similar gene expression profile as the tumour-derived
lines from the humanised mice.
BZLF1 BZLF1 encodes the major switch from latent to lytic cycle Zta or ZEBRA. It is
therefore of particular interest whether and how variation in the protein itself and within
the promoter impacts function and/or expression. There are now four variant types of
the gene defined based on differences to the prototype WT (B95.8): A, B, C (Luo et al.,
2011) and D (Lorenzetti et al., 2014). Whether or not BZLF1 variation corresponds to
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pathogenesis or whether it is geographically restricted is still controversial. In NPC pa-
tients from Tunisia, one study found BZLF1 variants differentially distributed between
tumour cells and lymphocytes (Sacaze et al., 2001). In a study from 2011, no association
between BZLF1 variations and EBVaGC or NPC in China was found (Luo et al., 2011),
but a later study showed that BZLF1 type B occurs slightly more often in lymphoma
compared to EBVaGC or NPC (Yang et al., 2014). In contrast to that, Lorenzetti et al.,
2014 found a subtype of BZLF1-A particularly frequent in lymphoma and BZLF1-C in
IM in patients from Argentina.
The promoter has also been classified into four types: Zp-P, which is identical to the
WT, as well as Zp-V1, Zp-V3 and Zp-V4 based on four positions (-196, -141, -106 and
-100) (Lorenzetti et al., 2009). First studies found a differential distribution of promoter
variants between malignant and benign EBV infections (Gutiérrez et al., 2002), but later,
malignancy associated variants such as Zp-V3 were also found in healthy carriers and
IM patients (Tong et al., 2003; Martini et al., 2007; Imajoh et al., 2012). In particular Zp-V3
was also associated with severe diseases such as chronic active EBV (CAEBV) (Jin et al.,
2010; Imajoh et al., 2012). However, functional studies to confirm potential associations
are lacking.
Virus strains
In EBV, most genes have only a low level of natural diversity on the amino acid level (less
than 5 %). The most variable genes are the latency genes (within and between EBV type
variation) (Chang et al., 2009; Palser et al., 2015) and many studies have focused on these
and other polymorphic genes to study variation. But this approach gives an incomplete
picture of variation, as information of linkage between variable sites and potential larger
scale rearrangements of genomic regions or recombination cannot be observed.
EBV genome sequencing The first complete EBV genome, strain B95-8, was published
in 1984 (Baer et al., 1984). The virus originated from the 883L cell line, which was es-
tablished by culturing B cells from a North American IM patient. This virus was used
to infect a marmoset B cell line, from which DNA was subsequently isolated and se-
quenced by Sanger sequencing of cloned EcoRI and BamHI fragments (Baer et al., 1984).
The genome has since been updated by using it as backbone and filling an atypical large
deletion in the BamHI A fragment with a sequence from the strain Raji (de Jesus, 2003).
Only for this historical reason is this sequence often referred to as the wild type (WT) or
reference sequence.
The first – and up until recently only – type 2 genome, AG876, was published al-
most 20 years later and originated from a BL case in Ghana (Dolan et al., 2006). The
sequence was obtained by digesting the genome into fragments which were then cloned
and Sanger sequenced. Genome comparison of the WT sequence and AG876 confirmed
how similar the genomic sequence of both types is apart from the typing genes.
In 2005, the Chinese strain GD1 from the southern Guangdong province was se-
quenced. The virus was isolated from the saliva of a NPC patient and used to infect
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umbilical cord mononuclear cells (Zeng et al., 2005). Here, the isolated DNA was then
PCR-amplified, cloned and Sanger sequenced. Six years later, another Guangdong strain,
GD2, was published. This genome is the first one derived from virus directly isolated
from clinical material (a NPC tumour) and sequenced using Next generation sequencing
(NGS) (Liu et al., 2011).
Due to the advancements of NGS technology, GD2 also marks the beginning of the
increase in EBV genome sequencing: HKNPC1, a NPC sample from Hong Kong in 2012
(Kwok et al., 2012); Akata, a Japanese BL cell line, and Mutu, a Kenyan BL cell line in
2012 (Lin et al., 2012); K4123-Mi and K4413-Mi, spontaneous LCLs (sLCLs) generated
from healthy North American donors, in 2013 (Lei et al., 2013); C666-1, a Chinese NPC
cell line, in 2013 (Tso et al., 2013); and M81, a Chinese NPC isolate, in 2013 (Tsai et al.,
2013). Moreover, due to EBV’s prevalence in the human population, one study used
sequencing raw data from the 1000 Human Genomes Project to filter out EBV-specific
reads and assemble full genomes (Santpere et al., 2014).
A further advancement in EBV sequencing occurred in 2014, when eight further NPC
samples from Hong Kong (HKNPC2 to -9) were published (Kwok et al., 2014). The pre-
vious sequencing attempts were tempered by the fact that DNA isolated from clinical
material and even cell lines only contained a very small percentage of virally derived
material. Kwok et al., 2014 were the first to publish EBV genomes obtained using a re-
cently developed targeted enrichment technique for pathogen genomics (Depledge et al.,
2011). In this method, isolated DNA is sheared and then hybridised with biotinylated
RNA baits which are complementary to sequences of interest. The baits are then pulled
out, bound to the sample sequences of interest, and after digesting the RNA, the en-
riched sample can be sequenced. Using this method, Palser et al., 2015 then sequenced
a big number of 71 new genomes from various tumour types and normal infections of
different geographic origins, including eleven additional type 2 sequences. Since then
more publications came out using this method (Liu et al., 2016; Chiara et al., 2016)
Table 1.2 lists all available whole genome sequences to date (April 2017).
There are phenotypic difference between strains: for example, the deletion in B95-8
affects one of the lytic origins of replication (Baer et al., 1984). Nevertheless, it is able to
establish LCLs from peripheral B cells. M81, an NPC isolate from Hong Kong, has been
found to have a reversed tropism relative to other known strains, i.e. it predominantly
infects epithelial cells probably due to an abundance of gp110 (Tsai et al., 2013).
Considering the whole genome, the most polymorphic genes are the latency genes.
A particularly high number of nonsynonymous changes are observed in EBNA2 and the
EBNA3 family, as well as LMP1. Among the lytic genes, the most diversity is found
in BDLF3 and BLLF1 (encoding for gp150 and gp350), BZLF1 (Zta), BRRF2 (tegument
protein), and BNLF2a (plays a role in immune evasion) (Palser et al., 2015). These genes
are likely partly or as a whole under positive selection due to being immunogenic.
Comparative analysis of whole genomes has also elucidated that recombination is
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a frequent event in EBV. Palser et al., 2015 described both inter- and intratypic recom-
binants, as did other publications, in particular in geographically constrained genomes
(Kwok et al., 2014; Santpere et al., 2014).
Name Type Geographic EBNA2 Accession Reference
origin type no.
WT IM USA 1 NC_007605 (Baer et al., 1984, l
de Jesus, 2003)
AG876 BL Ghana 2 NC_009334 (Dolan et al., 2006)
GD1 NPC—saliva China 1 AY961628 (Zeng et al., 2005) l
GD2 NPC—tumor China 1 HQ020558 (Liu et al., 2011) l
HKNPC1 NPC—tumor Hong Kong 1 JQ009376 (Kwok et al., 2012) l
Akata BL Japan 1 KC207813 (Lin et al., 2012) l
Mutu BL Kenya 1 KC207814 (Lin et al., 2012) l
K4123-Mi sLCL USA 1 KC440851 (Lei et al., 2013) l
K4413-Mi sLCL USA 1 KC440852 (Lei et al., 2013) l
M81 NPC Hong Kong 1 KF373730 (Tsai et al., 2013) l
HKNPC2 NPC Hong Kong 1 KF992564 (Kwok et al., 2014) l
HKNPC3 NPC biopsy Hong Kong 1 KF992565 (Kwok et al., 2014) l
HKNPC4 NPC biopsy Hong Kong 1 KF992566 (Kwok et al., 2014) l
HKNPC5 NPC biopsy Hong Kong 1 KF992567 (Kwok et al., 2014) l
HKNPC6 NPC biopsy Hong Kong 1 KF992568 (Kwok et al., 2014) l
HKNPC7 NPC biopsy Hong Kong 1 KF992569 (Kwok et al., 2014) l
HKNPC8 NPC biopsy Hong Kong 1 KF992570 (Kwok et al., 2014) l
HKNPC9 NPC biopsy Hong Kong 1 KF992571 (Kwok et al., 2014) l
Saliva1 Healthy saliva UK 1 LN824142 (Palser et al., 2015) l
HL01 HL UK 1 LN824226 (Palser et al., 2015) l
HL02 HL UK 1 LN827546 (Palser et al., 2015) l
HL04 HL UK 1 LN827564 (Palser et al., 2015) l
HL05 HL UK 1 LN824204 (Palser et al., 2015) l
HL08 HL UK 1 LN824225 (Palser et al., 2015) l
HL09 HL UK 1 LN827522 (Palser et al., 2015) l
HL11 HL UK 1 LN827524 (Palser et al., 2015) l
L591 HL cell line Germany 1 LN827523 (Palser et al., 2015) l
YCCEL1 GC cell line South Korea 1 LN827561 (Palser et al., 2015) l
HKN14 sLCL Hong Kong 1 LN824209 (Palser et al., 2015) l
HKN15 sLCL Hong Kong 1 LN827547 (Palser et al., 2015) l
HKN19 sLCL Hong Kong 1 LN824224 (Palser et al., 2015) l
D3201.2 NPC biopsy China 1 LN827549 (Palser et al., 2015) l
C666-1 resequence NPC cell line China 1 LN827525 (Palser et al., 2015) l
M-ABA LCL, NPC virus N. Africa 1 LN827527 (Palser et al., 2015) l
Daudi BL Kenya 1 LN827545 (Palser et al., 2015) l
BL36 BL N. Africa 2 LN827557 (Palser et al., 2015)
BL37 BL Africa 1 LN827526 (Palser et al., 2015) l
Makau BL Kenya 1 LN827551 (Palser et al., 2015) l
Mak1 duplicate BL Kenya 1 LN824203 (Palser et al., 2015) l
sLCL-IM1.02 sLCL, IM Australia 1 LN827596 (Palser et al., 2015) l
sLCL-IM1.05 sLCL, IM Australia 1 LN827590 (Palser et al., 2015) l
sLCL-IM1.09 sLCL, IM Australia 1 LN827567 (Palser et al., 2015) l
sLCL-IM1.16 sLCL, IM Australia 1 LN827799 (Palser et al., 2015) l
sLCL-IM1.17 sLCL, IM Australia 1 LN827583 (Palser et al., 2015) l
sLCL-IS1.01 sLCL, PTLD Australia 1 LN827570 (Palser et al., 2015) l
sLCL-IS1.03 sLCL, PTLD Australia 1 LN827595 (Palser et al., 2015) l
sLCL-IS1.04 sLCL, PTLD Australia 1 LN827597 (Palser et al., 2015) l
sLCL-IS1.06 sLCL, PTLD Australia 1 LN827584 (Palser et al., 2015) l
sLCL-IS1.07 sLCL, PTLD Australia 1 LN827594 (Palser et al., 2015) l
sLCL-IS1.08 sLCL, PTLD Australia 1 LN827553 (Palser et al., 2015) l
sLCL-IS1.10 sLCL, PTLD Australia 1 LN827592 (Palser et al., 2015) l
Chapter 1. Introduction 26
Name Type Geographic EBNA2 Accession Reference
origin type no.
sLCL-IS1.11 sLCL, PTLD Australia 1 LN827569 (Palser et al., 2015) l
sLCL-IS1.12 sLCL, PTLD Australia 1 LN827593 (Palser et al., 2015) l
sLCL-IS1.13 sLCL, PTLD Australia 1 LN827578 (Palser et al., 2015) l
sLCL-IS1.14 sLCL, PTLD Australia 1 LN827575 (Palser et al., 2015) l
sLCL-IS1.15 sLCL, PTLD Australia 1 LN827586 (Palser et al., 2015) l
sLCL-IS1.18 sLCL, PTLD Australia 1 LN827572 (Palser et al., 2015) l
sLCL-IS1.19 sLCL, PTLD Australia 1 LN827588 (Palser et al., 2015) l
sLCL-IS1.20 sLCL, PTLD Australia 1 LN827576 (Palser et al., 2015) l
sLCL-1.02 sLCL Kenya 1 LN827558 (Palser et al., 2015) l
sLCL-BL1.03 sLCL Kenya 1 LN827582 (Palser et al., 2015) l
sLCL-1.04 sLCL Kenya 1 LN827585 (Palser et al., 2015) l
sLCL-1.05 sLCL Kenya 1 LN827581 (Palser et al., 2015) l
sLCL-1.06 sLCL Kenya 1 LN827566 (Palser et al., 2015) l
sLCL-1.07 sLCL Kenya 1 LN827565 (Palser et al., 2015) l
sLCL-1.08 sLCL Kenya 1 LN827552 (Palser et al., 2015) l
sLCL-1.09 sLCL Kenya 1 LN827574 (Palser et al., 2015) l
sLCL-1.10 sLCL Kenya 1 LN827573 (Palser et al., 2015) l
sLCL-1.11 sLCL Kenya 1 LN827550 (Palser et al., 2015) l
sLCL-1.12 sLCL Kenya 1 LN824205 (Palser et al., 2015) l
sLCL-1.13 sLCL Kenya 1 LN827579 (Palser et al., 2015) l
sLCL-1.17 sLCL Kenya 1 LN827577 (Palser et al., 2015) l
sLCL-1.19 sLCL Kenya 1 LN827562 (Palser et al., 2015) l
sLCL-BL1.20 sLCL Kenya 1 LN827571 (Palser et al., 2015) l
sLCL-1.24 sLCL Kenya 1 LN827568 (Palser et al., 2015) l
pLCL-TRL1-pre1 sLCL, PTLD USA 1 LN824207 (Palser et al., 2015) l
pLCL-TRL1-post1 sLCL, PTLD USA 1 LN8242076 (Palser et al., 2015)
pLCL-TRL595 sLCL, PTLD USA 1 LN827559 (Palser et al., 2015) l
X50-7 LCL USA 1 LN827555 (Palser et al., 2015) l
Wewak1 BL PNG 2 LN827544 (Palser et al., 2015)
AFB1 LCL Unknown 2 LN827554 (Palser et al., 2015)
Jijoye BL Nigeria 2 LN827800 (Palser et al., 2015)
P3HR1 c16 BL Nigeria 2 LN827548 (Palser et al., 2015)
Cheptages BL Kenya 2 LN827556 (Palser et al., 2015)
sLCL-IS2.01 sLCL, PTLD Australia 2 LN827589 (Palser et al., 2015)
sLCL-2.14 sLCL Kenya 2 LN827560 (Palser et al., 2015)
sLCL-2.15 sLCL Kenya 2 LN827591 (Palser et al., 2015)
sLCL-2.16 sLCL Kenya 2 LN827580 (Palser et al., 2015)
sLCL-1.18 sLCL Kenya 2 LN827563 (Palser et al., 2015)
sLCL-2.21 sLCL Kenya 2 LN827587 (Palser et al., 2015)
sLCL-2.22 sLCL Kenya 2 LN831023 (Palser et al., 2015)
NA12878 Healthy* Europe 1 NA (Lei et al., 2013)
NA19114 Healthy* Africa 1 NA (Santpere et al., 2014)
NA19315 Healthy* Africa 1 NA (Santpere et al., 2014)
NA19384 Healthy* Africa 1 NA (Santpere et al., 2014)
EBVaGC1 EBVaGC biopsy China 1 KT273942 (Liu et al., 2016)
EBVaGC2 EBVaGC biopsy China 1 KT273943 (Liu et al., 2016)
EBVaGC3 EBVaGC biopsy China 1 KT254013 (Liu et al., 2016)
EBVaGC4 EBVaGC biopsy China 1 KT273944 (Liu et al., 2016)
EBVaGC5 EBVaGC biopsy China 1 KT273945 (Liu et al., 2016)
EBVaGC6 EBVaGC biopsy China 1 KT273946 (Liu et al., 2016)
EBVaGC7 EBVaGC biopsy China 1 KT273947 (Liu et al., 2016)
EBVaGC8 EBVaGC biopsy China 1 KT273948 (Liu et al., 2016)
EBVaGC9 EBVaGC biopsy China 1 KT273949 (Liu et al., 2016)
LC1 LC biopsy China 1 KT823506 (Wang et al., 2016)
LC2 LC biopsy China 1 KT823507 (Wang et al., 2016)
LC3 LC biopsy China 1 KT823508 (Wang et al., 2016)
LC4 LC biopsy China 1 KT823509 (Wang et al., 2016)
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Name Type Geographic EBNA2 Accession Reference
origin type no.
MP BL biopsy Brazil 1 KP968258 (Lei et al., 2015)
SCL BL biopsy Brazil 1 KP968259 (Lei et al., 2015)
CCH BL biopsy Brazil 1 KP968257 (Lei et al., 2015)
H018436D BL biopsy Ghana 1 KP968262 (Lei et al., 2015)
H058015C BL biopsy Ghana 1 KP968263 (Lei et al., 2015)
HU113931 BL biopsy Ghana 1 KP968261 (Lei et al., 2015)
H03753A1 BL biopsy Ghana 1 KR063342 (Lei et al., 2015)
H002213 BL biopsy Ghana 1 KP968264 (Lei et al., 2015)
CV- ARG BL biopsy Argentina 1 KR06 3343 (Lei et al., 2015)
RPF BL biopsy Brazil 1 KR06 3344 (Lei et al., 2015)
FNR BL biopsy Brazil 1 KR06 3345 (Lei et al., 2015)
VGO BL biopsy Brazil 1 KP968260 (Lei et al., 2015)
CAR sLCL, Healthy Italy 1 ERS1100719 (Chiara et al., 2016)
PP sLCL, MS Italy 1 ERS1100731 (Chiara et al., 2016)
MV sLCL, MS Italy 1 ERS1100733 (Chiara et al., 2016)
BL sLCL, MS Italy 1 ERS1100735 (Chiara et al., 2016)
VL sLCL, MS Italy 1 ERS1100730 (Chiara et al., 2016)
NM sLCL, Healthy Italy 1 ERS1100715 (Chiara et al., 2016)
MC sLCL, Healthy Italy 1 ERS1100718 (Chiara et al., 2016)
MFA sLCL, MS Italy 1 ERS1100723 (Chiara et al., 2016)
GV sLCL, MS Italy 1 ERS1100726 (Chiara et al., 2016)
GIOVS sLCL, Healthy Italy 1 ERS1100717 (Chiara et al., 2016)
CS sLCL, MS Italy 1 ERS1100724 (Chiara et al., 2016)
GR sLCL, Healthy Italy 1 ERS1100714 (Chiara et al., 2016)
PT sLCL, Healthy Italy 1 ERS1100716 (Chiara et al., 2016)
BA sLCL, MS Italy 1 ERS1100728 (Chiara et al., 2016)
MM sLCL, MS Italy 1 ERS1100734 (Chiara et al., 2016)
LOL sLCL, MS Italy 1 ERS1100725 (Chiara et al., 2016)
IM sLCL, MS Italy 1 ERS1100727 (Chiara et al., 2016)
GF sLCL, MS Italy 1 ERS1100729 (Chiara et al., 2016)
BR sLCL, Healthy Italy 1 ERS1100721 (Chiara et al., 2016)
CM sLCL, MS Italy 1 ERS1100732 (Chiara et al., 2016)
LUL sLCL, Healthy Italy 1 ERS1100722 (Chiara et al., 2016)
TM sLCL, MS Italy 1 ERS1100713 (Chiara et al., 2016)
SC sLCL, MS Italy 1 ERS1100710 (Chiara et al., 2016)
SA sLCL, MS Italy 1 ERS1100711 (Chiara et al., 2016)
RT sLCL, MS Italy 1 ERS1100712 (Chiara et al., 2016)
MST sLCL, Healthy Italy 1 ERS1100720 (Chiara et al., 2016)
CAS sLCL, MS Italy 1 ERS1100709 (Chiara et al., 2016)
TABLE 1.2: All published whole genome sequences to date (April 2016).
BL: Burkitt’s lymphoma; GC: gastric carcinoma; HL: Hodgkin’s lym-
phoma; IM: infectious mononucleosis; LC: Lung carcinoma; LCL: lym-
phoblastoid cell line; sLCL: spontaneous lymphoblastoid cell line; MS:
Multiple sclerosis; NPC: nasopharyngeal carcinoma; PTLD: posttransplant
lymphoproliferative disease; PNG: Papua New Guinea; N. Africa: North
Africa; *: Genomes assembled from read data of the 1000 Human Genomes
Project; 1: same donor.
Sequences included in the comparative genomics analysis in chapter 4 are
marked with l .
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1.8 Outline
Studying variation of EBV can answer many interesting questions: It can be a means
to better understand how virus variation impacts on pathogenesis of disease. It further
bares the evolutionary history in relation to its host and distribution across the world.
This thesis centres around genomic studies on the impact of host/virus interaction in
EBV infection using deep sequencing. I will present the results of these studies in three
chapters, which will deal with the following topics:
1. The optimisation of a target enrichment method to sequence EBV directly from
clinical material where human DNA is present in vast excess.
2. A comparative genomics analysis to elucidate the evolutionary history of EBV and
the relationship between different world-wide isolates. This includes the identifica-
tion of polymorphic genomic regions and of sites under selection as well as a com-
prehensive study of recombination through the generation of genome-wide linkage
data. This data is used to identify potential targets of T cell immunity. Additionally,
the population structure of EBV is examined.
3. The sequencing and analysis of whole EBV genomes from various clinical settings,
including infectious mononucleosis and immunosuppression with chronic EBV in-
fection, in terms of their inter- and intrahost diversity, as well as the comparison of
genomes derived from Asian patients with carcinoma and primary infection.
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Chapter 2
Materials & Methods
2.1 Materials & Reagents
2.1.1 Samples
Cell lines
DNA isolated from JSC-1, a (latent) EBV-infected, and Kaposi’s Sarcoma Herpesvirus
co-infected, primary effusion cell line (Cannon et al., 2000).
Clinical samples
Sample Date Source Age Sex From VL [copies/ml] Diagnosis
ebv1 19/10/2011 Blood 15 f GOSH 22,110 PTLD
ebv2 21/10/2011 Blood 15 f GOSH 24,782 PTLD
ebv3 01/11/2011 Blood 15 f GOSH 972 PTLD
ebv4 20/02/2012 Blood 15 f GOSH (CT) 34 PTLD
ebv5 01/03/2012 Blood 15 f GOSH 6,078 PTLD
ebv6 09/05/2012 Blood 5 m GOSH 942,609 Heart transplant
ebv7 08/05/2012 Blood 7 m GOSH 444,984 Immunodeficiency
ebv8 18/05/2012 Blood 7 f GOSH 1,200,000 Turner’s syndrome,
Heart transplant
ebv9 18/05/2012 Blood 3 f GOSH >2,000,000 Heart transplant
ebv11 23/05/2012 Blood 4 f GOSH 6,950,932 Cystic fibrosis,
Lung transplant
ebv13 15/04/2013 Blood 6 f GOSH > 2,000,000 Kidney transplant
ebv14 22/04/2013 Blood 5 m GOSH > 2,000,000 SOT
ebv15 31/05/2013 Blood 13 f GOSH 1,295,240 SOT
ebv16 26/11/2014 Blood GOSH 497,026 SOT
ebv17 26/03/2014 Blood GOSH 1,067,180 SOT
ebv18 02/12/2014 Blood GOSH 131,685 SOT
ebv19 27/03/2014 Blood GOSH 714,159 SOT
ebv20 07/10/2014 Blood GOSH 26,011 SOT
ebv21 06/01/2014 Blood GOSH 2,525,480 SOT
ebv22 07/08/2014 Blood GOSH 4,684,310 SOT
ebv23 06/08/2014 Blood GOSH 1,458,050 SOT
ebv24 27/11/2014 Blood GOSH 7,516 SOT
ebv25 15/01/2014 Blood GOSH 14,532,600 SOT
ebv26 04/12/2014 Blood GOSH 98,249 SOT
ebv27 19/02/2014 Blood GOSH 838,767 SOT
ebv28 Blood GOSH 10,298 SOT
ebv29 Blood GOSH 11,914 SOT
ebv30 Blood GOSH 473,352 SOT
ebv31 Blood GOSH 1,130,850 SOT
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Sample Date Source Age Sex From VL [copies/ml] Diagnosis
P1-B1 26/05/2015 Blood GOSH 66,473 PTLD
P1-T1 29/08/2015 Tumour GOSH 11,228,500 PTLD
P2-B1 04/10/2012 Blood GOSH 21,973 PTLD
P2-B2 18/11/2015 Blood GOSH 1,707,130 PTLD
P2-B3 18/01/2016 Blood GOSH 4,534,200 PTLD
P2-T1 02/10/2012 Tumour GOSH ND PTLD
P3-B1 03/11/2011 Blood GOSH 22,110 PTLD
P3-B2 03/09/2014 Blood GOSH 952,152 PTLD
P3-T1 09/09/2011 Tumour GOSH ND PTLD
P4-B1 15/03/2003 Blood GOSH >1,000,000 PTLD
P4-T1 26/03/2003 Tumour GOSH ND PTLD
VL [copies/µg]
P1-812 01/06/2007 Blood 6 f Toyoake, JP 114,182 IM
P1-833 12/06/2007 Blood 6 f Toyoake, JP 238 IM
P2-1213 07/12/2007 Blood 7 m Toyoake, JP 124,641 IM
P2-1246 19/12/2007 Blood 7 m Toyoake, JP 13,973 IM
P3-2670 18/04/2009 Blood 4 m Toyoake, JP 250,054 IM
P3-2740 11/05/2009 Blood 4 m Toyoake, JP 17,173 IM
P4-2274 19/12/2008 Blood 6 f Toyoake, JP 139,271 IM
P4-2392 06/02/2009 Blood 6 f Toyoake, JP 3,809 IM
P5-1294 11/01/2008 Blood 15 f Toyoake, JP 59,710 IM
P5-1323 18/01/2008 Blood 15 f Toyoake, JP 6,964 IM
P6-1751 23/05/2008 Blood 3 m Toyoake, JP 49,657 IM
P6-1789 04/06/2008 Blood 3 m Toyoake, JP 346 IM
P7-2315 14/01/2009 Blood 11 f Toyoake, JP 10,277 IM
P7-2634 03/04/2009 Blood 11 f Toyoake, JP 24,275 IM
P8-414 13/10/2006 Blood 7 m Toyoake, JP 22,197 IM
P8-516 15/12/2006 Blood 7 m Toyoake, JP 8,982 IM
P9-2631 08/04/2009 Blood 4 m Toyoake, JP 62,666 IM
P9-2645 13/04/2009 Blood 4 m Toyoake, JP 37,832 IM
P10-2187 31/10/2008 Blood 1 m Toyoake, JP 4,221 IM
P10-2777 20/05/2009 Blood 1 m Toyoake, JP 212 IM
P11-871 01/07/2007 Blood 1 m Toyoake, JP 24,101 IM
P11-920 24/07/2007 Blood 1 m Toyoake, JP 3,487 IM
P12-1026 29/08/2007 Blood 11 m Toyoake, JP 2,844 IM
P12-1078 25/09/2007 Blood 11 m Toyoake, JP 1,142 IM
TABLE 2.1: All clinical samples processed including patient information
where available. VL: viral load in copies/ml blood or copies/µg DNA,
respectively. GOSH: Great Ormond Street Hospital for children, Great Or-
mond St, London, UK; Toyoake, JP: Department of Pediatrics, Fujita Health
University School of Medicine, Toyoake, Japan; PTLD: post-transplant
lymphoproliferative disorder; SOT: solid organ transplant; IM: infectious
mononucleosis.
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2.1.2 Reagents
Reagent Supplier (Cat. No)
QIAamp DNA Blood Mini Kit Qiagen (51106)
QIAamp DNA mini kit Qiagen (51306)
Genomphi v3 GE Healthcare (25-6601-24)
Qubit dsDNA HS Assay Kit Invitrogen (Q32854)
Genomic DNA Clean & Concentrator Zymo Research (D4011)
Agencourt AMPure XP beads Beckman & Coulter (A63881)
Illustra GenomiPhi V2 GE Healthcare (25-6600-30)
Qubit dsDNA HS Assay Kit Thermo Fisher Scientific (Q32851)
TABLE 2.2: Reagents used in DNA preparation of clinical samples.
Reagent Supplier (Cat. No)
SureSelectXT Reagent kit, MSQ Agilent (G9612B)
Herculase II Fusion DNA Polymerase Agilent (600677)
Dynabeads MyOne Streptavidin T1 Thermo Fisher Scientific (65602)
1X Low TE Buffer Thermo Fisher Scientific 12090-015)
DNA 1000 Kit Agilent (5067-1504)
High Sensitivity DNA Kit Agilent (5067-4626)
D1000 ScreenTape Agilent (5067-5582)
D1000 Reagents Agilent (5067-5583)
High Sensitivity D1000 ScreenTape Agilent (5067-5584)
High Sensitivity D1000 Reagents Agilent (5067-5585)
TABLE 2.3: Reagents used for targeted enrichment.
Reagent Supplier (Cat. No) Assay
QuantiFast SYBR Green PCR kit Qiagen (204754) EBV load
QuantiTect SYBR Green PCR kit Qiagen (204143) Human load
Phusion New England Biolabs (M0530) PCR
Phusion HF buffer New England Biolabs (B0518S) PCR
GeneRuler 1kb DNA ladder Thermo Fisher Scientific (SM0312) Electrophoresis
Invitrogen 100 bp ladder Thermo Fisher Scientific (15628019) Electrophoresis
TABLE 2.4: Reagents used in PCR and qPCR.
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Reagent Supplier (Cat. No)
100 % Ethanol, molecular biology grade Sigma-Aldrich (E7023)
Nuclease-free Water Thermo Fisher Scientific (AM9932)
TABLE 2.5: Other general reagents.
Name Orientation Sequence Fragment Start End
length
PSE1 F CCCAGAACAGCACCCGAAA 98700 98719
PSE4 R GGGTAGATGGCGAGACTCTT 484 99164 99184
PSE5 R GATAGACTGGGAGGCCTGA 254 98936 98955
PSE9 F CTGGTTGATTACGGGGCACT 106976 106996
PSE10 R GCCTCTGTCTCCTGGTTGAC 1000 107956 107976
PSE11 R TTGTTGGAGACTACGTCCGC 1971 108927 108947
TABLE 2.6: Primers for shearing experiment (synthesised by Sigma-
Aldrich). PSE1 was paired with PSE4 and -5, PSE9 was paired with PSE10
and PSE11 to produce a product of the fragment length listed. Start and
end coordinates refer to the JSC-1 genome.
Name Orientation Sequence Assay
KRAS_F F GCCTGCTGAAAATGACTGAATATAAAC human load
KRAS_R R TGATTCTGAATTAGCTGTATCGTCAAG human load
EBV_F F CCGGTGTGTTCGTATATGGAG EBV load
EBV_R R GGGAGACGACTCAATGGTGTA EBV load
TABLE 2.7: Primers for qPCR (synthesised by Sigma-Aldrich). The EBV
primers are published in Wandinger et al., 2000.
2.2 Experimental methods
2.2.1 Whole genome sequencing of EBV from clinical samples
DNA extraction and preparation
Total DNA was extracted from whole blood using the QIAamp blood mini kit (Qia-
gen) and from frozen tumour samples using the QIAmp mini kit. DNA was quantified
using the Qubit 2.0 Fluoromoeter and the dsDNA HS kit (Life Technologies). Whole
genome amplification (WGA) was performed additionally for some clinical samples us-
ing Genomiphi V2 (GE Healthcare) according to manufacturer’s instructions (table 2.2).
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Targeted enrichment of EBV-specific sequences
For targeted enrichment, the SureSelectXT protocol (further referred to only as SureSelect)
was used. The protocol involves the following steps:
1. Shearing of genomic DNA samples
2. Preparation of SureSelect libraries
3. Amplification of SureSelect libraries
4. Hybridisation of DNA samples to RNA baits and capture
5. Amplification of captured libraries with indexing primers
For each sample, 3 µg or 200 ng of DNA was sheared using either the Covaris E210
or the E220 system. Illumina paired-end sequencing libraries were constructed using
the standard SureSelect protocol, version 1.4.1 or version 1.6, respectively, with given
additional alterations to optimise the protocol as described (see chapter 3). Before 2015,
SureSelect was performed manually; from 2015 onwards, the Agilent Bravo Automated
Liquid handling platform (henceforth referred to as the automation system) was used.
SureSelect baits Samples were enriched for EBV sequences as previously described
(Depledge et al., 2011).
Two sets of RNA baits were used throughout the project. Both were designed by
Daniel Depledge using the Agilent SureDesign software (Depledge et al., 2011). Set 1 was
based on the published whole genomes sequences available in 2012, including published
genomes from Baer et al., 1984; de Jesus, 2003; Dolan et al., 2006; Zeng et al., 2005; Liu
et al., 2011; Kwok et al., 2012, while set 2 was created as an update in 2015 to include the
diversity found in newly published genomes (extending it by the genomes published by
Lin et al., 2012; Lei et al., 2013; Tsai et al., 2013; Kwok et al., 2014 and Palser et al., 2015).
Both sets of baits were designed as overlapping 120-mers spanning the whole length of
the positive strand of the genome with a 5x coverage for set 1 and 12x for set 2. Baits
were synthesised by Agilent Biotechnologies.
Bait set 1 was used for all samples prepared up to 2015. This includes the optimisation
experiments presented in chapter 3, and the Japanese infectious mononucleosis data set
(on the automation system) which was then sequenced on a MiSeq (chapter 5). The bait
set 2 was used again on the IM data set, the additional samples of immunocompromised
children from the UK, as well as the paired tumour and blood samples (chapter 5).
Standard Agilent barcodes were added and all recommended quality control steps
included (using either a Agilent 2100 Bioanalyzer or an Agilent 2200 TapeStation).
Next generation sequencing
Libraries were either sequenced on the Illumina MiSeq platform with a v3 reagent kit
(300 cycles), or on the Illumina NextSeq with a 500/550 v2 reagent kit (300 cycles). Sam-
ples were demultiplexed using the automated workflow on the MiSeq to generate paired
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FASTQ files. For the NextSeq generated reads, an in-house script was used for demulti-
plexing.
2.2.2 Human and viral load assay
To determine human and viral loads, qPCRs were performed using primers listed in
table 2.7. If possible samples were prepared in duplicate. The gene KRAS was targeted
for the human load, while EBNA1 was targeted for the EBV load as previously described
(Jabs et al., 2001) (table 2.4).
2.2.3 PCR to test shearing efficiency of episomal DNA
In order to test whether the shearing process works for episomal DNA, a PCR assay was
used. Table 2.6 lists the primers and their coordinates as well as the expected fragment
length.
The PCR was set up in a 25 µl reaction with Phusion polymerase according to the
manufacturer’s protocol (table 2.8a).
Reagent [µl]
Nuclease-free water 15.75
HF Buffer 4
10 mM dNTPs 0.5
1 µM Forward Primer 1.25
1 µM Reverse Primer 1.25
Phusion 0.25
DNA 1
(A) Master mix.
Step Temp [oC] Time
Initial denaturation 98 30 s
35 cycles 98 20 s
X 30 s
72 X
Final extension 72 10 min
Hold 4 ∞
(B) PCR cycler program; X specified in text.
TABLE 2.8: PCR conditions for shearing experiment with Phusion poly-
merase.
PSE1/4 and PSE1/5 were run with an annealing temperature of 62oC and an elon-
gation time of 15 s. PSE9/10 and PSE9/11 were annealed at 64oC and 65oC with an
elongation time of 30 s and 60 s, respectively.
PCR products of PSE9/10 and PSE9/11 were run on a 1 % and product of PSE1/4 and
PSE1/5 on a 2 % agarose gel in TAE buffer.
2.3 Computational methods
2.3.1 Genome assembly
Different approaches were used to assemble the genomes of EBV throughout the work.
Except JSC-1, all samples have been de novo assembled. There are two final de novo
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pipelines (see below). Samples ebv6-15 have been assembled using CLC workbench,
whereas all other samples were processed using the open source pipeline using SPAdes.
Reference-guided assembly
JSC-1 was first assembled using a reference-guided approach. Reads were trimmed with
the FASTX toolkit (FASTX toolkit). Duplicates and low quality reads were removed using
QUASR v7 (QUASR) using a minimum quality threshold of 30 and minimum read length
of 50 bp.
Reads were then mapped against the type 1 reference genome with bwa 0.7.5a using
the algorithms aln and sampe (Li and Durbin, 2009). SAM files were then further pro-
cessed into BAM files using the samtools (Li et al., 2009) and a consensus generated using
QUASR.
De novo assembly using CLC Genomics Workbench
This assembly pipeline is referred to as pipeline 1 in the respective results chapters.
Paired-end sequence reads were processed using CLC Genomics Workbench 7 includ-
ing the CLC Microbial Genome Finishing Module (Qiagen).
Prior to assembly, reads were pre-processed: Duplicated reads were removed, the
remaining reads were trimmed based on base quality and further trimmed to a fixed
length (50 bp at the 3’ end and 10 bp at the 5’ end). To assess the percentage of reads
mapping to the target genome (on target reads, OTR) and to filter for EBV specific reads,
all reads were mapped against all available EBV genomes (standard parameters). Non
mapping reads were discarded, the remaining EBV specific reads were assembled using
the CLCbio de novo algorithm with standard parameters (CLC Workbench 7). If the num-
ber of reads exceeded 200-300k, the data set was subsampled as this process was found
to improve the assembly. The resulting contigs were then aligned against the reference
genome NC_007605 and manually merged. If the data set had been subsampled, previ-
ously excluded reads were mapped back to the contigs. A consensus sequence for each
genome was extracted under default parameters. Low coverage regions were defined as
having a read depth of <20 (Illumina Inc., 2010) and sequences here were written as N.
This pipeline was mainly used for the initial genome assemblies in chapter 3 and later
abandoned due to the proprietary character of the software. Moreover, the assembler,
while giving good results, is very slow and additional processing requires many manual
steps, in particular in the case of EBV due to the high number of contigs which likely
arise because of the high number of repeat regions in the EBV genome.
De novo assembly using open source tools
This assembly pipeline is referred to as pipeline 2 in the respective results chapters.
A mostly open source assembly pipeline was developed in our lab by Sofia Mor-
fopoulou, and was used for the majority of the samples (chapter 5).
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First, reads were trimmed using TrimGalore v0.3.7 (TrimGalore) with a quality thresh-
old of 20 and then aligned with BLASTN (Altschul et al., 1990) against a database of 124
EBV type 1 and 2 genomes in order to extract EBV-specific reads. Those were then de novo
assembled using SPAdes v3.5.0 (Bankevich et al., 2012) into contigs, which were filtered
for those of greather length than 200 bp with quast v2.3 (Gurevich et al., 2013). The order
and orientation of contigs were determined with BLASTN and a scaffold being generated
using an in-house R script. The quality checked reads were re-mapped against this pseu-
dogenome using BBMap (BBMap) and further processed into BAM-files with samtools
v0.1.19 (Li et al., 2009) and Picard (Picard). The consensus was extracted with QUASR
(QUASR), with the following parameters: minority bases were included as an ambiguity
code at a frequency of 0.5, minimal base quality was set to 20 and minimal depth to 20
(Illumina Inc., 2010). All bases below depth 20 were written as N.
2.3.2 Sequence and phylogenetic analysis
Multiple sequence alignment
Multiple sequence alignments were obtained using mafft v7 (Katoh and Standley, 2013)
and manually corrected using the alignment editor of MEGA (Tamura et al., 2013). SNPs
were called based on differences to the reference genome WT (Accession No. NC_007605)
and statistics calculated using the R packages adegenet (Jombart, 2008), ape (Paradis,
Claude, and Strimmer, 2004) and pegas (Paradis, 2010).
EBV-typing
Determination whether a genome is of type 1 or 2 was done calculating the genetic dis-
tance under the Kimura-2-parameter model (K80) (Kimura, 1980) for the CDS sequences
of EBNA2, EBNA3A, EBNA3B and EBNA3C to the type 1 and 2 reference strains (WT and
AG876).
Nucleotide diversity
Nucleotide diversity is a measure of genetic variation and is defined as the average num-
ber of differences between two sequences. It is defined as
pi =
n∑
i
n∑
j
xixjpiij
where xi and xj are the respective frequencies of the ith and jth sequences, piij is the
number of nucleotide differences per nucleotide site and n is the number of sequences
(Nei, 1987).
Nucleotide diversity was calculated as implemented in pegas either for the whole
ORF or in sliding windows of 100 bp with a step size of 1 bp for the whole genome
alignment.
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A SNP density plot was generated in adegenet. To test whether SNPs are randomly
distributed across the genome, a Monte Carlo test as implemented in the same R package
was run with 999 replicates.
Intrahost nucleotide diversity
Intrahost nucleotide diversity was computed for individual samples using an in-house
program developed by Prof. Richard Goldstein and Juliana Cudini. It is defined as the av-
erage number of nucleotide differences between reads at a site (Nei and Li, 1979). Strand
bias and random error rates were estimated and corrected using maximum likelihood
methods.
Minority variants
In order to call minority variants (i.e. variants with a frequency less than 0.5) within
one patient sample, quality checked reads were mapped against the consensus sequence
generated during genome assembly with BBMap v35 (BBMap). In the case of assemblies
generated with pipeline 1, raw reads were re-processed and mapped with BBMap against
the original consensus. The sam-file was converted into a bam-file and sorted with sam-
tools v0.1.19 (Li et al., 2009). Duplicates were removed using the MarkDuplicates tool
of the Picard toolbox v1.138 (Picard). The bam-file was then converted into a pileup-file
with samtools using the mpileup2cns option. All possible variants were called with
VarScan v2.3.7 (Koboldt et al., 2012), without any prior filtering except for the minimal
average mapping quality set to 20 (i.e. settings were as followed: --min-avg-qual 20
--min-var-freq 0 --p-value 99e-02 --min-coverage 1). Variants were then
filtered using an in-house python program by Dr. Samit Kundu called varsnp v2.1, which
allows to set a minimal frequency cut-off, a minimal coverage cut-off (see results chap-
ter) and a minimal number of reads per strand (set to 2). The resulting variants were then
checked for strand bias using an in-house R script that excludes variants where >90 %
of bases were mapped to one strand. Additionally variants that were called in areas that
mapped to repeat regions were excluded.
In some cases, mapping files have been randomly subsampled to a certain number of
reads prior to variant calling. This was to achieve comparable read depth across samples,
as read depth otherwise biases the number of minority variants called. The subsampling
was done using the DownsampleSam tool of the Picard toolbox.
Principal component analysis
Principal components analysis (PCA) is a commonly used tool to find patterns in complex
data, as it reduces the dimensionality of the data while retaining most of its variation. In
genomics, this is for example applied to detect population structure, clusters, or potential
outliers.
The aim is to convert a set of variables into a new set of linearly uncorrelated variables
which are called the principal components (PCs). These PCs are linear combination of the
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original variables and are ordered according to how much of the variation they contain.
This allows the exploration of the data, e.g. in a two dimensional plot of two PCs, onto
which the data is projected. Additionally, it enables the identification of original variables
that contribute most to the variance captured by a PC.
PCA was performed by using the implementation for SNP data in the R package
adegenet (Jombart, 2008) on the data sets further discussed in the individual chapters.
Different combinations of PCs were explored in two-dimensional scatterplots. Variables
(here, SNPs) contributing most to a certain PC were identified via their individual load-
ings, i.e. when their absolute loadings were higher than the third quartile of all absolute
loadings.
A complementary Neighbor joining (NJ) tree was calculated with ape. Note that this
is not representing a reliable phylogenetic tree, but is used to better visualise individual
genomes and clusters from the PCA scatter plots.
Phylogenetic and recombination analysis
Short introduction to phylogenetic trees and networks Phylogenetic trees are graph-
ical representations of the inferred evolutionary history of genes or organisms (taxa or
operational taxonomic unit, OTU). The joining of two branches implies a common evo-
lutionary origin. Various algorithms have been developed to infer a phylogenetic tree,
from distance-based methods to Maximum Likelihood (ML) and Bayesian approaches.
Distance based methods calculate a distance metric which measure how dissimilar
each pair of taxa are to each other. The simplest measure of distance is called p-distance
and is the number of nucleotide differences per site. However, in the case of recurrent
mutations, this model underestimates the true genetic distance, as it solely depends on
the observed states in the data. For this reason, genetic distances are inferred under some
evolutionary model which takes these scenarios into account.
The simplest model is the Jukes-Cantor-Model, also referred to as JC69 (Jukes and Can-
tor, 1969). Here, all base frequencies are assumed to be equal (i.e. 0.25) as are the substi-
tution rates between bases. Slightly more complex are Felsenstein’s F81 model (Felsen-
stein, 1981), which allows for varying base frequencies, and the K80 model (Kimura,
1980), which takes into account different rates between transitions (A to G and C to T, i.e.
purine to purine and pyrimidine to pyrimidine substitutions) and transversions (pyrim-
idine to purine or the other way around). The HKY85 model combines the two latter
models by allowing both for unequal base frequencies as well the distinction between
transitions and transversions (Hasegawa, Kishino, and Yano, 1985). A further extension
from here is the TN93 model (Tamura and Nei, 1993), where in addition two cases of tran-
sitions (purine and pyrimidine transitions) are allowed to have varying rates. The most
complex model, is the GTR (generalised time-reversible) model (Tavaré, 1986), where all
parameters are free, i.e. varying rates for every kind of substitution, no matter whether it
is a transversion or transition, as well as variable base frequencies.
One common distance based method to infer a phylogenetic tree is the Neighbor join-
ing (NJ) algorithm. It assumes at the beginning a star-like topology of the tree without
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FIGURE 2.1: The split network on the left represents the two conflicting
phylogenetic trees on the right. (After Lemey, P., Salemi, M., and Van-
damme, 2009)
internal branches. Internal branches are introduced by joining taxa A and B together in
such a way that the length of the internal branches (and by that the total length of the
tree) is minimised. The length of the joining branch to A is dependent on the average
distance of all taxa to A minus the average distance of all remaining taxon pairs.
Distance based methods usually result only in one tree. Maximum Likelihood meth-
ods, on the other hand, calculate different tree topologies and try to find the optimal or
best-fitting tree. As the names states, their optimality criterion aims to find the most likely
tree, i.e. it considers the probability that a certain tree topology could have given rise to
the observed data given an evolutionary model. There are different heuristic search al-
gorithms to find the tree, but they are all generally quite computationally expensive.
However, they deliver a statistical framework to evaluate the support of branches.
Phylogenetic trees make the assumption that the underlying evolutionary process
can be explained as a linear, tree-like process (Huson, 1998). In the case of recombination,
however, a number of different tree topologies might be suitable to support the data,
as recombination allows the exchange of whole fragments between taxa (for example
different virus isolates of the same viral species). Phylogenetic networks are therefore
a better way of representing this kind of data. However, their conception can be quite
varied, but are defined by Huson and Bryant, 2006 as any network in which taxa are
represented by nodes and their evolutionary relationship by edges. Thus, it includes
phylogenetic trees as a special case. Other types can be split networks, which depict in-
compatible or ambiguous signals within the data through parallel edges. Internal nodes
do therefore not necessarily represent ancestral species. Hence, these networks can be
seen as "implicit" representation. In reticulate networks, on the other hand, additional
edges connecting "conventional" tree branches describe a putative evolutionary history,
i.e. internal nodes do represent ancestral species. This makes these networks an "explicit"
phylogenetic representation (Huson and Bryant, 2006).
Construction of phylogenetic trees If not stated otherwise, phylogenetic trees were
generated using the program raxml, which uses a Maximum Likelihood approach under
the GTR model of nucleotide substitution and the Gamma model of rate heterogeneity
with a rapid bootstrap analysis of 500 runs.
Chapter 2. Materials & Methods 40
Split network Split networks were generated in Splitstree4 using the uncorrected p-
distance and the NeighborNet algorithm (Huson and Bryant, 2006). It represents a set of
incompatible splits from the data.
Testing for presence of recombination A test for the presence of recombination is the
PHI-test, which is simple and robust. It is able to distinguish between recurrent muta-
tions and recombination in various circumstances (Bruen, Philippe, and Bryant, 2006).
The test statistic Φw (or PHI, pairwise homoplasy index) is based on the notion of com-
patability/incompatability between sites. A pair of sites is compatible if their genealog-
ical history can be explained without involving homoplasies (convergent or recurrent
mutations) or recombination events. Φw is based on the calculation of the a mean incom-
patibility score between nearby sites up to w bases apart, and can be interpreted as the
minimum number of homoplasies that are needed in any tree to explain the history of
the pair of sites (Bruen, Philippe, and Bryant, 2006).
The test was both employed on the whole genome alignment of 83 type 1 sequences,
various subsets of SNPs, see Chapter 4, as well as in a sliding window approach across
the whole genome alignment in windows of 100 bp with PhiPack (Bruen, Philippe, and
Bryant, 2006).
Determination of recombination breakpoints Recombination may bias the estimation
of dN/dS (i.e. the ratio of synonymous to nonsynonymous substitution rates) as a mea-
sure for molecular adaptation at the codon level by increasing the number of false pos-
itively selected sites (Anisimova, Nielsen, and Yang, 2003). It is therefore important to
take into account the effect of recombination prior to conducting selection analysis. This
can be done by determining the recombinant fragments, for which then individual phy-
logenetic trees are reconstructed. Using the relevant tree for each fragment, dN/dS ratios
are then estimated separately for every region (see section "Selection analysis") (Pérez-
Losada et al., 2015).
To detect possible recombination breakpoints, the GARD algorithm (Kosakovsky Pond
et al., 2006) which is part of the HyPhy v.2.2 package (Pond, Frost, and Muse, 2005) was
used.
GARD (Genetic Algorithm Recombination Detection) works by identifying whether
there is phylogenetic incongruence in a multiple sequence alignment and allows thereby
the detection of more than one recombination breakpoint. It splits the alignment into a
growing number of non-recombining fragments, reconstructs a phylogenetic tree for ev-
ery fragment and uses then the small sample Akaike’s Information Criterion to evaluate
the goodness-of-fit and choose the best model. The best breakpoints are determined ei-
ther exhaustively (for two fragments) or heuristically (for more than two) (Kosakovsky
Pond et al., 2006).
The coding sequences (CDS) of all ORFs (repeats excluded) were scanned for recom-
bination breakpoints prior to selection analysis. In cases of recombination, alignments
were split at the estimated breakpoints under consideration of the reading frame.
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Analysis of linkage disequilibrium
Linkage disequilibrium (LD) is the non-random association of alleles. It can be influenced
by various factors, such as selection, the physical linkage between sites and recombina-
tion. Because recombination is more likely to occur between two distant sites, there is a
negative relationship between LD between two sites and their physical distance between
them. In other words, recombination reduces the LD between two sites.
Different measures for LD exist. A common measure is the the square of the corre-
lation coefficient between the occurrence of different nucleotides at different sites. It is
defined as
r2 =
D2
pA(1− pA)pB(1− pB)
with
D = pABpab − paBpAb.
Conventionally, pA is the frequency of nucleotide A at the first site and pB the fre-
quency of B at the second site etc. pAB is the allele frequency with nucleotide A present
at the first site and B present at the second (Balding, Bishop, and Cannings, 2007; Haydon,
Bastos, and Awadalla, 2004). Lower case a and b signify the second nucleotide present at
the respective sites.
Significance of the association can be assessed using the relationship between the test
statistic of the contingency table test, X2, and r2
X2 = nrˆ2
where X2 is asymptotically χ2 distributed with one degree of freedom. However, for
small samples sizes n, the χ2 is unlikely to hold (Balding, Bishop, and Cannings, 2007),
which is why in the case of our data set we chose a different test for LD.
Across the whole genome The whole genome alignment of type 1 sequences was re-
stricted to its 5,190 biallelic sites where maximally one sequence was missing. LD was
analysed between all possible combinations of biallelic SNPs. The significance of LD was
assessed using Fisher’s Exact test on the 2 × 2 contingency table, with a pair of SNPs
being significantly associated if p < 0.05 under Bonferroni correction.
Detection of local clusters of LD In order to detect local signatures of linkage, a sliding
window approach was used. Here, the p-values of a window were compared to the
distribution of p-values drawn from the genome-wide set of comparisons with a Mann-
Whitney-Wilcoxon U test. This “null distribution“ of p-values was created by sampling
the diagonal ribbon of the genome-wide association matrix with a quantile-function in
order to create a representative sample of the same size as the window.
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Using windows of varying size based on a fixed number of biallelic SNPs is problem-
atic because the masked repeat regions increased the window sizes dramatically. Addi-
tionally, we found a correlation between the biallelic SNP density and the power of the
test (Pearson’s correlation test with r=0.14 and p = 1.06e-05). In consequence, windows
of a fixed size of 1,400 bp were used in which 20 biallelic SNPs were uniformly sampled.
This size is a trade-off between having enough statistical power across the genome and
resolution (figure 2.2).
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FIGURE 2.2: Genome map of linkage disequilibrium. LD score, computed
in 1400 bp windows across the genome (WT reference coordinates). Values
above 5 (circa top 5% values) are highlighted in red. The background is
grey for areas of no data, and pink for polymorphism density of less than
20 biallelic SNPs per 1400 bp window, indicating a drastically reduced test
power.
2.3.3 Gene network analysis
Short introduction to graph theory In order to understand the linkage between SNPs
better, one can represent this as a network which can in turn be understood as graphs.
A graph G is defined as a pair (V,E) where V is a set of vertices (or nodes) and E is
a set of edges which connect nodes, defined as E = {(i, j)|i, j ∈ V }. When two nodes i
and j are connected with an edge, they are called neighbours.
Graphs can be either undirected or directed. In the latter case, the graph G is defined
as an ordered triplet G = (V,E, f) with f being a function that maps each edge in E to a
ordered pair of vertices in V . In this work, however, we focus on undirected graphs.
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A graph G can also be weighted. In that case, the set of edges E is associated with
a weight function w : E → R. This can be interpreted as the relevance of a connection
between two nodes.
Network of linked genes A network was constructed and analysed with the R pack-
age igraph (Csardi and Nepusz, 2006), where each node represents an ORF. An edge
between two nodes was drawn if there was at least one pair of nonsynonymous SNPs in
LD between them. The edges were weighted by a linkage score based on the number of
linked nonsynonymous SNPs between two ORFs normalized for the ORF and genome
lengths. The n × n matrix where n is the number of nodes containing all linkage scores
between nodes i and j if there is an edge and 0 if there is no edge is called the adjacency
matrix A.
The nodes of the network were divided into two sets of nodes, a) those ORFs known
to encode antigens (immunogenic, IG) and b) those that do not (non-immunogenic, NIG).
This classification was based on the experimentally confirmed antigens found in the IEDB
database (Immune Epitope Database), with restriction to those antigens whose epitopes
have been confirmed by at least two studies.
In order to identify important subgraphs/nodes, several methods were used:
Hierarchical clustering was performed using the distance matrix D = 1−A, where A
is the adjacency matrix (linkage score).
Another concept to rank nodes and thereby identifying important nodes in a network
is centrality. There are two main notions how to interpret "importance". One notion
relates to the flow or transfer across the network (not further considered here), the other
one relates to the involvement of nodes in the cohesiveness of the network. There are
many different centralities defined on different properties. Degree centrality is a ranking
nodes based on their degree, closeness centrality ranks based on the average shortest path
from a certain node to all other nodes and betweenness centrality ranks those nodes higher,
that act as a bridge along the shortest paths between two other nodes.
Instead we chose eigenvector centrality, which measures the influence of a node in a
network. In contrast to ranking nodes based on their degree, a node can have a high
eigenvector centrality even if it is not highly connected. Instead, this node might have
few, but important neighbours. The basic idea is therefore that influential nodes are in-
fluential, because they are connected to other influential nodes. (This notion is related to
Google’s PageRank algorithm.)
Given an adjacency matrix A = (ai,j) of a network, the eigenvector centrality xi of
node i with k neighbours is defined as
xi =
1
λ
∑
k
ak,ixk
where λ 6= 0 is a constant. This means, the centrality of the node i is the ith component
of the first eigenvector x of A and the relation can be written as Ax = λx. Because all
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entries in the eigenvector are required to be non-negative, only the largest eigenvalue
λmax fulfills this (Pavlopoulos et al., 2011).
2.3.4 Population structure analysis
The population structure was analysed with structure v2.3.4 (Pritchard, Stephens, and
Donnelly, 2000) using the automisation and parallelisation pipeline strauto v1.0 (Chhatre
and Emerson, 2016).
Structure is a clustering method to infer population structure based on multilocus
genotype data. It assumes the existence of k populations, to which individuals are prob-
abilistically assigned. It also allows for individuals to be of admixed genetic background,
in which case they are assigned to more than one population. The assumption of the
model is that within populations loci are unlinked and in Hardy-Weinberg equilibrium.
Structure was run ten times for every k ranging from 1 to 10 with the admixture
model and the correlated allele frequency model. The outputs are cluster member co-
efficient matrices, which contain the admixture proportions for each individual. To infer
the number k clusters that best fits the data, the likelihood values of the models were
assessed using Evanno’s method (Evanno, Regnaut, and Goudet, 2005) as implemented
in structure harvester (Earl and VonHoldt, 2012). This ad hoc approach estimates the num-
ber of clusters k using the statistic ∆k, which is based on the rate of change in the log
probability of the data between successive k values.
Because structure is based on stochastic simulation, every replicate run can result in
different outcomes. Cluster labelling is random, i.e. what is called "cluster A" in replicate
1 can be "cluster C" in another replicate. Results for the best fitting k were therefore
further analysed with CLUMPP (Jakobsson and Rosenberg, 2007) using the FullSearch
algorithm, which permutates the cluster member coefficients of the result matrix of every
replicate run such that replicate runs match each other as closely as possible. It also
outputs the mean of the permuted matrices across replicates. The program distruct was
then used to visualise results (Rosenberg, 2004).
2.3.5 Selection analysis
Considering the results from the recombination analysis, genes were then tested for the
presence of detectable selection. Two tests were employed: Tajima’s D, using the R pack-
age pegas, and codeml from the paml package v4.8 (Yang, 2007).
Tajima’s D Tajima’s D is a summary statistic method calculated over the whole gene,
whose test statistic considers the relative frequency of polymorphic sites (Tajima, 1989).
The observed values from an alignment are compared to the expected values assuming
a null model of neutral evolution. This null model makes a number of assumptions: all
mutations are either lethal or neutral, a constant effective population size and mutation
rate, no recombination or migration, random mating and an infinite sites model, i.e. each
mutation occurs at a different site. The test statistic D is defined as follows
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D =
θΠ − θS√
V ar(θΠ − θS)
where θΠ is the average number of pairwise differences (reflecting individual se-
quence divergence) and θS the number of segregating sites (reflecting population diver-
sity). Both parameters are estimators for the population genetics parameter θ. If all as-
sumptions of the null model of neutral evolution are met, they are expected to result from
the same underlying processes (genetic drift) and their difference and in consequence D
is zero. Selection, however, (and other violations of the null model assumptions) affects
the values of the respective θ estimators, causing D to be non-zero. Depending on the
direction of deviation from zero, different inferences can be made about evolutionary
forces acting on a gene. Significance of D was assessed at a threshold of α = 0.05 under
assumption of a beta distribution (Tajima, 1989).
Positively selected sites with codeml The second selection test employed detects spe-
cific sites within a gene that are under positive selection (positively selected sites, PSS)
using a Maximum Likelihood approach using the program codeml (Yang, 2007). A mea-
sure of selection is dN/dS, the ratio non-synonymous to synonymous substitution rates,
also termed ω. Values <1, =1 and >1 indicate purifying selection, neutral evolution and
positive selection, respectively.
Model p Parameters
M0 (one ratio) 1 ω
M1a (neutral) 2 p0, (p1 = 1− p0),
ω0 < 1, ω1 = 1
M2a (selection) 4 p0, p1, (p2 = 1− p0 − p1),
ωo < 1, ω1 = 1, ω2 > 1
M7 (beta) 2 p, q
M8 (beta &ω) 4 p0, (p1 = 1− p0),
q, p, ωS > 1
TABLE 2.9: Site-wise codon models used from the codeml program.
p is the number of free parameters in the ω distribution (parameters in
brackets are not free).
Input for this program are the codon corrected CDS alignments (or recombinant frag-
ments) and their respective ML trees. Branch lengths of nucleotide trees represent esti-
mated nucleotide substitutions per nucleotide site. To estimate the branch lengths as the
number of nucleotide substitutions per codon site, model M0 was applied first.
Using site-wise models that allow ω to vary among codons, four models were tested
in two pairs against each other in a likelihood-ratio test (LRT) (Anisimova, Bielawski,
and Yang, 2002; Yang and Swanson, 2002): The M1a-M2a comparison tests a model of
nearly neutral evolution (ω either <1 or =1) against a model of positive selection (ω can be
<1, =1 and >1); The M7-M8 comparison tests two models where ω is assumed to follow
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a beta distribution, which is bounded by 0 and 1, with M8 adding an additional class
of sites with a free ω parameter, allowing for positive selection. The alternative model
(M2a or M8) was considered to be a better fit with the Likelihood ratio test (LRT) with a
significance threshold of α = 0.05. Given a significant model for positive selection, the
Bayes empirical Bayes (BEB) criterion was used to calculate the posterior probability of
each site to be under positive selection. Hence, sites with P > 95 % were considered to
be PSS.
2.3.6 T cell epitope prediction
MHC binding prediction 
 incl allele variants
top 1% ranked peptide 
candidates containing a 
PSS
prediction of binding 
properties for mutant allele 
for epitope candidates for 
HLAs common in Europe
IC50 of ANN and SMM 
< 50 nM      high 
< 500 nM    intermediate 
< 5000 nM  low affinity
FIGURE 2.3: Scheme for epitope prediction.
T cell epitopes are peptides, usually derived from pathogens, that are presented on
major histocompatibility complex (MHC) molecules and elicit a T cell mediated immune
response. In humans, the MHC is also called human leukocyte antigen (HLA).
The IEDB analysis resource consensus tool was used to predict MHC binding for
MHC class II (Wang et al., 2008; Wang et al., 2010a) and MHC class I (Kim et al., 2012) for
selected EBV proteins that contain PSS. The consensus tool combines predictions from a
number of algorithms (ANN (Nielsen et al., 2003; Lundegaard et al., 2008), SMM (Peters
and Sette, 2005) and comblib (Sidney et al., 2008)). For the prediction, the HLA allele ref-
erence set was used which comprises the most common HLA alleles and is representative
of commonly shared binding specificities (Vita et al., 2014).
Protein sequences including variant alleles were used as input for the prediction. The
top 1% peptides from the MHC binding prediction were screened whether they con-
tained one of the previously determined sites under positive selection. If so, the effect
of observed variations of the PSS were compared regarding their binding properties as
reflected by the estimated IC50 value to HLA alleles common in Europe. Peptides were
considered to be putative high affinity epitope candidates if there was a difference be-
tween variants. A rule of thumb as given by IEDB is that IC50 values <50 nM are high,
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<500 nM intermediate and <5000 nM low affinity (Immune Epitope Database; Sette et al.,
1994).
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Chapter 3
The application of target enriched
whole genome sequencing of EBV to
clinical blood samples
3.1 Introduction
Whole genome sequencing (WGS) of viruses allows the study of genetic variants that
have an impact on disease development. It enables to assessment of intra- and interhost
population structures, low-level drug resistance, and transmission. Moreover, WGS en-
ables the identification of sites that are under selection, e.g. through host interactions.
On a greater scale, WGS gives a comprehensive picture of variation across the genome,
and allows study of populations on a local and global scale, and gives insight into the
evolution of the viruses within patients.
Sequencing directly from clinical samples, however, is challenging as host DNA is
present in vast excess to viral DNA. Direct sequencing of clinical samples in which path-
ogens are present leads to proportional representation of sequence reads derived from
virus and host, but is only feasible in situations where virus is naturally present at ex-
tremely high titres, e.g. tumours in the case of EBV (Hsieh et al., 2007). This approach
often requires large quantities of clinical material for successful virus genome recovery
(Liu et al., 2011).
For this reason, several standard techniques are applied to enrich for the virus prior
to sequencing, including in vitro culturing or amplification via polymerase chain reaction
(PCR). Both methods can introduce novel polymorphisms that may bias results. PCR in
particular has a higher error rate in low titre samples as more PCR cycles are needed to
generate sufficient material for sequencing. For example, the high fidelity polymerase
Phusion has a low error rate of 4.4 × 10−7 to 9.5 × 10−7 (compared to e.g. Taq poly-
merase with 2.28× 10−5), but this still leads to 1.32 to 2.85 % of DNA molecules contain-
ing an error after 30 cycles for a 1 kb template (according to manufacturer’s data). In a
comparative study of genome amplification methods, PCR has been found to introduce
the highest bias (Pinard et al., 2006). Additionally, repeat regions, secondary structures
and locally high GC-content can be PCR-inhibitory. Large genomes, such as those from
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herpesviruses, are particularly problematic. Although technically possible, a large num-
ber of overlapping PCRs are required to span the whole genome and additional primer
sets are needed in case of diverse genotypes or general high diversity. Recombination
of co-amplified DNA molecules that are genetically distinct is another known problem,
leading to artificial recombinants (Liu et al., 2014). Moreover, detection of minority vari-
ants can be hampered by uneven amplification across the genome (Houldcroft, Beale,
and Breuer, 2017).
In the case of EBV, establishing a lymphpoblastoid cell line (LCL) may introduce a bias
towards viral strains that most effectively immortalise B cells, thereby losing information
about intrahost variation. Additionally, passaging may introduce other new genetic vari-
ations in the form of point mutations, deletions or genomic rearrangements. This has
been described in CMV, for example (Dargan et al., 2010), but also the first sequenced
genome of EBV, B95-8 (Baer et al., 1984) which was cultured in a marmoset B cell line
and exhibited a large non-canonical deletion spanning the BamHI A fragment (de Jesus,
2003).
Targeted enrichment is a novel technique originating from exome sequencing, where
specific regions of interest are selected for prior to deep-sequencing. This method was
first adapted and applied to viral genome sequencing by Depledge et al., 2011 and has
since been used for a number of distinct DNA and RNA viruses (Kwok et al., 2015; Palser
et al., 2015; Depledge et al., 2014; Christiansen et al., 2017; Hage et al., 2017) as well as
other pathogens (Melnikov et al., 2011; Brown et al., 2015; Christiansen et al., 2014) to se-
quence directly from clinical samples. This method has the advantage of using relatively
few PCR cycles, the preservation of minor variant frequencies as seen in vivo (Depledge
et al., 2014) and the possibility of automation (Depledge et al., 2011). However, costs for
this method are high and it is by design limited to pathogens with known genomes.
Here, I will demonstrate the utility of target enrichment on clinical EBV samples by
comparing and contrasting multiple protocols as well as the manual versus the auto-
mated preparation of samples. The focus will be on blood samples, which represent
both the serum and lymphocyte compartment of EBV infection. These samples are from
paediatric patients from two settings: immunocompromised transplant recipients and
infectious mononucleosis. Both patient groups have elevated EBV titres in the blood
compared to asymptomatic, healthy carriers, and are therefore ideal candidates to adapt
target enrichment of EBV for WGS from blood. Sequencing directly from blood elim-
inates the need of culturing EBV prior to sequencing while also allowing the study of
EBV from clinical settings that are non-malignant.
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3.2 Results
3.2.1 Shearing efficiency of episomal DNA
The first step in the SureSelect protocol is the shearing of the DNA sample via ultrasoni-
cation, with a target fragment size of 150 to 200 bp. SureSelect was originally developed
for exome sequencing, i.e. of DNA from long, linear chromosomes. The episomal nature
of EBV DNA could potentially lead to less efficient shearing. While fragment size dis-
tribution is checked as a standard quality control step after shearing with a bioanalyzer,
the human DNA in excess might mask if the viral DNA is not sheared properly. A sim-
ple PCR-based assay was therefore designed to test this. Primers were designed for the
EBV episome using two forward primer and four reverse primers generating fragments
in approx. 250 bp, 500 bp, 1 kb, and 2 kb size. A PCR was performed on sheared and
non-sheared DNA samples of the EBV-infected cell line JSC-1.
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FIGURE 3.1: Shearing experiment. *: 100 bp ladder; **: 1 kb ladder.
Figure 3.1 shows the result of this PCR. All fragments could be detected in the non-
sheared DNA samples, as expected (marked with an arrow). In the sheared DNA sample,
the small fragments of 200 and 500 bp length could still be detected. The 1 kb fragment
band was only faint, indicating that less of the product has been amplified, while the 2 kb
product could not be detected at all. This indicates that larger fragments of the episome
are either only present in smaller amounts or absent in the sheared sample, and confirms
the typical fragment size distribution on a bioanalyzer chip (figure 3.2): a peak around
200 bp, a tail around 500 bp, and barely any signal for larger fragments.
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FIGURE 3.2: Typical fragment size distribution after shearing of genomic
DNA.
This shows that episomal DNA is as efficiently sheared as long, linear DNA molecules.
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3.2.2 Targeted enrichment of a EBV+ cell line (JSC-1)
In order to verify and test the bait set used to select for EBV-specific reads, DNA from the
cell line JSC-1 was enriched for EBV sequences using the manual SureSelect protocol with
3 µg of input DNA and sequenced on an Illumina MiSeq. Reads were quality controlled
and assembled against the type 1 reference genome (NC_007605, here referred to as WT).
In total, 979,674 paired-end reads were obtained of which 656,700 were EBV-specific.
This makes an on target read (OTR) percentage of 67 %, showing that enrichment worked
very well. 97.3 % of the genome was covered with depth >20x with a mean depth of
approximately 1000. Figure 3.3 shows the coverage plot, depicting the number of reads
mapped across the genome.
Coverage is uneven across the genome. Many areas of low coverage correspond to
the major repeat regions (shaded areas in the coverage plot). These areas cannot be confi-
dently assembled or mapped given the short read lengths of Illumina sequencing. Reads
are often shorter than the genomic repeats, meaning these short reads can map at multi-
ple locations. Thus in all analyses of EBV genomes, these areas will be masked for this
reason.
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FIGURE 3.3: Number of mapped reads (coverage) against the WT reference
of JSC-1 reads. Areas of low coverage often correspond to repeat regions
shaded in grey.
3.2.3 Targeted enrichment of EBV from blood extracts
The targeted enrichment approach was applied to a first batch of different DNA ex-
tracts from blood of one immunocompromised, paediatric transplant patient from the
UK. Prior to enrichment, samples were subjected to whole genome amplification (WGA).
The enrichment protocol was the manual protocol with 3 µg input of DNA.
Table 3.1 lists the samples, viral loads and respective read counts as well as OTRs. It
was not possible to retrieve full genomes, as all samples had <1000 OTR, which amounted
to only 0.01 % to 0.03 % of EBV-specific paired-end reads, suggesting that enrichment
failed.
While viral titres were not low in clinical terms, the titres were too low for successful
enrichment as effectively only 30 to 1700 viral copies would be contained in 3 µg input
material. Therefore, six additional DNA blood extracts from six immunocompromised
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Sample Viral load Read pairs OTR OTR %
[copies/ml] pairs
ebv1 22,000 1,110,989 259 0.02
ebv2 25,000 1,887,738 332 0.02
ebv3 1000 2,145,258 734 0.03
ebv4 34* 2,553,556 342 0.01
ebv5 6000 2,012,518 229 0.01
TABLE 3.1: Sample and sequencing information for blood DNA samples.
Read pairs: total number of read pairs from the sequencer. OTR: on target
reads, the number of paired-end reads mapped to EBV, without duplicate
reads; *: CT value of the PCR product
children with a higher viral load were chosen. They were treated the same (manual 3 µg
protocol). Table 3.2 lists the sample and sequencing data.
Sample Viral load Read pairs OTR OTR %
[copies/ml] pairs
ebv6 943,000 805,280 956 0.12
ebv7 445,000 739,987 1,768 0.24
ebv8 1,200,000 903,760 4,885 0.54
ebv9 >2,000,000 1,047,922 14,661 1.40
ebv10 1,400,000 821,088 4,406 0.54
ebv11 710,000 1,356,031 5,765 0.43
TABLE 3.2: Sample and sequencing information for blood DNA samples
with higher viral loads.
Viral loads for all samples were one to two orders of magnitude higher and enrich-
ment improved as OTR percentages increased by one to two orders of magnitude. The
highest OTR % was found in sample ebv9 with 1.4 % of paired-end reads mapping to
EBV, which might be reflective of the extremely high viral load (only a minimum value
of greater than 2 million copies/ml is available for this sample). However, compared to
other herpesviruses previously sequenced in our group using SureSelect, OTR percent-
age was still far lower relative to viral load (personal communication with J. Breuer). For
sequencing VZV from blood, for example, using the same 3 µg protocol, OTR percentage
was 71 % (Depledge et al., 2011).
Varying amount of DNA input
As mentioned before, SureSelect was originally designed for exome sequencing. The
application of this method to virus WGS, however, is quite different as non-target DNA
is present in such vast excess. It was therefore investigated, whether the input in terms
of total number of viral copies is more important for enrichment success than the input
in terms of total amount of DNA.
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FIGURE 3.4: Ratio of viral versus human DNA at different steps in the
SureSelect protocol on a logarithmic scale. Values at the end of the bars
represent the actual (non-logarithmic) ratios.
Sample ebv9 was therefore treated with the 3 µg SureSelect protocol using either 3 µg
and 5 µg total input DNA. At every important step of the protocol viral and human loads
were determined by qPCR to identify steps in which viral copies might be potentially lost
and to assess success of enrichment. These steps are: pre-capture (i.e. prior to hybridis-
ation for enrichment) (1) before and (2) after the PCR step, and (3) post-capture after the
final PCR amplification.
Figure 3.4 shows ratio of viral to human DNA at the three steps during the SureSelect
protocol. Pre-capture, human DNA is present in excess compared to viral DNA (3 to
7-fold more human copies than viral ones). Here, the pre-capture PCR step decreases
the difference between viral to human DNA, and a greater decrease can be observed in
the sample using 3 µg total DNA input. Enrichment reversed the ratio in both samples.
Using around 1.6 times more total DNA input resulted in a 10-fold enrichment increase.
That is more than would be expected and could be due to a PCR bias leading to an in-
crease in duplicate reads.
DNA Read pairs OTR OTR %
input pairs
3 µg 225,627 20,786 9.21
5 µg 167,964 18,635 11.09
TABLE 3.3: Sample and sequencing information for ebv9 with varying in-
put amounts of DNA into the SureSelect protocol.
The final libraries were sequenced on a MiSeq. Table 3.3 shows the sequencing data.
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In accordance with the qPCR results, using more input DNA resulted in a higher per-
centage of reads mapping to EBV, but the difference was not as stark as in the qPCR, as
only approximately 1.2 % more reads mapped to EBV. This means that using 1.6 times
more DNA input (and consequently also viral copies) resulted in an approximate 1.2-fold
increase of OTR percentage. This suggests that using more total DNA input than the rec-
ommended protocol is not detrimental, and that the total number of viral copies in the
input is an important factor for enrichment success.
Effect of WGA and controlling for loss
As clinical material is often scarce, a standard method for amplification of genomic mate-
rial is WGA with Phi29 DNA polymerase, where random primers are used in a non-PCR
reaction. I therefore wanted to test the effect of WGA with SureSelect on success of en-
richment.
An additional source of problems for enrichment is loss of genetic material. The first
part of the protocol (library preparation) contains numerous washing steps; at each of
them, around 20 % of material is estimated to be lost (according to manufacturer’s in-
formation). Because the number of viral genomes is a determining factor for success of
capture, it was tested whether more viral copies are being lost during library preparation
than would be expected.
To test this with a larger number of samples, the qPCR experiment from the section
above was repeated for the remaining samples (ebv6, -7, -8, -11; there was not enough
material left for ebv10) with fresh extracts of whole blood from the same patients. Due
to scarcity of clinical material, the standard amount of 3 µg of input DNA was used. The
qPCR was performed in duplicates for every sample collected at each of the three major
protocol steps (as described above).
Previously, these samples were subject to WGA (table 3.2). Here, all four samples
were used directly without WGA. While a comparison of the effect of WGA with the
previous run would be possible, in order to account for preparation variability (see be-
low), two of the samples were additionally treated with WGA in this experiment (ebv8G,
ebv11G).
Viral loads were also measured for the fresh extracts. Table 3.4 shows the number of
EBV genome copies that went into the SureSelect protocol. To account for the loss in the
library preparation, which consists of four clean up steps, actual and expected total copy
numbers were calculated, assuming that 20% are being lost at each of the four clean-up
steps. For ebv6, the deviation from the expected value was greater with one order of
magnitude, although it still fell within the range of one standard deviation (SD) of the
actual number. But this SD of the actual copy number is fairly large due to a higher SD
of the measured Ct value (>0.3), suggesting the actual copy number is not very accurate.
For all other samples, the actual number of copies fell within the range of the expected
number of copies (and all samples had an acceptable SD of the Ct value). This highlights,
that the clean up steps are critical, but also suggests that they are not necessarily biased
towards a more preferential loss of viral material.
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Sample # copies in 3 µg exp. # copies # copies SD
ebv6 34,000 16,000 8,000 10,000
ebv7 32,000 13,000 19,000 11,000
ebv8 40,000 16,000 15,000 6,000
ebv11 31,000 13,000 11,000 2,000
TABLE 3.4: Expected and actual number of EBV copies pre-capture/pre-
PCR assuming a maximum 20 % loss during each of the four clean up
steps. SD: standard deviation of qPCR quantity determination.
Figure 3.5 shows the ratio of viral to human load at different protocol steps for ebv8
and ebv11 with and without WGA. For ebv8, the WGA-treated sample was less enriched
in EBV sequences (1.5-fold difference). After sequencing, however, a higher percentage of
paired-end reads mapped to EBV from the WGA-treated sample (1.66 % versus 0.77 %,
table 3.5). This is surprising and might be be due to PCR duplicates which have been
removed from the mapping.
The qPCR determining human loads for the post-capture/post-PCR step failed for
both ebv11 samples and ratios could not be calculated. Viral loads for these samples are
153,348 copies/ml for ebv11 without WGA and 127,589 copies/ml with WGA. This is not
very meaningful in terms of enrichment success though, as concentrations differ. In the
final sequencing, only 0.08 % more paired-end reads mapped to EBV in the WGA-treated
sample (0.3 % versus 0.22 %, table 3.5).
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FIGURE 3.5: Ratio of viral versus human DNA at different time steps on
a logarithmic scale. The two samples ebv8 and ebv11 have been used di-
rectly or treated with genome amplification (WGA) after extraction. Values
at the end of the bars are the actual (non-logarithmic) mean ratios for all
samples. Ratios for the post-capture step for ebv11 are missing values, not
zero (see text).
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Sample Read pairs OTR OTR %
pairs
ebv6 2,071,862 22,694 1.10
ebv7 3,099,870 30,028 0.97
ebv8 1,541,928 11,913 0.77
ebv8G 2,092,063 34,796 1.66
ebv11 2,658,858 5,785 0.22
ebv11G 2,511,284 7,586 0.30
TABLE 3.5: Sample and sequencing information for blood samples en-
riched without and with WGA (samples marked with a G).
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FIGURE 3.6: Average ratios of viral versus human DNA at different time
steps on a logarithmic scale. Values at the end of the bars are the actual
(non-logarithmic) mean ratios for all samples. Standard deviation marked
by whiskers.
Figure 3.6 shows the average ratios of viral to human load of all other samples. Pre-
capture, ratios were very similar across samples (SDpre−PCR = 0.0024, SDpost−PCR =
0.0028) . The post-capture ratios had a greater variability between samples (SDpost−capture =
15.72). Ultimately, this shows that enrichment worked for all of them, but OTR output
per individual sample is still fairly poor compared to other herpesviruses (table 3.5).
When comparing the OTR percentages of ebv6, -7, -8 and -11 of this SureSelect run
(table 3.5) with the previous run (table 3.2), they varied. Samples ebv6, -7, and -8 had
higher OTR percentages in run 2, but ebv11 had a lower value. One difference between
the runs is the prior WGA of run 1, while run 2 was sequenced directly without WGA.
However, another factor to account for is variability during the protocol execution. There
can be variability between SureSelect runs: for example, the hybridisation step in the
manual protocol, during which the samples are treated directly on a 65oC cycler, is very
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sensitive to time and handling of the plates as evaporation affects its efficiency. While
utmost care was taken during the preparation of the samples, the relative contribution of
human error and variability likely differs between runs (i.e. practice makes perfect).
As ebv8 and ebv11 are only two samples treated in the same run with and without
WGA, whether the effect of WGA solely on enrichment is positive or negative is hard
to determine here. On the one hand, it is useful to amplify the amount of DNA avail-
able when dealing with scarce clinical material. On the other hand, there is a danger of
introducing bias, e.g. amplification of contaminant DNA present in kits, or non-specific
extension of random primers. Even though the reaction is supposed to be nonspecific, a
small but significant bias in amplification for any form of WGA has been shown (Pinard
et al., 2006). In a recent comparison of WGA kits and their contaminant effect, the Illus-
tra Genomiphi V2 kit (also employed here) had the largest amount of nonspecific back-
ground reads (Thoendel et al., 2017). WGA in conjunction with SureSelect was previously
tested for bias for WGS of VZV. In this study, no bias was found regarding both the con-
sensus sequence and the population structure (Depledge et al., 2014). However, VZV has
generally a far lower GC content than EBV (46 % versus 60 %), making the application of
WGA amplification possibly less problematic, as it has been found that Phi29 polymerase
efficiency is linked to regional GC content (Bredel et al., 2005) and leads to misrepresen-
tation of GC regions (Arriola et al., 2007). In consequence of all of these consideration, it
was decided to forego WGA if possible (i.e. if enough material available), as the benefits
do not outweigh the risks.
Varying amount of RNA baits for capture
It was tested whether the carry-over of nonspecific DNA can be reduced by decreasing
the amount of baits used in the hybridisation reaction. The rationale behind this is that
enrichment works well in conditions where there are fewer baits than template DNA.
Having more baits than template DNA, however, could lead to a large amount of non-
specific binding to non-target DNA, leading to a dilution of the OTR.
For this, DNA from three additional blood samples of immunocompromised paedi-
atric patients was extracted and used in the 3 µg SureSelect protocol. Dependent on the
total amount of DNA available after the first PCR step for each sample, different number
of hybridisation reactions were set up. The standard amount of tier 1 RNA baits is 2 µl
(which was estimated to contain 50k-100k copies of each individual bait, personal com-
munication D. Depledge). Sample ebv13 was hybridised with 2 and 0.5 µl, ebv14 with 2,
1 and 0.5 µl, and ebv15 with 2 and 0.5 µl baits.
Table 3.6 lists the sample and sequencing information. For every sample, reducing the
number of baits increased the OTR percentage. Using 0.5 µl instead of 2 µl increased OTR
percentage from 1.3-fold (ebv14) up to 1.8-fold (ebv13). This suggests that the ratio of
baits and template has an influence on efficiency and that using less baits is advantageous
for WGS of pathogens from clinical samples, where target template is scarce.
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Sample Viral load Baits [µl] Read pairs OTR OTR %
[copies/ml] pairs
ebv13 > 2,000,000 2 2,842,761 69,410 2.44
0.5 3,209,553 143,600 4.47
ebv14 > 2,000,000 2 3,009,397 534,177 17.75
1 3,172,899 656,110 20.68
0.5 3,260,671 758,340 23.26
ebv15 1,300,000 2 3,091,208 30,771 1.00
0.5 2,763,682 38,512 1.39
TABLE 3.6: Sequencing data of the bait dilution experiment using the 3 µg
protocol.
SureSelect 200 ng protocol
In the beginning of 2014, Agilent provided a new protocol for SureSelect which allowed
a lower amount of input DNA (200 ng). Principal modifications in the protocol were
1) to shear in a lower volume (50 µl instead of 130 µl), which allowed the removal of one
purification step, and 2) the dilution of the adapters in order to maintain the optimal ratio
for ligation.
Using DNA extracts of whole blood of immunocompetent, paediatric infectious mono-
nucleosis patients from Japan, the 200 ng and 3 µg protocol were compared while also
testing varying dilutions of RNA baits. The DNA samples were provided by Tetsushi
Yoshikawa (Department of Pediatrics, Fujita Health University School of Medicine, Toyo-
ake, Japan).
Independent of the protocol, dilution of baits improved the OTR percentage in three
of four cases with an increase ranging from 1.4-fold to 3.6-fold, while the OTR percentage
was retained in the other single case (table 3.7). The OTR percentage in three of four cases
was increased in the 200 ng protocol (comparison of samples treated with the same bait
dilutions). Only in one case was the OTR percentage lower in the 200 ng protocol than in
the 3 µg protocol (P2-1246 with 1 µl baits).
Sample Viral load Protocol Baits [µl] Read pairs OTR OTR %
[copies/µg] pairs
P2-1213 125,000 3 µg 1 1,974,835 1,157 0.06
0.1 2,344,993 1,436 0.06
200 ng 1 1,497,801 3,778 0.25
0.1 2,214,579 7,548 0.34
P2-1246 14,000 3 µg 1 1,968,292 1,247 0.06
0.1 144,649 205 0.14
200 ng 1 2,138,754 885 0.04
0.1 1,795,753 2,710 0.15
TABLE 3.7: Sequencing data of the bait dilution experiment using the 3 µg
and 200 ng protocol.
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The viral load data of these samples were provided as copies/µg of DNA, making a
comparison with the OTR data dependent on viral load from previous analysed samples
of immunocompromised patients hard.
While there are less viral genomes in the starting material of 200 ng DNA, the protocol
has one less clean up step, saving approximately 20 % of DNA. OTR percentages being
higher in most cases with the 200 ng protocol as well as when diluting baits supports
the rationale that increasing the ratio of target to bait improves SureSelect performance
through a more favourable hybridisation, in particular in samples with low target titres.
Together, these data support the use of the 200 ng protocol and bait dilutions. It allows
to use less clinical material in addition to saving reagents.
Automation system
In June 2014, the lab acquired an Agilent Bravo automation system, on which the whole
library preparation including capture is performed. It also allows the preparation of up
to 96 samples per run instead of the 12-16 sampling using a manual approach. 20 DNA
extracts from whole blood from eleven immunocompetent, Japanese IM patients (part of
the same data set as above, see table 2.1) underwent library preparation and the 200 ng
SureSelect protocol with a bait dilution of 1:10 (0.2 µl) on the automation system. Final
libraries were then sequenced on a MiSeq.
Table 3.8 shows the sample and sequencing data of the first runs. In a previous experi-
ment, two samples of the same original sample set – P2-1213 and P2-1246 – were prepared
manually (table 3.7. Their viral loads were approximately 125,000 and 14,000 copies/µg,
respectively. Samples from this experiment here with a similar viral load are P1-812
and P4-2274 (114,000 and 139,000 copies/µg) as well as P3-2740 and P7-2315 (17,000 and
10,000 copies/µg). The OTR percentages for all four samples prepared on the automa-
tion system are several fold higher compared to the respective sample of similar viral
load from the manual run (6.38 % and 16.18 % compared to 0.34 %, and 0.83 and 1.17 %
compared to 0.15 %). This could be due to a more homogeneous treatment of samples, as
they were prepared in parallel rather than sequentially.
These data shows that performance is at least as good as the manual protocol and
support the use of the automation system for SureSelect.
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Sample Viral load Read pairs OTR OTR %
[copies/µg] pairs
P1-812 114,000 1,901,552 121,401 6.38
P3-2670 250,000 1,836,143 148,897 8.11
P3-2740 17,000 1,573,383 13,131 0.83
P4-2274 139,000 1,717,515 277,885 16.18
P4-2392 34,000 899,732 13,653 1.52
P5-1294 60,000 1,539,674 81,563 5.30
P5-1323 7,000 1,747,803 11,587 0.66
P6-1751 50,000 1,916,406 147,200 7.68
P6-1789 350 1,811,779 1,040 0.06
P7-2315 10,000 1,617,971 18,878 1.17
P7-2634 24,000 1,138,767 20,707 1.82
P8-414 22,000 1,814,167 282,930 15.60
P8-516 9,000 1,480,851 31,102 2.10
P9-2631 63,000 1,631,433 178,955 10.97
P9-2645 38,000 1,451,477 102,018 7.03
P10-2187 4,000 1,712,846 4,248 0.25
P10-2777 210 1,299,344 1,783 0.14
P11-871 24,000 1,703,065 242,028 14.21
P12-1026 3,000 1,428,766 25,066 1.75
P12-1078 1,000 1,743,347 1,089 0.06
TABLE 3.8: Sequencing data of infectious mononucleosis samples pre-
pared on the automation system.
OTR vs. viral load
To demonstrate the relationship between OTR percentage (and therefore genome se-
quencing success) and viral input, all sequenced samples from blood extracts of immuno-
compromised patients (data set presented in this chapter as well as chapter 5, table 5.4
and table 5.1) were plotted (figure 3.7). The IM samples were excluded from this graph,
as their viral titres were provided in a different unit.
Black symbols represent samples for which a whole genome with at least 20x coverage
could be recovered, while grey symbols represent the samples for which that was not the
case. Samples, for which viral loads were given as >2,000,000 are plotted at 2,000,000, but
marked as a white symbol. Triangles and circles refer to the 3 µg and 200 ng protocol,
respectively.
Viral load and OTR are correlated (R2 = 0.9). Samples with higher viral titres result
in a higher number of EBV-specific reads, independent of the protocol. According to
this graph, the limit of this method lies between 20,000 and 40,000 copies/ml. For lower
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FIGURE 3.7: On target reads (OTR, percentage of EBV-specific reads) as a
function of the viral load when sequencing with targeted enrichment from
whole blood extracts. Grey: Samples where the whole genome could not
be recovered. Black: Samples where the whole genome (>90 %) could be
recovered. White: Genomes could be recovered, but no accurate viral load
was given (>2,000,000); triangles: 3 µg protocol; circles: 200 ng protocol.
viral loads, enrichment and sequencing success appears stochastic and may be strongly
influenced by the sample type, DNA quality and relative amount of virus present.
3.2.4 Final assemblies of first blood-derived EBV genomes
To obtain the final assemblies of the blood-derived EBV genomes from immunocompro-
mised patients, reads were pooled from the different SureSelect experiments. They were
processed and assembled using de novo assembly pipeline 1 (chapter 2). Samples ebv1-5
and -11 all had too few OTR and were discarded.
In total, seven full genomes could be recovered directly from clinical blood samples.
Table 3.9 lists the sample data as well as sequencing and assembly data for the com-
bined assemblies. As some samples have been sequenced more often than others, read
numbers and depth differ between samples. The average read depth is given after re-
moval of duplicate reads and ranged from ≈ 45 to ≈ 3700, although uneven across the
genome (figure 3.8). The dominant peak observed in many of the samples is not due
an over-representation of reads because of homology with human genomic areas, as a
blastn search against the human nucleotide database did not deliver any significant hits;
it corresponds to the viral IR1 repeat and results from reads derived from each repeat
unit mapping to a smaller condensed assembled version in the primary de novo consen-
sus sequence. In the final consensus sequence, this area – together with the other major
repeat regions – was extended to the length of the repeat in the WT genome but masked
with ’N’ for subsequent analyses due to their accurate assembly being precluded by short
Illumina reads.
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Sample Viral load Read pairs OTR % Depth Cov
[copies/ml]
ebv6 944,000 4,150,874 1.6 45 95
ebv7 445,000 6,208,600 1.4 57 98
ebv8 1,200,000 7,277,442 1.8 129 95
ebv9 >2,000,000 5,509,174 9.8 438 100
ebv13 > 2,000,000 12,110,184 4.1 472 100
ebv14 > 2,000,000 18,894,696 24.9 3650 100
ebv15 1,295,000 11,715,202 1.4 154 99
TABLE 3.9: Sample information and assembly statistics of seven blood-
derived EBV genomes from immunocompromised children. Depth: Aver-
age read depth after removal of duplicated reads. Cov: Percentage of the
genome that could be recovered at min. 20x (excluding repeat regions).
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Figure continues on the next page.
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FIGURE 3.8: Coverage plots of immunocompromised patient samples af-
ter duplicate removal. Mapping is done against the sample consensus se-
quence directly after assembly (i.e. repeat regions are not masked or con-
sidered specifically).
To discriminate as to whether samples were type 1 and type 2, the genetic distance of
the typing genes EBNA2 and -3A-C to the type 1 and 2 reference strains (figure 3.9) was
calculated. All samples belonged to type 1 as distance for each gene was always lowest
to the type 1 reference.
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FIGURE 3.9: Genetic distance (K80 model) of EBNA2 and -3 genes of sam-
ples of immunocompromised patients from the UK to type 1 (WT) and
type 2 (AG876) reference sequences.
3.2.5 Comparison of blood-derived vs. tumour/LCL-derived EBV genomes
As these were the first EBV genome sequences derived directly from blood, the ques-
tion arose whether they exhibit any genetic differences to LCL- or tumour-derived EBV
genomes. To address this, a whole genome multiple alignment was created using these
seven genomes supplemented with all published type 1 sequences (marked with a black
circle in table 1.2).
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Analysis of genetic variability revealed no significant differences were found in con-
sensus sequences between the tumour/LCL-derived and blood circulating EBV genomes.
They displayed a similar average number of SNPs and hotspots of diversity are in the
same areas as previously described. Figure 3.10 shows the nucleotide diversity across
the genome separately for blood- (n=7), tumour- (n=46) and LCL (non-malignant, n=29)-
derived sequences. High diversity areas correspond to the known polymorphic genes
EBNA2, EBNA1, LMP1. Note that the higher peaks for the blood-derived genomes is an
artefact from the far lower number of sequences. This also applies for the peak around
59,000 nt, corresponding to the BOLF1 gene, which has a large proportion of missing data
in the blood sequences, reducing the number of sequences (and therefore comparisons)
even further.
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FIGURE 3.10: Nucleotide diversity calculated in sliding windows (size
200 bp, step size 50 bp) for different groups of sequences. Green: blood-
derived sequences (n=7), violet: tumour-derived sequences, orange: LCL-
derived sequences (from non-malignant settings). Positions refer to the
WT genome. Major repeat regions are excluded.
Table 3.10 shows the average pairwise distances within group of sequences. The aver-
age pairwise distance is lowest for blood, followed by LCLs and highest in tumours. The
set of tumour sequences contains a number of Chinese NPC-derived sequences which are
known to differ most from other genomes. Pairwise distances have therefore also been
calculated for the tumour-derived genomes for the NPC and non-NPC tumour subsets.
The distance between non-NPC samples is with 0.0056 closer to both blood and LCLs,
while the NPC samples are as expected for more similar to each other. This suggests
that the higher average pairwise distance for all tumours results from a sampling effect
(i.e. inclusion of a group of very distant sequences), and is not due to a generally higher
diversity within tumour-derived versus blood-derived sequences.
No polymorphisms were found limited solely to virus circulating in blood. This is
supported by the finding that sequences derived from blood did not cluster separately in
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Dist SD
Blood 0.0051 0.0014
Tumour 0.0063 0.0023
LCL 0.0055 0.0024
Tumour - NPC 0.0033 0.0028
Tumour - non-NPC 0.0056 0.0021
TABLE 3.10: Average pairwise distances between genomes derived from
blood, tumours and LCLs (non-malignant settings), calculated using the
K80 distance model. SD: standard deviation.
a whole-genome based PCA (figure 3.11, blood-derived samples are marked by a white
circles). Here, principal components (PC) 1 and PC2 discriminate between Asian and
non-Asian genomes, whereas PC2 and PC3 as well as PC3 and PC4 discriminate between
some of the African, and the Western and Asian genomes. (The same PCA is shown in
supplementary figure A.1 with all sampled labelled by their geographic origin.) Also
in higher principal components, accounting for less percent of total variation, samples
never clustered based on their compartmental origin.
The latency genes LMP1, LMP2, EBNA1, EBNA2, and EBNA3A-C are functionally
important in establishing and maintaining latency. In addition several are oncogenes.
The PCA of these gene sequences revealed no discernible difference between blood-
derived and tumour-derived EBV genomes. Figure 3.12 (left panel) shows that the se-
quences recovered directly from whole blood are never specifically discriminated from
other genomes. Instead, they frequently cluster with other LCL- or tumour-derived
genomes. The right panels of figure 3.12 show unrooted Neighbor joining (NJ) trees of
these genes. They do not depict the evolutionary relationship between the samples, but
should be interpreted as a simple distance-based clustering to complement the PCA plot.
The figure depicts only the first two PCs, but the non-segregation was also observed for
higher components examined.
In figures 3.11 and 3.12, samples derived from IM patients (usually transformed LCLs)
are also specifically marked (grey triangles) as examples of isolates from non-cancerous
pathologies. However, LCL-derived IM samples could never be discriminated (together
with the blood-derived samples or on their own) by the PCA.
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FIGURE 3.11: PCA of whole genome sequences for type 1. Specifically
marked are blood-derived samples (white circles) and isolates from IM pa-
tients (grey triangles). The bar plot in every corner shows the eigenvalues
for every principal component (PC), i.e. their influence on the variation
of the data. The colouring is an RGB translation of each sequence’s PCs
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and 3.11c shows PC3 against PC4. The histogram in the corner of each
PCA plot shows the distribution of eigenvalues (i.e. contribution) of the
PCs from left to right, with plotted PCs being highlighted.
Chapter 3. The application of target enriched whole genome sequencing of EBV to
clinical blood samples
67
WT
Akata
GD1
GD2
HKNPC1
K4
12
3−
Mi
K4423−M
i
M81
Mu
tu
eb
v1
3
eb
v1
4
ebv15
ebv6
ebv7
ebv8
ebv9
KF
99
25
64
KF
99
25
65
KF992566
KF992567
KF
99
25
68
KF
99
25
69 KF992570
KF992571
LN
82
41
42
LN824203
LN824204
LN824205
LN8
242
07
LN
82
42
09
LN824224
LN824225
LN82
4226
LN82752
2
LN827523
LN827
524
LN827525
LN
82
75
26
LN827527
LN827545
LN827546
LN827547LN
82
75
49
LN8
275
50
LN827551
LN
827
552
LN827553
LN827555
LN8
275
58
LN827559
LN827561
LN8275
62
LN827564
LN
82
75
65
LN
82
75
66
LN827567
LN
82
75
68
LN827569
LN82
7570
LN
82
75
71
LN827572
LN
82
75
73
LN8
275
74
LN827575
LN827576
LN
82
75
77
LN827578
LN
827
579
LN
827
581
LN
82
75
82
LN827583
LN827584
LN
82
75
85
LN827586
LN827588
LN827
590
LN827592
LN827593
LN
82
75
94
LN827595
LN82
7596
LN827597
LN827799
● ●
●
●
●
●
●
NJ tree of EBNA1
−3 −2 −1 0 1
−2
.5
−2
.0
−1
.5
−1
.0
−0
.5
0.
0
0.
5
1.
0
PC1 (48.48%)
PC
2 
(2
1.
47
%
)
●●
●
●
●
●
ebv134ebv15ebv6ebv7
ebv8
ebv9
● Blood
IM
 Eigenvalues 
PCA of EBNA1 
 axes 1−2
(A) EBNA1
−1.5 −1.0 −0.5 0.0 0.5 1.0 1.5
−3
−2
−1
0
PC1 (41.53%)
PC
2 
(2
6.
21
%
)
●
●
●
●
●ebv13
ebv14
ebv15
ebv6ebv7
● Blood
IM
 Eigenvalues 
PCA of EBNA2 
 axes 1−2
WT
Ak
at
a GD1
GD2
HK
NP
C1
K4123−Mi
K4423−Mi
M81
Mutu
ebv13
ebv14
ebv
15
ebv6
ebv7
KF
99
25
64
KF99
2565
KF992566
KF992567
KF9
925
68
KF
992
569
KF992570
KF9
9257
1
LN
82
41
42
LN
824
203
LN824204
LN824205
LN
82
42
07
LN
82
42
09
LN
82
42
24
LN
82
42
25
LN8
242
26
LN827522
LN827523
LN8275
24
LN8275
25
LN827526
LN827527
LN
82
75
46
LN
82
75
47
LN
82
75
49
LN827550
LN
827
551
LN827552
LN
82
75
53
LN82
7555
LN827558
LN
82
75
59
LN827561
LN827562
LN827564
LN827565
LN827566
LN827567
LN827568
LN
82
75
69
LN
82
75
70
LN827571
LN
82
75
72
LN827573
LN827574
LN827575
LN827576
LN
82
75
77
LN827578
LN827579
LN827581
LN827582
LN827583
LN827584
LN827585
LN
82
75
86
LN827588
LN827590
LN
82
75
92
LN827593
LN827594
LN
82
75
95
LN827596
LN8
2759
7
LN
82
77
99
●
●
●
●
●
NJ tree of EBNA2
(B) EBNA2
Figure continues on the next page.
Chapter 3. The application of target enriched whole genome sequencing of EBV to
clinical blood samples
68
WT
Ak
ata
GD1
GD
2
HK
NP
C1
K4123−Mi
K4
42
3−
M
i
M8
1
Mutu
ebv13
eb
v1
4
ebv15
eb
v6
eb
v7
ebv8
ebv9
KF
99
25
64
KF
99
25
65
KF
992
566
KF
99
25
67
KF99
2568K
F992
569
KF
99
25
70
KF
99
25
71
LN
824
142
LN824203
LN
82
42
04
LN
82
42
05
LN824207
LN8
242
09LN8
242
24
LN8
2422
5
LN
82
42
26
LN827522
LN8
275
23
LN827524
LN
827
525
LN
82
75
26
LN827527
LN
82
75
45
LN827
546
LN8
275
47
LN827549
LN827550
LN827551
LN827552
LN8275
53
LN827555
LN827558
LN827559
LN827
561
LN827562
LN827564
LN827565
LN827566
LN827567LN827568
LN827569
LN82
7570
LN827571
LN827572
LN827573
LN827574
LN
82
75
75
LN827576
LN827577
LN827578
LN827579
LN827581
LN827582
LN827583
LN827584
LN827585
LN827586
LN
82
75
88
LN827590
LN8
275
92
LN827593LN827594
LN827595
LN827596
LN827597
LN827799
●
●
●
●
●
●
●
NJ tree of EBNA3A
−3 −2 −1 0 1 2 3
−4
−3
−2
−1
0
1
PC1 (24.77%)
PC
2 
(2
1.
41
%
)
●
● ●
●
●
●
ebv13
ebv14 ebv15ebv6
ebv7
ebv8ebv9
● Blood
IM
 Eigenvalues 
PCA of EBNA3A 
 axes 1−2
(C) EBNA3A
WT
Akata
GD1
GD2
HKNPC1
K4123−Mi
K4
42
3−
M
i
M81
Mutu
ebv13
ebv14
eb
v1
5
eb
v6
eb
v7
ebv8
eb
v9
KF992564
KF992565
KF992566
KF992567
KF
99
25
68
KF
992
569KF992570
KF992571
LN
82
41
42
LN824203
LN824204
LN824205
LN824207
LN
82
42
09
LN8
242
24
LN824225
LN82
4226
LN82752
2
LN
82
75
23
LN827524
LN827525
LN827526
LN827527
LN
82
75
45
LN827546
LN8
275
47
LN827549
LN827550
LN827551
LN8
275
52
LN
82
75
53
LN
827
555
LN827558
LN827559
LN827561
LN827562
LN82
7564
LN827565
LN827566
LN
82
75
67
LN827568
LN
82
75
69
LN
82
75
70
LN827571
LN827572
LN8275
73
LN827574
LN
82
75
75
LN
82
75
76
LN
82
75
77
LN827
578
LN827579
LN827581
LN8
2758
2
LN827583
LN827584
LN827
585
LN8
275
86
LN
82
75
88
LN827590
LN827592
LN
82
75
93
LN827594
LN
82
75
95
LN827596
LN
827
597
LN827799
●
●
●
●
●
●
●
NJ tree of EBNA3B
−1 0 1 2 3 4
−4
−3
−2
−1
0
1
2
3
PC1 (28.57%)
PC
2 
(1
7.
95
%
)
●
●
●
●
●
ebv13
ebv14
ebv15
6
ebv78ebv9
● Blood
IM
 Eigenvalues 
PCA of EBNA3B 
 axes 1−2
(D) EBNA3B
Figure continues on the next page.
Chapter 3. The application of target enriched whole genome sequencing of EBV to
clinical blood samples
69
−3 −2 −1 0 1 2 3
−2
−1
0
1
2
PC1 (25.3%)
PC
2 
(2
0%
) ●
●
●
●
●
ebv13
ebv14
ebv15
ebv6
ebv7
ebv8
ebv9
● Blood
IM
 Eigenvalues 
PCA of EBNA3C 
 axes 1−2
W
T
Akata
GD1
GD2HKNPC1
K4
12
3−
M
i
K44
23−
Mi
M81
Mu
tu
ebv13
ebv
14
ebv15
eb
v6
ebv
7
ebv8
ebv9
KF992564KF992565
KF992566
KF992567
KF992568KF992569
KF992570
KF992571
LN
824
142
LN824203
LN8
242
04
LN824205
LN824207
LN824209LN824224
LN824225
LN824
226
LN8275
22
LN827523
LN827524
LN827525
LN82
7526
LN
82
75
27
LN
82
75
45
LN827546
LN827547
LN827549
LN
82
75
50
LN827551
LN
82
75
52
LN827553
LN827555
LN
82
75
58
LN827559
LN82756
1
LN827562
LN827
564
LN
82
75
65
LN
82
75
66
LN82
7567
LN
82
75
68
LN827569
LN827570LN
82
75
71
LN827572
LN
82
75
73
LN
82
75
74
LN
82
75
75
LN
827
576
LN827577
LN82
7578
LN
82
75
79
LN
82
75
81
LN
82
75
82
LN
82
75
83
LN827584
LN827585
LN827586
LN
82
75
88
LN8
275
90
LN827592
LN8
275
93
LN827594
LN827595
LN8
2759
6
LN827597
LN827799
●
●
●
●
●
●
●
NJ tree of EBNA3C
(E) EBNA3C
−3 −2 −1 0 1 2
−1
0
1
2
3
4
5
PC1 (42.13%)
PC
2 
(1
4.
58
%
)
●
●
●
●
●
●
●
ebv13
ebv14ebv15
ebv6
ebv7
ebv8
ebv9
● Blood
IM
 Eigenvalues 
PCA of LMP1 
 axes 1−2
WT
Ak
at
a
GD1
GD
2H
KN
PC
1
K4123−M
i
K4423−Mi
M8
1
Mu
tu
ebv13
ebv14
ebv15
ebv6
eb
v7
ebv8
ebv9
KF99
2564
KF9
925
65
KF99
2566
KF992567
KF992568
KF
99
25
69
KF
99
25
70
KF
99
25
71
LN
82
41
42
LN8242
03
LN
82
42
04
LN
82
42
05
LN824207
LN
82
42
09
LN82422
4
LN824225
LN824226
LN827522
LN827523
LN827524
LN
82
75
25
LN827526
LN827527
LN
82
75
45
LN827546
LN827
547
LN
82
75
49
LN82
7550
LN827
551
LN8
2755
2
LN827553
LN827555
LN8
275
58
LN827559
LN
82
75
61
LN827562
LN827564
LN8
275
65
LN
827
566
LN827567
LN
82
75
68
LN827569
LN827570
LN
82
75
71
LN827572
LN
82
75
73
LN
82
75
74
LN827575
LN827576
LN
827
577
LN827578
LN827579LN
82
75
81
LN827582
LN827583
LN827584
LN
82
75
85
LN827586
LN827588
LN827590
LN827592
LN827593
LN827594
LN827595
LN827596
LN827597
LN827799
●
●
●
●
●
●
●
NJ tree of LMP1
(F) LMP1
Figure continues on the next page.
Chapter 3. The application of target enriched whole genome sequencing of EBV to
clinical blood samples
70
WT
Akata
GD1
GD2
HKNPC1
K4
12
3−
Mi
K4423−Mi
M81
Mutu
ebv1
3
eb
v1
4
ebv15
eb
v6
eb
v7
eb
v8
eb
v9
KF992564
KF992565
KF992566
KF992567
KF992568
KF992569
KF992570
KF992571
LN824142
LN
824
203
LN
82
42
04
LN8
242
05
LN
82
42
07
LN824209
LN824224
LN
82
42
25
LN8
242
26
LN
82
75
22
LN
82
75
23
LN827524
LN827525LN
82
75
26
LN827527
LN
82
75
45
LN
82
75
46
LN827547
LN827549
LN827550
LN
827
551
LN827552
LN827553
LN82
7555
LN827558
LN
82
75
59 LN827561
LN8
2756
2
LN
82
75
64
LN827565
LN827566
LN827567
LN
827
568
LN827569
LN
82
75
70
LN827571
LN8275
72
LN827573
LN
82
75
74
LN827575
LN827
576
LN827577
LN827578
LN8
275
79LN8
275
81
LN827582
LN827583
LN827584
LN827585
LN827
586
LN827588
LN827590
LN827592
LN827593 LN
82
75
94
LN827595
LN
82
75
96
LN8
275
97
LN82779
9
●
●
● ●
●
●
●
NJ tree of LMP2
−4 −3 −2 −1 0 1
−1
.5
−1
.0
−0
.5
0.
0
0.
5
1.
0
1.
5
PC1 (50.3%)
PC
2 
(9
.8
1%
)
●
●
●
●
●
●
●
ebv13
ebv14
ebv15
ebv6
ebv7
ebv8
ebv9
● Blood
IM
 Eigenvalues 
PCA of LMP2 
 axes 1−2
(G) LMP2
FIGURE 3.12: Left Panel for subfigures 3.12a-3.12g: PCA results for the
first two principal components (PCs) of the latency genes. The first two
PCs do not distinguish between EBV sequences from natural infection
vs. tumours, nor do any of the higher principal components (data not
shown). Specifically marked are the non-cancerous samples, i.e. blood-
derived samples (white circles) and isolates from IM patients (grey trian-
gles). The bar plot in every corner shows the eigenvalues for every prin-
cipal component (PC), i.e. their influence on the variation of the data. The
colouring is an RGB translation of each sequence’s PCs scores. The his-
togram in the corner of each PCA plot shows the distribution of eigenval-
ues (i.e. contribution) of the PCs from left to right, with plotted PCs being
highlighted.
Right Panel for subfigures 3.12a-3.12g: Simple clustering based on a Neigh-
bor joining (NJ) tree of the latency genes.
3.3 Discussion
3.3.1 Optimisation of SureSelect for EBV sequencing from whole blood
Here, the SureSelect protocol was optimised to enrich DNA extracts from blood for EBV
prior to WGS. The method was first described for viral genome sequencing by Depledge
et al., 2011. The sequences described here are the first EBV whole genome sequences
sequenced directly from blood. Other published genomes have been sequenced either
from tumour tissue or cell cutures - with the exception of one saliva sample (Palser et al.,
2015) - where viral titres are generally a lot higher.
The SureSelect protocol is a nascent method and has been repeatedly updated through-
out the study. The data presented here indicate that protocols using 200 ng of input DNA
produce better outcomes than those using 3 µg, despite having less total viral genomes
in the starting material. This is beneficial as it saves precious clinical material. More
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importantly, it was found that diluting the RNA baits during the hybridisation-based en-
richment increases the proportion of EBV-specific reads, particularly when viral loads are
low. Both factors should result in a increasingly favourable ratio between baits and tar-
get DNA during hybridisation, which allows for more efficient binding and reduces the
carry-over of non-target sequences. This has an additional advantage of reducing costs
associated with library preparation.
Independent of the protocol used, the success of target enrichment is highly depen-
dent on the viral load (figure 3.7), with a higher proportion of viral DNA leading to more
EBV-specific reads in the final library. The current minimal threshold of detection found
in this work lies between 20k-40k EBV genomes/ml. This threshold is less for other
herpesviruses (personal communication with J. Breuer), possibly due to intrinsic features
of the viruses’ genomes (e.g. GC content). In the future, this might be further improved
to a point through improved reagents. The threshold of detection is also partly linked
to the technical limits within the protocol (i.e. loss during purification and statistical dis-
tribution of correctly ligated adapters). However, this also highlights the importance of
knowing exactly how much virus is present in the starting sample, in particular if re-
ceiving samples from other institutions, in order to choose the appropriate protocol and
sequencing platform.
Generally, coverage was found to be uneven across the genome. This is partly due to
the intrinsic nucleotide composition of the EBV genome. For example, the overall GC-
content is around 60 % (Kwok et al., 2012; Lei et al., 2013). But in some regions, GC
content exceeds 80 %, which can reduce efficiency and bias negatively the PCR steps in-
volved, and make it more likely that independent of the sample quality, certain genomic
regions might be missed.
An additional source of variability in outcome could be the genetic distance of the
strains present in the sample from the references used in bait design. For this reason, the
EBV RNA bait set was updated in 2015, the new design taking into account the increased
variation observed in more recent genome sequencing studies (see chapter 2).
Independent of these intrinsic factors, OTR outcome can vary between runs and be-
tween samples due to human error and sequential processing, especially during critical
steps. In this regard, the automation system reduces the variation during the preparation
allowing for greater consistency in results. Moreover, it has the advantage of allowing
high throughput preparation of samples, saving both cost and time.
3.3.2 Differences between EBV genomes derived from blood versus tumours
and LCLs
Previously published EBV genomes have, with a single exception, been derived from ei-
ther tumours or LCLs (Palser et al., 2015). However, establishing an LCL may introduce
a bias towards viral strains that most effectively immortalise B cells. Additionally, pas-
saging virus may introduce new mutations. Moreover, tumour-derived genomes may
contain genome alterations that are not representative of naturally circulating strains, ei-
ther due to selection processes for strains that are (more) oncogenic, or because the virus
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persists now in an altered cell environment where selection pressures differ (e.g. replica-
tion via massive clonal expansion of B cells rather than lytic replication).
In the analyses presented here, however, no blood-specific genetic variations were
detected and the PCA analysis did not identify any discernible differences between EBV
genomes derived from blood versus tumours/LCLs (on the SNP level). This indicates a
lack of detectable differential selective pressure in either cell culture, tumour or naturally
circulating virus. Moreover, widening the subset to genomes most representative of nat-
ural infection (i.e. including IM-derived LCLs) did not change the observed results either.
Instead, these results confirm the previous finding of geographical segregation through
the three first principal components (Palser et al., 2015). The geographic signals, how-
ever, might also override signals relating to compartmentalisation, and even sampling of
different regions and compartments would be necessary to answer these questions. In
addition, variation between compartments due to different modes of replication, might
be more likely reflected on the minority level. This is further explored in chapter 5.
The same rationale holds for the identification of malignancy-associated variations.
As many strongly EBV-associated malignancies show geography-dependent incidence
rates (e.g. BL, NPC), it is hard differentiate between variation due to geography versus
malignancy. However, this work has established EBV sequencing directly from blood,
enabling whole genome studies to compare both tumour and blood-derived genomes
from specific high incidence areas, allowing the disentanglement of these variables and
the identification of potential disease associated variations.
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Chapter 4
Comparative genomic analysis of
world-wide EBV strains
4.1 Introduction
EBV is a world-wide distributed virus infecting only humans, whose divergence time
from other γ-herpesviruses has been estimated to be 90-100 million years ago (McGeoch
et al., 1995). This indicates a close coevolution for a long period of time with humans and
their related primates and ancestors.
Whole genome sequencing of viruses gives comprehensive information about diver-
sity and consequently can also be used to determine the phylogenetic relationships be-
tween samples, identify areas of the genome under selection and elucidate how the virus
population is structured.
The first EBV genome, strain B95-8, was published in 1984 (Baer et al., 1984). It
was isolated from a North American infectious mononucleosis patient, and served as
the backbone of what is used as the reference genome for EBV now, by filling a non-
representative 11 kb deletion with a segment derived from the Raji sequence in 2003 (de
Jesus, 2003). This marks the beginning of actual EBV genome sequencing, as more and
more sequences have slowly been published since then. GD1 and GD2, both from South
Chinese NPC patients, were published in 2005 and 2011, respectively, with GD2 being
the first strain to have been sequenced by NGS technology. AG876 was the first type 2
genome, derived from a Ghanian Burkitt’s lymphoma in 2006 (Dolan et al., 2006). In
2012, two Burkitt’s lymphoma derived genomes were sequenced, Akata from Japan and
Mutu from Kenya (Lin et al., 2012). In 2013, four more genomes were published: two
sLCL derived sequences from the USA, K4123-Mi and K4413-Mi, and a NPC isolate from
Hong Kong, M81 (Lei et al., 2013; Tsai et al., 2013) and C666-1, a NPC cell line (Tso et al.,
2013).
Finally, the introduction of target capture (Depledge et al., 2011) allowed a dramatic
increase of genomes, with nine more NPC derived genomes published in 2014 (Kwok
et al., 2014) and 71 genomes from various geographic origins and malignancies in 2015
(Palser et al., 2015). Moreover, three nearly complete genomes were constructed using
the data of the 1000 Genomes Project (Santpere et al., 2014) and 12 Burkitt’s lymphoma
isolates from Ghana, Brazil and Argentina (Lei et al., 2015). The large number of genome
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sequences now available from various geographic origins as well as different tumour and
tissue types allows a comprehensive comparative analysis.
In this chapter, results of a comparative genomics analysis of seven whole genome
EBV sequences derived from blood described in the previous chapter 3 as well as 76
type 1 EBV genome sequences which became available in Genbank at the time of this
study are presented.
There are several questions: How are genomes altered by evolutionary forces? Are
there biological correlates of these evolutionary forces? What is the phylogenetic rela-
tionship between strains and how is this related to population structure?
4.2 Results
4.2.1 Data set
The data set consisted of 76 type 1 EBV whole genome sequences available in Genbank
(marked sequences in table 1.2), comprising samples from various geographical regions
and pathologies. It was further increased by sequencing EBV from whole blood ex-
tracts of pediatric, immunocompromised patients from the UK. In total, seven full EBV
genomes were recovered directly from blood (see chapter 3, table 3.9).
All analyses presented in this chapter have been conducted on consensus genome
sequences. The major repeat regions FR, IR1, IR2/NotI, IR3, IR4/PstI and TR have been
masked throughout the analysis.
In total, the data set is comprised of sequences derived from circulating and oncogenic
virus genomes from Europe, North America, Australia, Africa and East Asia.
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4.2.2 Genome-wide recombination analysis
Ascertaining the evolutionary relationship between the seven sample sequences and pre-
viously published sequences by calculating a phylogenetic tree is difficult. A PHI-test
(Bruen, Philippe, and Bryant, 2006) found significant evidence for recombination (p < 0.05)
and a genome-wide PHI-profile scan revealed areas of significant recombination through-
out the genome (figure 4.1). The presence of numerous parallel edges between branches
in a split network confirms this, as they depict incompatible or ambiguous signals within
the data (figure 4.2). Consequently, recombination has to be carefully considered and
whole genome tree topologies are likely to be affected by it.
A useful way to assess recombination on a greater scale is to consider linkage disequi-
librium (LD), i.e. the correlation between the occurrence of polymorphisms at different
loci in the genome (Haydon, Bastos, and Awadalla, 2004). Two loci are considered to be in
LD when they occur together more often then would be expected from a random distri-
bution of allele frequencies. There are several factors influencing LD, e.g. genetic linkage
(due to physical proximity), selection and recombination. LD will be lower for example
if there is recombination occurring between two sites. As it is more likely for recombi-
nation to occur between distant sites, there is a negative relationship between estimated
LD of two biallelic sites and the physical distance between them (Balding, Bishop, and
Cannings, 2007).
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FIGURE 4.1: Profile plot of p-values of the PHI-test across the genome.
The PHI-test was conducted in windows of 1000 bp with a step size 25 bp
for all type 1 sequences. The blue line marks the significance threshold of
α = 0.05. In other words, all peaks lower than the blue line mark areas
of the genome that show evidence of recombination. Repeat regions are
marked in grey.
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FIGURE 4.2: Split network of the whole genome alignment of type 1 se-
quences. Taxa are colour-coded based on their geographic origin. Blue:
Asian sequences; Green: African sequences; Red and Pink: Europe and
America; Orange: Australia. Genomes derived from blood and saliva are
marked with a red *.
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Evidence of genome-wide linkage-disequilibrium
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FIGURE 4.3: Heatmap displaying the significant Bonferroni-corrected p-
values of Fisher’s Exact test as measure of LD between biallelic sites that
are at least once in LD with another site. Insignificant results (p < 0.05) is
white. The darker colour indicates smaller p-values. Axis values refer to
coordinates of every 100th biallelic site.
Figure 4.3 shows the level of LD throughout the genome as measured by Fisher’s Exact
test for all biallelic sites. In total, 88,787 pairs of loci were found to be in LD, which are
comprised of 1,857 individual sites of the 5,190 biallelic sites analysed. There are 81,525
pairs with at least one site being located in an ORF and 49,718 pairs where both sites fall
within ORFs. Of these, there are 8,038 pairs where both sites are synonymous, 23,172
pairs with at least one nonsynonymous site and 18,508 pairs where both sites lead to
nonsynonymous changes.
Figure 4.4 depicts the distribution of (corrected) p-values as a measure of LD depend-
ing on the distance between two linked sites. According to this, our test measure is not
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overly dependent on distance between two linked sites, i.e. we find equally statistically
"strong" LD between sites very far apart as well as closer together. Only very proximate
sites (in 0-1 kb distance of each other) show a noticeably lower distribution of p-values.
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FIGURE 4.4: Distribution of p-values of Fisher’s Exact test for all pairs in
LD over site pair distance. The distance between two sites in LD has been
binned into distance classes of 1 kb size.
From figure 4.3 it can be seen that LD is being detected throughout the genome, even
between sites very far apart. This long-range LD is counterintuitive given the evidence
of pervasive recombination (figure 4.1). Focusing on the subset of sites that are in LD
with each other (n=1,857), recombination networks (supplemental figure B.1, B.2, B.3)
and PHI-test (all sites in LD: p < 0.05, all nonsynonymous sites in LD: p < 0.05, all syn-
onymous sites in LD: p < 0.05) still gave evidence for recombination occurring within
these subsets. Similarly, filtering the alignment for pairs of SNPs that are strongly in LD
with each other based on a p-value threshold, did not diminish the signal of recombina-
tion (PHI-test for sites in LD with thresholds smaller than 0.01, 0.02 and 0.00005: p < 0.05;
supplemental figures B.4, B.5, B.6).
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Population structure of EBV
I therefore investigated whether this pattern of linkage can be explained by an under-
lying population structure, potentially of mixed genetic background (i.e. allowing for
recombination), using the software structure (Pritchard, Stephens, and Donnelly, 2000).
This software tries to cluster loci into a predefined k number of clusters (populations),
while allowing for individuals to have an admixed genetic background. The best fitting
number of populations has been determined using Evanno’s method (Evanno, Regnaut,
and Goudet, 2005). According to this ad hoc method, the number of clusters is chosen
such, that the statistic ∆k is maximal. This is depicted in supplemental figure B.8, which
shows the 2 clusters best describe the data. Figure 4.5 shows the results for different
subsets of biallelic sites assuming a population number of k = 2.
Using all biallelic sites throughout the genome (panel A in figure 4.5), all isolates from
Asia belong to one population (blue), while the majority of African and Western isolates
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FIGURE 4.5: Population assignment for all genome sequences assuming
a population number of k = 2 for different subsets of sites. Every bar
represents a strain that has been preassigned to either "Africa", "Asia" or
"Western" (comprised of American, European and Australian isolates). The
colouring of the bars represents the proportion of the input sites that have
been assigned to a certain population.
A) all sites; B) all sites in LD; C) nonsynonymous pairs of sites in LD; D)
synonymous pairs of sites in LD; E) sites not in LD.
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belong the other one (orange), suggesting the existence of an Asian virus population
and a population of viruses that is spread throughout the rest of the world. A few iso-
lates, however, have been partly assigned to the Asian population. This notably includes
LN824142, a saliva-derived isolate from a healthy individual in the UK, and LN827799,
an IM-isolate from Australia.
Restricting the data set to all biallelic sites in LD (panel B) does not change the pro-
portional assignment of isolates to populations, and neither does it in the subset of pairs
of synonymous sites in LD (panel D). But pairs of sites in LD that result in nonsynony-
mous changes (panel C) give a slightly different picture: The majority of nonsynonymous
SNPs in LD found in the two previously mentioned sequences (LN824142, LN827799) as
well as a few others, all of which showed an admixed genetic background, has been
assigned to the Asian population. These other isolates are four Hodgkin’s lymphoma
isolates from the UK (LN824204, LN824226, LN827522, LN827564), two PTLD samples
(LN827578, LN827586) and three further IM samples (LN827590, LN827596, LN827799)
from Australia.
On the other hand, polymorphic sites not in LD with any other site do not show
evidence for a defined population structure (panel E).
In order to see whether there might be a finer structure within the non-Asian popula-
tion, that is being masked by the stronger signal of the Asian isolates, structure analysis
has been repeated with Asian sequences removed. However, it was not possible to deter-
mine a suitable number of clusters based on the k range tested, indicating that the data
does not contain structure or is too subtle or disrupted to be detected.
Analysis of linked genes
It is interesting that the majority of nonsynonymous polymorphisms in LD occurring in
the recombinant "Western" isolates are assigned to the blue, supposedly Asian cluster,
as selection can act primarily on polymorphisms that result in amino acid changes. I
therefore wanted to explore this subset of sites further.
There are no obvious regions of the genome that are excluded in terms of the oc-
currence of linked sites (in general and nonsynonymous, see supplemental figure B.7).
Figure 4.6 shows the top 1 % of linked ORFs, meaning those which contain the most non-
synonymous SNPs in LD with each other. Many of these genes are known to be antigens
(marked by an asterisk). This led to the hypothesis that adaption to the host immune
system and maintenance of a certain subset of variation might play a role in the genetic
structure observed.
To test this, the data set of genes was divided into two sets: genes that are known
to code for immunogenic (IG) proteins and those that do not (NIG). This list is based on
the Immune Epitope Database (IEDB) (Immune Epitope Database) with restriction to those
antigens whose epitopes have been confirmed by at least two studies and are listed in
table 4.1. Nonsynonymous sites within these ORFs belonging to IG are more often in
LD with each other than would be expected if a uniform distribution of links across all
genes is assumed (p < 2.2e−16, Chi-square test, figure 4.7a), even when excluding links
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FIGURE 4.6: Genome map depicting the EBV ORFs in blue on the outside.
The grey bars mark the repeat regions, which have been excluded from
analysis. The outer track depicts the nucleotide diversity. The connection
across the genome mark the top 1 % of ORFs that are most often linked via
nonsynonymous sites. The red ribbons outline the ORF, while the indivual
black lines mark the specific pairs of sites in LD. The colour-coded arrows
relate to the encoded protein’s function. The asterisk marks those ORFs
whose products contain epitopes.
between proximal SNPs (figure 4.7b). Similarly, genes belonging to NIG are less often
linked with each other.
As sites are linked with each other across the whole genome. i.e. SNPs (and ORFs)
are not only linked to one but several other SNPs (and ORFs), I sought to study this
interconnectedness with a graph theoretical approach (see Methods). The resulting gene
network consisted of 73 genes, 19 of them belonging to IG and 54 belonging to NIG,
respectively. Edges were weighted based on a linkage score (see Methods). This linkage
score is significantly higher for edges between genes both belonging to IG, than between
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Protein ORF # of # of
epitopes references
Envelope glycoprotein B BALF4 1 2
DNA polymerase catalytic subunit BALF5 1 6
Putative BARF0 protein BARF0 1 2
Capsid protein VP26 BFRF3 1 3
Envelope glycoprotein GP350 BLLF1 1 3
mRNA export factor ICP27 homolog BMLF1 3 103
DNA polymerase processivity factor BMRF1 BMRF1 5 16
Major tegument protein BNRF1 2 4
Protein BOLF1 BOLF1 1 2
Replication and transcription activator BRLF1 7 44
Envelope glycoprotein H BXLF2 3 10
Trans-activator protein BZLF1 BZLF1 15 96
Epstein-Barr nuclear antigen 1 EBNA1 52 163
Epstein-Barr nuclear antigen 2 EBNA2 5 16
Epstein-Barr nuclear antigen 3 EBNA3A 18 209
Epstein-Barr nuclear antigen 4 EBNA3B 15 108
Epstein-Barr nuclear antigen 6 EBNA3C 21 103
Latent membrane protein 1 LMP1 9 55
Latent membrane protein 2 LMP2 26 216
TABLE 4.1: List of 19 genes considered to code for immunogenic proteins.
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(A) Oberserved and expected number of links
between nonsynonymous sites between dif-
ferent categories of genes (Chi-square test,
p < 2.2e−16).
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(B) Observed and expected number of links be-
tween nonsynonymous sites with a minimal
distance of 1 kb between different categories
of genes (Chi-square test, p < 2.2e−16).
FIGURE 4.7
IG-NIG and NIG-NIG nodes (Mann-Whitney U test, p = 1.86e−7 for IG-IG vs. NIG-
NIG, and p = 3.55e−5 for IG-IG vs. NIG-IG, respectively; supplemental figure B.9). The
distance of genes towards each other does not have an effect on the linkage score between
nodes (no significant difference between all combinations of inter-gene distance classes
with Mann-Whitney U test, supplemental figure B.10).
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(A) Bar plot of the clustering coefficient (transitivity) for every node in the network.
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(C) Violin plots of the clustering coefficient (transitivity) and degree divided into the vertex types
IG and NIG. There is a significant difference between the groups IG and NIG for both measures
(Mann-Whitney U test).
FIGURE 4.8: Gene network properties.
Gene network properties and topology Figure 4.8a shows the local transitivity, or clus-
tering coefficients, for every gene (node) of the network. The clustering coefficient C for
a node i is defined as
Ci =
2e
k(k − 1)
where k is the degree of the node i (the number of edges with which it it is connected
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to ther nodes, which equals the number of its neighbours) and e the number of edges be-
tween the k neighbours of i. In other words, it measures the ratio of the number of edges
between the neighbours of i to the total possible number of such edges (Pavlopoulos et
al., 2011). It is bounded by 0 and 1. The closer it is to 1, the more likely the network is to
form clusters. In general, the clustering coefficients are fairly high for every node, indi-
cating that the clusters are not separate but interconnected (because every node has many
interconnected neighbours). However, nodes of type IG have a significantly lower clus-
tering coefficient than those of type NIG (Mann-Whitney U test, p = 3e−4; figure 4.8c).
The global clustering coefficient of the network is Cg = 0.75. This high overall value
again underlines that the graph is quite dense. The actual density of the graph (ratio
between the number of edges to the possible number of edges) is 0.54 and supports this
notion.
The degree of every node is shown in figure 4.8b. Again, there is a significant differ-
ence between the degree of nodes belonging to the type IG and NIG, with NIG having in
general fewer neighbours than IG (Mann-Whitney U test, p = 1.2e−4; figure 4.8c).
Comparing the two plots 4.8a and 4.8b, one node that sticks out is BPLF1 of type
NIG, which, interestingly, has the lowest clustering coefficient (CBPLF1 = 0.58) but the
highest number of neighbours (degree) of all nodes (kBPLF1 = 69), i.e. it is linked to 69
of the 72 other nodes in the network. This means, many nodes are connected to it, but
these neighbours are not necessarily all interconnected with each other. In terms of the
network topology, this indicates, that BPLF1 behaves a little bit like a hub in the network.
Another characteristic of a network is whether it is assortative or dissassortative. If
nodes with a certain characteristic (for example a high degree of connectivity or a vertex
label) have the tendency to be connected with other nodes of the same characteristic, it is
called assortative. It is dissassortative, on the other hand, if high degree nodes have a ten-
dency to be connected to low degree nodes. The measure of the assortativity coefficient
is basically equivalent to the Pearson’s correlation coefficient. The degree assortativity
coefficient is rdegree = −0.16, and it is rtypes = −0.05 if based on vertex label IG vs. NIG.
The absolute of both values is not particularly high, meaning there is no clear tendency
to be dissassortative or assortative in the way nodes are connected with each other.
To conclude this exploratory section, the network is fairly dense and strongly con-
nected (i.e. there are no disconnected components).
Identifying biologically meaningful subnetworks and ranking of nodes The are sev-
eral approaches to identify important subgraphs or nodes within the network:
1. Community clustering on the graph to find one or several (biologically meaning-
fully) connected subgraphs. These are usually based on paths and walks through
the graph and the optimisation of some modularity score;
2. Clustering based on the adjacency matrix of n × n nodes (n being the number of
nodes in the network) where every entry between node i and j is the edge weight
of the two nodes;
3. Ranking of nodes based on network centrality.
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Various graph clustering algorithms implemented in igraph were applied, such as:
• Clustering based on edge betweenness, i.e. the modularity of the network, where a
group of nodes is densely connected to themselves but sparsely connected to other
modules. The modularity score of the network is negative, however, indicating
that the network does not consist of modules. It identified 34 clusters, 32 of them
consisting of a single node, and two clusters containing 6 and 34 nodes, respectively.
• The walktrap algorithm, which tries to find densely connected subgraphs via ran-
dom walks. It identified nine clusters.
• The fast greedy algorithm tries to find subgraphs by optimising the modularity score.
It identified four clusters.
• A last algorithm tries to find structure based on propagating labels. In the beginning,
each node has a unique label, and at every step, each node adopts the label of the
majority of the neighbours. In this gene network, this resulted in only one cluster.
These clustering methods yielded inconclusive results (supplemental figure B.11), i.e.
identified clusters varied greatly in number and showed little overlap. This is proba-
bly due to the strongly connected nature of the network, as most of these algorithms are
based in some way on the topology of the network. This approach was therefore dis-
carded.
Figures 4.9a and 4.9b show the subgraphs of the network that are connected with
edges with weights of A) top 1% and B) top 5% of the linkage score. The histogram
shows that very high linkage scores are rare, and even within the top 5%, values range as
low as 0.18.
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Figure continues on the next page.
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FIGURE 4.9: Filtering of the gene network based on the edge weight (link-
age score).
Figure 4.10 shows the hierarchical clustering approach based on the adjacency matrix.
The distance matrix used for the clustering is based on the linkage score, i.e. the higher
the linkage score between two genes, the smaller the distance between them. This is
a similar approach (in this case of a highly connected network) of filtering based on the
linkage score as in figure 4.9. Nodes belonging to IG are coloured orange, those belonging
to NIG are coloured blue. Marked in grey are the nodes that show some weak clustering:
There are two clusters that are successively being formed with increasing distance (i.e.
decreasing linkage score) until they are joined. LMP1 and BcRF1 form the first cluster
which increases in size until the small cluster made of EBNA1 and LMP2 is merged with
it. Further decreasing the distance from there leads only to other nodes being successively
added to this cluster. This indicates again the network is very interconnected and not
highly structured, but this approach was able to identify one small cluster of particularly
strongly linked genes.
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FIGURE 4.10: Hierarchical clustering of gene network. The distance is
calculated based on their linkage score (edge weight), i.e. the higher the
linkage score between two genes, the smaller the distance between them.
Nodes belonging to IG are coloured orange, nodes belonging to NIG are
coloured blue. Marked in grey are the two main clusters that are being
joined at low distance already.
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Alternatively, identifying the most important genes in a network can be done by rank-
ing nodes based on their properties. Eigenvector centrality does this by measuring the
influence of a node, i.e. a node’s score is higher if it is connected to other high-scoring
nodes. Figure 4.11 illustrates this. All genes are coloured based on their ranking within
the network. Of the top 25 highest ranked genes, 13 belong to the group IG (in total
there 19 IG nodes) (table 4.2). However, five more of these genes also appear in the IEDB
database as antigens, but did not meet the rather conservative criterion of a minimum of
two independent references.
LMP2
BNRF1
BCRF1
EBNA2
BHRF1
BFLF2
BFLF1
BFRF1A
BFRF1 
BFRF2
BFRF3
BPLF1
BOLF1
BORF1
BORF2
BMRF1
BMRF2
BMLF1
BSLF2
BSLF1
BLLF3
BLRF1
BLLF1
EBNA3A
EBNA3B
EBNA3C
BZLF2
BZLF1
BRLF1
BRRF1
BRRF2
EBNA1
BKRF2
BKRF3
BKRF4BBLF4
BBRF1
BBRF2
BBLF2−BBLF3
BBRF3
BBLF1
BGLF5BGLF3
BGRF1−BDRF1
BGLF2
BGLF1
BDLF4
BDLF3
BDLF2
BDLF1
BcLF1
BcRF1
BTRF1
BXLF2
BXLF1
BXRF1
BVRF1
BVLF1
BVRF2
LF3
LF2
RPMS1
LF1
BILF1
BALF5
BALF4BARF0
BALF3
BALF2
BARF1
BNLF2B
BNLF2A
LMP1
S
p
e
c
tr
a
l (
d
iv
e
r
g
e
n
t)
Sc
or
e
max
min
IG
NIG
FIGURE 4.11: Gene network coloured by Eigenvector centrality.
Gene network coloured by Eigenvector centrality, with warm colours indicating higher
and cooler colours lower scores, respectively. Square node symbols denote genes
belonging to IG, circular nodes denote genes belonging to NIG.
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Eigenvector ORF Protein IG
rank
1 BPLF1 Large tegument protein deneddylase m
2 EBNA3B Epstein-Barr nuclear antigen 4 l
3 BOLF1 Protein BOLF1 l
4 BNRF1 Major tegument protein l
5 EBNA3C Epstein-Barr nuclear antigen 6 l
6 EBNA1 Epstein-Barr nuclear antigen 1 l
7 BRRF2 Tegument protein m
8 BcLF1 Major capsid protein m
9 BXLF2 Envelope glycoprotein H l
10 BcRF1 TBP-like protein
11 BALF4 Envelope glycoprotein B l
12 BDLF2 BDLF2 (Glycoprotein)
13 BXLF1 Thymidine kinase m
14 LMP2 Latent membrane protein 2 l
15 BBLF1 Tegument protein UL11 homolog
16 BDLF3 BDLF3 (Glycoprotein)
17 BZLF1 Transactivator protein l
18 BVLF1 BVLF1
19 BVRF2 Capsid scaffolding protein m
20 EBNA3A Epstein-Barr nuclear antigen 3 l
21 BKRF2 Envelope glycoprotein L
22 BBLF4 DNA replication helicase
23 LMP1 Latent membrane protein 1 l
24 BMLF1 mRNA export factor ICP27 homolog l
25 BARF0 BARF0 l
TABLE 4.2: Most influential nodes in the network. Circles in the column la-
belled IG mark proteins for which an immune response has been reported,
with filled circles fulfilling the criterium of having at least two references
and empty circles having fewer than two.
4.2.3 Prediction of novel T cell epitopes for EBV
Figure 4.12 shows the results of a number of evolutionary analyses plotted against the
genome map of EBV.
Selection
To test for positive and negative selection, the summary statistic method Tajima’s D
(Tajima, 1989) was used and results are shown in track A. Tajima’s D uses information
about the number of polymorphic sites within an alignment to infer the presence or ab-
sence of selection on a gene in comparison to a null model of neutral evolution. Under
the null model, D is expected to equal zero. Negative D values result from an excess of
rare alleles, i.e. a high number of segregating sites compared to a low number of pairwise
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A
B
C
FIGURE 4.12: Circular EBV genome map showing the combined results
of various evolutionary analyses. The outermost tracks marks the ORFs
around the genome. The grey track inbetween and the grey shading mark
the repeat regions that have been excluded from the analysis.
Track A: Red arrows show recombination breakpoints as detected with
GARD. Blue arrows denote positive selected sites (PSS). Tajima’s D val-
ues are plotted for every gene (or gene fragments in case of recombina-
tion). Red and green background refers to negative and positive values,
respectively. Filled circles are tested significant with p < 0.05. Track B: Nu-
cleotide diversity calculated in windows of 100 bp with step size of 1 bp.
Track C: Genome-wide sliding window scan of LD in windows comprising
20 SNPs. Shown are only the windows of significant hotspots of local LD.
differences, indicating a) a recent bout of positive selection, b) purifying selection or c) a
population expansion after a recent bottleneck. PositiveD values, in contrast, result from
an abundance of intermediate-frequency alleles, which can be indicative of a) balancing
selection, b) a population structure or c) a decreasing population. Here, the majority of
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ORFs (or fragments) had negative D values. The highest positive D value was found in
EBNA1 with 0.55, which is still a low value and not significant. Seven genes had signifi-
cant, negative D values (p < 0.05, filled black circles in figure 4.12: BALF1, BILF2, BLLF1,
BLRF1, BPLF1, BVRF1 and LMP1). Of these seven genes, thee showed evidence of recom-
bination (red arrows in track A mark the likely recombination breakpoint) and D values
were significant for one of the recombining fragments, respectively (BVRF1, BPLF1 and
BLLF1). Given the data set, a recent population expansion is an unlikely scenario as
EBV is spread worldwide and sequences are derived from different geographical regions
rather than a small subset. Moreover, sampling dates vary over decades. This also makes
it unlikely for the rare alleles to result from a recent bout of positive selection that have
not yet reached fixation in the population. The most likely explanation is therefore that
purifying selection is acting on these genes or gene fragments. All Tajima’s D values are
listed in supplemental table B.2.
Detection of specific sites within a gene that are under positive selection (positively
selected sites, PSS) was performed using codeml from the paml package (Yang, 2007).
Here, codon substitution models are used that allow the ratio of non-synonymous to
synonymous substitutions to vary among sites. Specific codons under positive selection
(PSS) were detected in 23 genes (figure 4.12, blue arrows in track A; supplemental table
B.1) and are reported for both the model comparison M1a-M2a (nearly neutral evolution
against positive selection) and M7-M8 (ω follows a beta distribution, with M8 addi-
tionally allowing for positive selection). With the exception of a few sites, all PSS were
supported by both the simpler and robust model (M2) as well as the more sensitive and
complex model (M8) (Yang, 2007) (supplemental table B.1).
A large number of PSS was found for the latency genes EBNA3A-C, EBNA1 and
LMP1. Most of them lie within known epitopes for CD4+ and CD8+ T cells and likely
represent adaptations for immune escape.
Nulceotide diversity
Track B in figure 4.12 shows the nucleotide diversity in sliding windows of 100 bp.
The ten ORFs with the highest diversity are in decreasing order LMP1, EBNA1, BZLF1,
BRRF2, EBNA3B, BDLF3, LMP2, EBNA3C and EBNA3A (supplementary table B.2). Eight
of these are immunogenic genes according to table 4.1.
The distribution of biallelic SNPs across the genome is shown in supplemental figure
B.13. SNPs are not completely randomly distributed across the genome, instead there
seem to be hotspots based on a Monte Carlo test as implemented in adegenet (p = 0.001).
Local linkage disequilibrium
A sliding window approach was used in order to detect local signatures of LD. The areas,
which have been found to show significant high local linkage compared to the rest of the
genome are shown in track C of figure 4.12. These areas fall within 29 ORFs as shown in
table 4.3.
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ORF Protein PSS
BALF3 Tripartite terminase subunit 1 l
BBLF1 Tegument protein UL11 homolog
BBLF2-BBLF3 Helicase-primase subunit BBLF2/3
BBLF4 DNA replication helicase
BBRF1 Portal protein
BBRF3 Envelope glycoprotein M l
BcLF1 Major capsid protein
BcRF1 TBP-like protein BcRF1 l
BDLF1 Triplex capsid protein 2
BDLF4 Uncharacterized protein BDLF4
BGLF1 Capsid vertex component 1
BGLF5 Shutoff alkaline exonuclease
BKRF2 Envelope glycoprotein L
BKRF3 Uracil-DNA glycosylase
BNLF2B Uncharacterized protein BNLF2b l
BORF1 Triplex capsid protein 1
BORF2 Ribonucleoside-diphosphate reductase large subunit
BPLF1 Large tegument protein deneddylase l
BRLF1 Replication and transcription activator l
BRRF1 Transcriptional activator BRRF1
BRRF2 Tegument protein BRRF2 l
BVRF1 Capsid vertex component 2
BXLF1 Thymidine kinase
BZLF1 Trans-activator protein BZLF1 l
EBNA1 Epstein-Barr nuclear antigen 1 l
EBNA3B Epstein-Barr nuclear antigen 4 l
EBNA3C Epstein-Barr nuclear antigen 6 l
LF1 Uncharacterized LF1 protein l
LMP1 Latent membrane protein 1 l
TABLE 4.3: ORFs and their encoded proteins that display local high LD
and whether they contain any PSS.
Epitopes
The presence of local LD while being under positive selection and showing a high degree
of diversity could be indicative of a protein being immunogenic. Maintaining diversity
within epitopes helps the virus to evade the immune system. Many of these characteris-
tics are being shown by known strong immunogenic proteins such as LMP1, the EBNAs
and BZLF1. I therefore sought whether it is possible to identify proteins/genes, that show
similar characteristics but are not known to be immunogenic.
The procedure of predicting T cell epitopes is described in detail in chapter 2. In short,
protein sequences that contain positively selected sites (PSS) are being screened for pep-
tides that can be presented by MHC (i.e. the "wild type" and mutant variant). A predicted
peptide is being considered as a candidate for further analysis if it a) belongs to the top
1 % of predicted peptides (in total) and b) contains at least one PSS. The HLA-specific
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binding properties are then compared between variants of the peptide based on their
predicted IC50 value (derived from two different algorithms, ANN and SMM), which
measures the peptide’s predicted affinity, in other words whether a variation induces a
strong effect in binding affinity to evade the immune system. Previous studies have sug-
gested a IC50 value of 500 nM as a affinity threshold for HLA presentation associated
with potential immunogenicity for HLA class I restricted epitopes (Sette et al., 1994).
Generally speaking, IC50 values of <50 nM are considered high affinity, <500 nM inter-
mediate affinity and <5000 nM low affinity. The majority of known epitopes have high or
intermediate affinity. Peptides binding only with low affinity may exist, but there are no
known T cell epitopes with IC50 values >5000 nM (Immune Epitope Database). A potential
epitope has therefore been chosen if a variation leads to change in affinity.
"Positive control" First, however, I wanted to see, whether this approach works for
known immunogenic genes and whether it is possible to predict epitopes that have been
described experimentally. The prediction approach was applied to the latency proteins
EBNA1, EBNA2, EBNA3A, EBNA3C and LMP1 and then compared the prediction results
to known epitopes listed in IEDB.
Table 4.4 shows the results for this. For 4 proteins, the same or similar epitopes were
identified.
Gene PSS Pred. HLA Pred. peptide Exp. HLA Exp. peptide
EBNA1 411 B*53:01 HPVGEADYF B*53 HPVGEADYF
B*35:01 HPVGEADYF B*35:01 HPVGEADYFEY
DRB3*01:01 PFFHPVGDADYFEYL ND RPFFHPVGDADYFEY
EBNA3A 333 B*08:01 FLRGRAYGI B*08 FLRGRAYGL
459 B*35:01 YPLHEQHGM B*35:01 YPLHEQHGM
655 DRB1*08:02 QVADVVRAPGVPAMQ ND QVADVVRAPGVPAMQF
EBNA3C 141 DRB1*03:01/ ILCFVMAARQRLQDI DR13 ILCFVMAARQRLQDI
DRB3*02:02/
DRB3*01:01
LMP1 18 DRB1*09:01 PPRRPPLSSSLGLAL DR9 GPPRRPPLSSSLGLALL
TABLE 4.4: Positive control for epitope prediction procedure. The table
lists those genes and the respective PSS for which a peptide was predicted
to be an epitope as well as the predicted HLA allele. It compares it to
the experimentally confirmed peptide and its HLA restriction. The PSS
position refers to the amino acid position in the protein.
Prediction of novel epitopes I then applied this procedure to three proteins: BcRF1,
BRRF2 and BPLF1. BcRF1 displays a certain degree of variability and contains highly
locally linked sites. There are two sites under positive selection. Tajima’s D is negative
(-0.91) but not significant, indicating there is a slight excess of rare alleles. BRRF2 has two
PSS, shows the fourth highest nucleotide diversity and is also a local LD hotspot. Last,
BPLF1 has 21 PSS and one recombining fragment is under significant purifying selection
(D = −2.9). The two selection tests are not conflicting, as positive selection can act on
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specific sites, while over the whole gene, purifying selection can be the driving force of
evolution. There’s a hotspot of local linkage within the same fragment.
Interestingly, in the previous analysis of the gene network of linked, nonsynonymous
sites, a significantly higher number of neighbours (degree of a node) was found for im-
munogenic genes than for nonimmunogenic genes (figure 4.8c). The ORFs encoding for
the three selected proteins, which have been classified as NIG, also have high degrees
compared to the other NIG nodes (figure 4.8b).
Gene PSS HLA Start End Length Peptide IC50 IC50
ANN SMM
BcRF1 738 A*03:01 729 738 10 ITLLLAHLRK 42 19.33
ITLLLAHLRR 879 274.92
A*03:01 730 738 9 TLLLAHLRK 44 66.34
TLLLAHLRR 888 274.92
BRRF2 184 B*08:01 175 184 10 LVALRGHVQL 1126 454.59
LVALRGHVQP 22899 3833.72
DRB1*03:01 181 195 15 HVQLAYDARVLTPDF 160 30
HVQPAYDARVLTPDF 1922 763.1
DRB1*03:01 180 194 15 GHVQLAYDARVLTPD 162 17.5
GHVQPAYDARVLTPD 1762 1372.8
260 B*07:02 255 263 9 APETLRDYL 123 180.26
APETLQDYL 2972 638.1
323 B*07:02 321 329 9 RPRFSALPP 28 106.88
RPQFSALPP 655 632.25
323+325 B*07:02 321 329 9 RPRFSALPP 28 106.88
RPQFLALPP 1693 1034.88
BPLF1 12 B*07:02 11 20 10 RPRGTGPVRG 217 122.13
RTRGTGPVRG 18374 2740.44
B*07:02 11 18 8 RPRGTGPV 66 462.39
RTRGTGPV 908 21330.9
B*07:02 11 19 9 RPRGTGPVR 100 42.84
RTRGTGPVR 14526 3146.95
796 B*08:01 788 796 9 LIRSRDRSA 26 83.67
LIRSRDRSS 10066 83.76
1535 A*01:01 1533 1541 9 FTDIETGPL 57 356.9
FTEIETGPL 880 1440.62
2895 B*07:02 2893 2901 9 APRPQKTQA 16 50.69
APSPQKTQA 210 345.06
B*07:02 2893 2902 10 APRPQKTQAQ 187 181.06
APSPQKTQAQ 1997 1108.72
2895+2897 B*07:02 2893 2901 9 APRPKKTQA 15 59.14
APSPKKTQA 173 402.62
B*07:02 2893 2902 10 APRPQKTQAQ 16 50.69
APSPKKTQAQ 1561 924.31
TABLE 4.5: Candidate peptides from epitope prediction for both MHC I
and II. Presented are the comparison of both aminoacid variants and their
predicted IC50 value based on two algorithms (ANN and SMM). Start and
end coordinates as well as the PSS position refer to the amino acid positions
of the protein.
Based on our filtering criteria, a number of putative epitopes could be identified. The
results are listed in table 4.5 and figure 4.13, which graphically illustrates how the changes
in PSS highlighted in table 4.5 change the affinity of being presented by MHC. Note that
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FIGURE 4.13: Predicted IC50 values (on a log scale) of the ANN (top) and
SMM algorithm (bottom) of candidate peptides. Var1 (light grey) and Var2
(dark grey) refer to the changes at PSS as highlighted in table 4.5. The
background colour indicates the affinity of this peptide being presented
by an MHC molecule.
these are not distinct peptides. For BcRF1, two peptides for MHC I have been predicted.
Both are highly similar and have a predicted specificity for HLA A*03:01, for which the
variation from K to R decreases its binding affinity. For BRRF2, four peptides for MHC I
and two for MHC II could be predicted. Again, the two predicted MHC II epitopes are
highly overlapping. Moreover, there are two MHC I epitopes predicted containing two
PSS that are very close together. Depending on the combination of variations, the binding
affinity is further decreased. In the case of BPLF1, in total nine peptides that could be
potentially be presented by MHC I molecules have been predicted, some of them being
very similar or containing multiple PSS.
4.3 Discussion
4.3.1 Recombination and linkage disequilibrium
Recombination plays an important role in viral evolution as it is, beside mutations, a
source of genetic diversity. By combining variants that occur on different genomes, it
allows the introduction of new haplotypes.
Recombination is also a means to maintain the virus genome’s integrity in the state of
latency when it is constantly exposed to mutagenic agents. Employing the host cell’s ho-
mologous recombination (HR) repair pathway has been proposed as a mechanism to cir-
cumvent this (Brown, 2014; Wilkinson and Weller, 2004). This is in concordance with the
observation that DNA mismatch repair and recombination proteins are involved in her-
pesvirus replication (Wilkinson and Weller, 2004). Interestingly, α- and γ-herpesviruses
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seem to utilise different HR initiating sequencing. In α-herpesviruses, inverted and tan-
dem repeat sequences are the most prevalent, whereas it is specific short, GC-rich se-
quences in γ-herpesviruses (Brown, 2014).
It is therefore easy to imagine that in the case of co-infection, the employment of the
host’s HR-machinery might lead to recombinant strains.
The advancement in EBV whole genome sequencing has allowed for recombination
to be observed (Palser et al., 2015; Kwok et al., 2014; Santpere et al., 2014). These studies
have mostly looked at selected strains and showed recombination breakpoints between
a number of genomes. Instead of focusing on specific strains, I wanted to look at recom-
bination and its traces more comprehensively. Evidence for recombination breakpoints
was found throughout the genome. This is in concordance with an in silico study that
analysed the occurrence of potential recombination inducing sites relatively uniformly
across the EBV genome (Brown, 2014).
Despite this, many variable sites were observed to be in linkage disequilibrium with
each other, i.e. they always occur in the same strains together, even over long distances.
This is surprising as recombination disrupts linkage between sites. Moreover, this seems
to be different from other herpesviruses: In human cytomegalovirus (HCMV), a recent
study found no LD in the majority of the genome due to unrestricted recombination, ex-
cept for a few regions where recombination seems to be constrained in order to maintain
diversity (Lassalle et al., 2016).
In general, LD can indicate a population structure, which might be due to geographic
variation. However, evidence was still found for recombination occurring within the
subset of sites in LD (supplemental figures B.1-B.6).
There are two possible scenarios: a) an ancient population structure that has only re-
cently begun to recombine or b) this is a steady state maintained by selection for epistasis.
Further work is necessary to completely answer this question. One can however spec-
ulate that an ancient structure being erased by recombination is the more parsimonious
explanation in comparison to a high number of loci being under epistatic constraints, but
both hypotheses are not mutually exclusive.
Two inter- and intra-recombining subpopulations
Population structure analysis revealed that the majority of the structure observed can
be explained by dividing the set of sequences into two populations. One population
seems to be mainly comprised of isolates from Asia, while the other population contains
genomes from the rest of the world, i.e. isolates from Africa as well as "Western" countries
such as Australia, the UK and the USA. This confirms previous findings where Asian
type 1 sequences cluster quite distinctly from other genomes in a PCA (Palser et al., 2015).
There are also a few admixed isolates, i.e. where the genome has been partially assigned
to both populations, which would suggest recombination events between them. One
sequence from the UK, LN824142, seems to be belong to the Asian population rather
than the other one. However, the geographic label of the isolates is based on where
they have been isolated and is not necessarily the actual origin of the virus. It is easily
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imaginable that a sequence isolated in the UK or Australia, countries with a mixed ethnic
population, could originally be an Asian strain, as primary infection often occurs through
close family members in early age. This highlights a big drawback of this sort of analysis:
More information about where virus actually comes from, the ethnicity of the donor etc.
would be needed.
Recombination is also occuring within these subpopulations, as evidence was found
for recombination within the subset of sites in LD (and by further filtering based on the
class of sites, such as only nonsynonymous sites in LD, or a p-value threshold, supple-
mental figures B.1-B.6). In fact, database sequences from the dataset used have been de-
scribed as recombinants. HKNPC2, for example, seems to be a recombinant of HKNPC7
and -9 (Kwok et al., 2014), all of them isolates from Hong Kong that have been clearly as-
signed to the Asian population (named by their accession number in figure 4.5 KF992564,
KF992569 and KF992571, respectively). Similarly, LN824224 has partially high similarity
to four other southeast Asian isolates (Palser et al., 2015).
Interestingly, for admixed individuals the majority of the site data set is assigned to
the Asian population when being restricted to only nonsynonymous sites in LD (mem-
bership coefficients around 0.7 or higher, figure 4.5, panel C). This is also true for isolates,
which, when considering all sites, have only a very small percentage of the genome as-
signed to the Asian population (membership coefficients of 0.2-0.5). This opens the pos-
sibility that there might be functional linkage, for example because of constraints due to
protein-protein interactions (PPI), or because of immune-selection.
There are two publications on the EBV interactome, Calderwood et al., 2007 and Fos-
sum et al., 2009. Based on their data, the EBV PPI networks of selected nodes identified
via hierarchical clustering (figure 4.10) and centrality (figure 4.11) from the gene network
are shown in supplemental figure B.12. The hierarchical clustering approach is based
on the nodes’ linkage score, i.e. it represents the most strongly linked nodes. However,
there is only one known interaction between LMP1 and the major capsid protein (BcLF1)
(figure B.12a), which is only a low confidence interaction (Calderwood et al., 2007) and
makes little sense in the virus’ life cycle. The PPI network of the centrality-ranked nodes
(table 4.2, figure B.12b) shows more possible protein interactions. Some of them are low
confidence interactions, some of them are questionable regarding their localisation and
their respective roles in different aspects of the life cycle. For example, BRRF2 is a tegu-
ment protein, whereas its potential interaction partner LMP2A is a host membrane bound
protein expressed during latency mimicking antigen-independent B cell receptor signal-
ing (Kang and Kieff, 2015). Similarly, BDLF3 is a host membrane glycoprotein responsible
for immune evasion through MHC internalisation during late lytic cycle (Quinn et al.,
2016) whereas EBNA3A is active during latency in the nucleus (Kang and Kieff, 2015).
Other proteins are not further characterised in their function, such as BARF0. However,
some of the interactions make a little more sense: BPLF1 which plays among other func-
tions a role in the envelopment of the capsid interacts with both BALF4, an envelope
glycoprotein, and BOLF1, a tegument protein possibly involved virion assembly; BNRF1
and BBLF1 are both tegument proteins.
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While there are a number of interactions reported, the PPI data has to be considered
with care. It is based on Yeast two hybrid (Y2H) screenings, a technique with a num-
ber of disadvantages. For once, a false positive rate of up to 70% has been reported in
Y2H data sets (Deane et al., 2002). This can be because of non-specific binding due to
unusually high protein expression from plasmids. Another reason is that proteins might
theoretically be able to bind each other, but this does not necessarily occur under natu-
ral conditions, because they are expressed at different time points in the viral life cycle
(structural proteins during late lytic cycle versus latent genes, e.g. in the case of BcLF1
and LMP1) or they are localised in different compartments of the cell.
Results of the analysis of linked genes supports the hypothesis of HLA adaptivity, as
I found that immunogenic genes are more often linked with each other than would be
expected by chance. This refers to nonsynonymous sites, i.e. sites on which selection can
act. Moreover, 13 of the 25 most influential nodes in the gene network are immunogenic
genes. In addition, three genes for which epitopes were predicted in silico (table 4.5) are
also included in this list.
One could therefore hypothesise, that it is beneficial for the virus to retain certain
combinations of polymorphisms in immunogenic genes. This might be, because the virus
has adapted to HLA alleles common in the subpopulation it is circulating in. This is in
concordance with a model of non-overlapping combinations of epitope regions, that are
being held in LD despite genetic exchange via recombination between pathogens in other
parts of the genome (Gupta et al., 1996). Nevertheless, protein-protein interactions can-
not be excluded either. In fact, both options are not mutually exclusive.
The whole matrix of sites in LD is vast, comprising of approximately 89,000 pairs of
loci in LD. The major difficulty lies in disentangling the noise (e.g. sites in LD due to
hitch-hiking) from the informative sites. Here, I included in the analysis all sites in LD
with a corrected p-value of 0.05. This value might have been too lenient, and a stricter
filtering to begin with could help reducing the noise in the data, highlighting more rel-
evant linkages. Another idea could be to weight linked pairs differently depending on
their distance. As observation of linkage of proximal sites is more likely, those linkages
might have a lower weight than long range linkages.
Moreover, studying more closely the admixed individuals is of interest, as these are
the ones in which sites have been kept in LD on the amino acid level despite recombina-
tion between the two subpopulations.
Additionally, it could be of interest to focus on specific interaction pairs to address
specific biological questions. For instance, proteins known to interact with each other
(EBNA2 and the EBNA3-family, for example) would be a good target to specifically see
which sites are linked in which strains, in which domains these interactions fall, and how
they might affect function.
Interestingly, a recent paper (Chiara et al., 2016) has been published that also inves-
tigated EBV’s population structure on a slightly bigger, but largely overlapping data set
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(including type 2). They found ten subpopulations of EBV, eight of them containing
isolates that could be assigned with low admixture that showed correlation with the ge-
ographic origin. Their findings seem reasonable also in the light of recent migration and
admixture.
Given how different Asian strains are from the rest of the world, it might be possible
that there is a less distinct population structure present within the non-Asian genomes
that was missed by structure. But when restricting the data set to non-Asian genomes,
it was not possible to identify a fitting number of k with Evanno’s method (Evanno,
Regnaut, and Goudet, 2005), which is indicative of much stronger admixture of genomes.
Another obvious reason for the different findings is that the data here were analysed
for a maximum number of populations of k = 10, thereby underestimating the number of
populations. However, repeating our analysis for larger number of k (ranging from 0 to
20), k = 2 was still found to be the best fitting number of populations (Evanno, Regnaut,
and Goudet, 2005). It is not clear from the paper by Chiara et al., 2016 which models
implemented in structure were used and how the number of populations was inferred.
4.3.2 Epitope prediction
Based on the whole genome analysis of various EBV strains I was able to identify areas
of the genome were hotspots of local LD correlated with higher nucleotide diversity. Re-
combination and mutation rates have opposite effects on nucleotide diversity, the former
decreasing it while the latter increases it. However, low diversity regions can also be the
result of strong purifying selection. The concomitant occurrence of high LD and high
nucleotide diversity indicates that recombination occurs less frequently in these areas. In
other words, there might be constraints on recombination in order to maintain diversity.
One possible explanation for viruses is that of immune evasion.
These characteristics are being shown by genes that are known to code for strong im-
munogenic targets, such as the latency genes and BZLF1. Based on the results of applying
the epitope prediction procedure to known epitopes, I was prompted to apply this ap-
proach to previously unknown or little studied immunogenic genes, which show similar
characteristics.
By also taking into account the results of selection analysis, I was able to predict a
number of peptides in the genes of BcRF1, BPLF1 and BRRF2 to be potential targets of
immune recognition. It has to be noted that this analysis was restricted to HLA alleles
common in Europe.
Little is known about BcRF1 function, but it has recently been shown to form a com-
plex with the TATT motif, which is often present in γ-herpesviruses instead of the more
common TATA-box (Gruffat et al., 2012) in the promotors of late genes. The protein is in-
volved in a viral complex with five more proteins (encoded by BDLF3.5, BDLF4, BVLF1,
BGLF3, BFRF3) that is responsible and essential for the initiation of late viral gene tran-
scription (Aubry et al., 2014). This mechanism of late viral transcription is conserved
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within β- and γ-herpesviruses (Aubry et al., 2014) and is necessary for productive infec-
tion. To date, no epitopes have been described for this protein.
BPLF1 is the largest ORF in the EBV genome. It is expressed in lytic cycle and encodes
the large tegument protein. Additionally to its Deneddylase activity, which contributes
to prevention of S phase progression of the host cell, it displays deubiquitinase (DUB)
activity (van Gent et al., 2014). By suppressing TLF- and TRAF6-mediated activiation of
NF-κB, it plays a role in innate immune evasion (van Gent et al., 2014; Saito et al., 2013).
The DUB catalytic domain can be found in the N-terminal part of the protein between
sites 1-269. Three very similar peptides that have been predicted as epitopes fall into this
area of the protein. The majority of the gene has been positively tested with Tajima’s D,
indicating strong purifying selection selection due to functional constraints. However,
many sites have been detected to be under positive selection.
Finally, the late gene BRRF2 encodes another tegument protein, but is functionally not
well described. It is likely located in the tegument (Johannsen et al., 2004) but has also
been detected in the cytoplasm of cells during lytic cycle (Watanabe et al., 2015). During
analysis, no T cell epitope was known for this protein; however, elevated antibody titres
against BRRF2 in multiple sclerosis patients have been described (Cepok et al., 2005). I
was able to predict a number of potential epitopes. One of them (RPRFSALPP, position
321-329) contains two PSS very close together, and the additional mutation further de-
creases the affinity to bind HLA B*07:02. Interestingly, the IEDB has been updated since
this work has been done and in fact, a very similar peptide (VPRPRFSAL, position 319-
327) has been previously determined similarly by in silico prediction and further its bind-
ing affinity for B*07 validated in vitro, although it eclicited only a weak IFN-γ response
in primary PBMCs from EBV+ donors (Turcˇanová and Höllsberg, 2004).
It would be of great interest to conduct a similar study in order to validate the binding
specificity in vitro and also to confirm whether a response in primary PBMCs of EBV+
positive donors can be detected. This is also why the selection of candidate peptides has
been restricted to those with binding specificities for HLA alleles common in Caucasians.
A possible drawback of our approach is the restriction to sites under positive selec-
tion. There are other regions in the genome that show a reasonable amount of variation
while being strongly in local LD, that would also functionally make sense to be immuno-
genic. One such gene is BcLF1 which encodes the major capsid protein. It contains a very
big hotspot of local LD. Moreover, there are three epitopes described experimentally in
the IEDB, though they have not been confirmed by further studies.
In addition to that, some epitopes in EBV are highly conserved (Duraiswamy et al.,
2003; Chiu et al., 2014; Palser et al., 2015), and not all epitopes are necessarily under
positive selection. Due to the dual nature of EBV’s lifestyle, one can imagine that some
epitopes in latency genes, in particular those driving the proliferation of B cells (EBNA2,
EBNA3A, and EBNA3C), are partly under purifying selection. Hiding too efficiently from
the immune system at this critical stage would likely increase the cancer rate by promot-
ing unrestricted proliferations, thereby shortening the lifespan of the host and in conse-
quence the time available to EBV for transmission.
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Another disadvantage is that the quantitative estimations of IC50 values from the
prediction tools deviate systematically from experimental IC50 values (Immune Epitope
Database). The operators of IEDB are currently undertaking an evaluation of the correla-
tion between predicted IC50 values and the antigenicity of peptides.
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Chapter 5
Whole genome sequencing of EBV
from various clinical settings
5.1 Introduction
EBV plays a role in a large number of malignancies. Here, I used whole genome sequenc-
ing in combination with targeted enrichment to retrieve and analyse EBV whole genome
sequences from various clinical settings, including: immunodeficiency after transplan-
tation/Post transplant lymphoproliferative disorders (PTLD), infectious mononucleosis
(IM), and nasopharyngeal carcinoma (NPC).
Posttransplant lymphoproliferative disorders Posttransplant lymphoproliferative dis-
orders (PTLD) is a collective term for haematopoeitic lesions that occur in patients hav-
ing undergone transplantation. The majority are of B cell origin, but 7-15 % are of NK or
T cell origin (Swerdlow, 2007). PTLD is highly associated with EBV infection with around
60-80 % of PTLD being EBV+ (Capello, Rossi, and Gaidano, 2005). PTLD can be classi-
fied into two groups: 1) early, polyclonal lesions and 2) monoclonal lesions that include
polymorphic and monomorphic PTLD (Swerdlow et al., 2008).
The loss of immune control over EBV replication is thought to be one of the main
causes for the lymphoproliferation. This is supported by the correlation between PTLD
incidence and immunosuppressive dose (Juvonen et al., 2003) and the increase of EBV
infected B cells in blood and tissue (Gulley and Tang, 2010). Consequently, a key compo-
nent of PTLD treatment is the withdrawal of immunosuppression (Odumade, Hogquist,
and Balfour, 2011).
In this chapter, I will present the results of sequencing and analysis of EBV genomes
from tumours and blood of immunocompromised paediatric patients, to answer the
question whether the virus found in tumour and blood is the same. Further questions
relating to this are: Is it possible to detect multiple infections in blood or tumour? How
does the virus change over time in immunosuppressed patients?
Infectious mononucleosis Upon primary infection, EBV can cause infectious mononu-
cleosis (IM) with an incubation period of approximately six weeks. The symptoms of IM
include a sore throat, cervical lymph node enlargement, fever and fatigue. While most
symptoms last only between two and four weeks, fatigue can last for months (Balfour,
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Dunmire, and Hogquist, 2015). Diagnosis of IM cannot be determined solely based on
clinical manifestations, but has to be confirmed, for example with a heterophile antibody
test (Basson and Sharp, 1969).
Immunoglobulin M antibodies targeting the viral capsid antigen (VCA) are being pro-
duced during the acute (0-3 weeks after onset) and sub-acute phase (4 weeks-3 months)
by around 75 % of patients (Balfour et al., 2013), but diminishes during convalescence
(4-6 months). After the onset, IgG antibodies targeting VCA are produced by all patients
(Balfour et al., 2013), whereas IgG antibodies against EBNA1 develop only during conva-
lescence (Balfour, Dunmire, and Hogquist, 2015). Profiles of these EBV-specific antibodies
are therefore being used to determine the phase of EBV infection.
During acute illness, viral loads are high both in the blood and saliva compartment.
The peak of viral load in serum and PBMCs occurs in the first week after onset of illness,
and decreases afterwards. The kinetics of this decrease, however, can be very different
from patient to patient (Berger et al., 2001). In saliva, on the other hand, EBV DNA can be
detected for at least 6 months after onset of illness. This indicates a consistent infectivity
of saliva even after symptoms have declined (Fafi-Kremer et al., 2005).
In this chapter, I will report on the sequencing and analysis of longitudinal samples
of paediatric IM patients from Japan. Questions behind this analysis are the following:
Is there a change over time observable within the genomes? Is the primary infection due
to a single virus variant or can we detect multiple infections (over time)? If we observe
changes in the genomes, where do they occur and do they correlate with changes in viral
load?
Nasopharyngeal carcinoma Nasopharyngeal carcinoma (NPC) is, globally seen, a rare
tumour. However, prevalence rates vary greatly geographically. For example, there is
less than 1 case in 100,000 populations in North America and Europe. In Southern China,
South East Asia and North Africa, however, rates are higher. In Southern China, for ex-
ample, the annual age standardised incidence rate is 20-30 cases per 100,000 populations
in men, and 8-15 cases per 100,000 populations in women (WHO, 2014).
NPC is a cancer of epithelial origin, linked with latent EBV infection and often infil-
trated by lymphocytes. Especially in endemic regions, tumours are always EBV+ (Chua
et al., 2016).
Here, I did not sequence additional samples from the NPC setting. However, there are
multiple, mostly Asian, NPC-derived EBV genomes available in the Genbank database.
In fact, the majority of EBV genomes from Asia are NPC-derived. Therefore I sought
to compare the publicly available Asian NPC genomes to the IM-derived genomes from
Japan as representatives of Asian sequences from a NPC non-endemic region where inci-
dence rates are low and stable (Kimura et al., 2011). To date, comparison between NPC-
endemic and non-endemic regions has been restricted to specific ORFs (Sandvej, Zhou,
and Hamilton-Dutoit, 2000).
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5.2 Results
FIGURE 5.1: ML tree of published type 1 genomes including sequences
from this chapter. Black circles indicate bootstrap values >90. Highlighted
in blue: Asian cluster. Highlighted in orange: "Western"/African cluster
(see chapter 4). Marked in light green: paired tumour and blood samples
from paediatric patients in the UK; dark green: immunocompromised (IC)
paediatric patients from the UK; red: paediatric IM samples from Japan. *:
sequence classified as type 2. Specifically marked with a "Px" are patient
for whom multiple samples are available (from tumour-blood and IM data
sets).
Figure 5.1 shows a phylogenetic tree of the published sequences described in chapter 4 as
well as all novel genomes generated in this project that will be individually highlighted
and discussed in the following sections.
Note that not all nodes in this tree are well supported (i.e. bootstrap values >90, as
indicated by a black circle in the tree). This is likely due to recombination which affects
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tree topology and has been discussed earlier (chapter 4). However, towards the root and
towards the leaves of the tree, nodes are usually well enough supported, especially in the
cases where multiple isolates from the same patient were available, so that isolates can
be put into context with each other and roughly to other published genomes.
5.2.1 Paired blood and tumour samples of immunocompromised paediatric
patients
DNA extracts from whole blood and tumour biopsies from paediatric solid organ trans-
plant recipients were enriched for EBV specific sequences using the 200 ng SureSelect
protocol on the Bravo automation system and sequenced on the Illumina NextSeq plat-
form. Table 5.1 lists sample and sequencing information. The blood sample of patient 1
was excluded, as coverage and depth was poor (33 % of the genome covered with an
average depth of 5). Similarly, the blood sample of patient 4 was excluded as it failed
library preparation. In the further analysis, only samples marked by a l in table 5.1 are
considered (n = 9).
Genomes were quality checked and de novo assembled using pipeline 2 (see chapter 2).
Figure C.1 shows the coverage plots of retained samples after removal of duplicates.
Blood samples had lower depths across the genome, while the tumour samples had a
higher data output. This was expected as blood samples have much lower viral loads.
In consequence, we have paired tumour and blood samples for two patients with
good coverage, both in depth and across the genome, as well as two additional tumour
samples.
Patient Sample Date Source Viral load Read pairs OTR % Depth Cov
[copies/ml]
1 P1-B1 26/05/2015 blood 66,000 4,978,502 0.8 3 33
P1-T1 29/08/2015 tumour 11,229,000 5,973,819 79.1 4892 100 l
2 P2-B1 04/10/2012 blood 22,000 4,827,991 2.1 26 99 l
P2-B2 18/11/2015 blood 1,707,000 5,936,426 2.3 30 97 l
P2-B3 18/01/2016 blood 4,534,000 5,227,303 3.6 30 99 l
P2-T1 02/10/2012 tumour ND 5,718,349 77.2 4508 100 l
3 P3-B1 03/11/2011 blood 22,000 3,924,866 2.2 45 94 l
P3-B2 03/09/2014 blood 952,000 7,450,997 2.2 16 100 l
P3-T1 09/09/2011 tumour ND 5,483,779 66.9 2004 100 l
4 P4-B1 15/03/2003 blood >1,000,000 - - - -
P4-T1 26/03/2003 tumour ND 7,996,268 81.7 5885 100 l
TABLE 5.1: Sample and sequencing information for paired tumour and
blood samples. OTR: On target reads in percent. Cov: Percentage of the
genome that could be covered (repeats excluded). Depth: Average read
depth after removal of duplicate reads. All samples that have been in-
cluded for further analyses are marked by a l .
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Description of consensus sequences
In order to determine the type of EBV patients are infected with, the distances of the
typing genes EBNA2 and -3 genes to the type 1 and type 2 reference sequences (WT and
AG876) were calculated. In all samples, the genetic distances were greatest to type 2,
indicating all patients carry EBV type 1 (figure 5.2).
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FIGURE 5.2: Genetic distance (K80 model) of EBNA2 and -3 genes of paired
tumour and blood samples to type 1 (WT) and type 2 (AG876) reference
sequences.
Figure 5.1 depicts by means of a phylogenetic tree how the isolates fall into context
with each other and other published genomes.
All paired tumour and blood samples (coloured in light green) lie within the cluster
of Western/African sequences (tree highlighted in orange, see chapter 4). Samples from
the same patient (of patient 2 and 3) cluster closely together and are very similar to each
other as indicated by the short branch lengths. The tumour and first blood samples were
taken close together (∆tP2 = 2 d and ∆tP3 = 55 d), while follow up blood samples were
taken several years later (table 5.1). Despite this, variation over time is very limited. No
consensus level changes in patient 2 could be detected. For patient 3, there are three SNP
differences (table 5.2). Two of the SNPs lead to an amino acid change: V250I occurs in the
BORF1-encoded triplex capsid protein and I343M in the BGLF1-encoded capsid vertex
component 1 (CVC1). Neither fall within known epitopes or known functional domains
of the proteins.
The blood samples at both time points have mixed allele frequencies at these loci
as observed in the pileup files of the assembly, even if the consensus base call is not
an ambiguous one, while the tumour sample is homogenous at these positions. This
suggests that either the mutations were acquired by some viruses in the blood after the
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tumour was established, or that the virus present in the malignant B cell which formed
the tumour did not carry these variations.
Therefore, the next step was to look more comprehensively at the intrahost variation
in these patients and to compare the diversity found in blood versus tumour.
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P3-T1 G A A
P3-B1 R C G
P3-B2 A A R
nonsyn l l
ORF BORF1 BGLF1
TABLE 5.2: SNPs in longitudinal data of paired blood and tumour samples
of patient 3 on the consensus level. The isolates are ordered by sample
date. If variants variants occurred at a frequency level of 0.5, ambiguity
codes are introduced (R= G/A), otherwise the base with a frequency >0.5
is called. N denotes missing data. Positions are WT coordinates.
Description of intrahost variation
As stated previously, the average read depth varies greatly between tumour- and blood-
derived samples, as the tumour has likely a much higher viral load (although the actual
viral loads have not been determined for these particular samples). In order to reduce the
impact of depth when comparing diversity of intrahost samples from different compart-
ments of the same patient and across patients, the tumour samples have been subsampled
to 34k mapping reads in order to achieve a comparable average depth of 30.
The resulting average depth across all samples is fairly low (on average 29.5). Cut-
off values were therefore chosen for minimal depth as 20 and the minimal frequency as
20 %, as these settings allowed the condition of having 2 independent reads per strand to
support the variant. For further parameters see chapter 2.
The fraction of the (subsampled) genomes with depth ≥ 20 was as this:
P1-T1: 0.6, P2-B1: 0.6, P1-B2: 0.7, P2-B3: 0.7, P2-T1: 0.7, P3-B1: 0.8, P3-B2: 0.2, P3-T1:
0.7, P4-T1: 0.7, without excluding the repeat regions in this fraction. In some cases, only
a small portion of the genome fulfils this basic conditions for variant calling, indicating
that possible variation even at medium frequency is likely not going to be detected.
Table 5.3 lists the minority variants found in this data set. The subsampled tumour
samples is at this frequency level (20 %) conserved even on the minority level, as no
variants in those samples were detected. For patient 2, three variants have been found
in the blood, two in the first sample (P2-B1), and another, different one in the second
sample (P2-B2), all of them around a frequency of 21-22 %. For sample P2-B1, these two
variants fall within the ORF BLLF1, which encodes the envelope glycoprotein gp350, and
lead both to amino acid changes at two consecutive positions in the protein (S508I and
P509L).
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Pos Ref Var Cov Read1 Read2 Freq ORF nonsyn
P2-B1 78339 G A 27 20 6 22.22 BLLF1 P509L
78342 G A 28 21 6 21.43 BLLF1 S508I
P2-B2 54559 G C 24 18 5 20.83
P3-B1 57474 G A 43 33 10 23.26
115271 C A 54 33 21 38.89 BGLF1 S272F
138051 G A 43 29 14 32.56 BILF2 G62V
P4-T1* 113928 G A 7468 7005 461 6.17
TABLE 5.3: Minority variants of samples from immunocompromised chil-
dren with PTLD. Pos: WT position. Ref: Consensus base. Var: Minor
variant base. Cov: Read depth at this position. Read1/2: Number of reads
supporting the consensus or variant base, respectively. Freq: Minor variant
frequency. ORF: Open reading frame. nonsyn: Amino acid change from
consensus to variant at the respective protein position.
The tumour sample marked by a * is not subsampled.
For patient 3, there are three minor variants found in the first blood sample (P3-B1),
two of them leading to nonsynonymous changes in the proteins encoded by BGLF1 and
BILF2, respectively. BGLF1 encodes the capsid vertex component 1 (CVC1) and BILF2
codes for a predicted glycoprotein.
While epitopes have been described for gp350 and CVC1, the observed minor vari-
ants do not fall into them (Immune Epitope Database) or for that matter in any functional
domain.
The position 63696 which was variable on the consensus level, was not reported as
a minority variant as the coverage was too low at this position. Similarly, the other two
consensus level positions are not reported even if they look heterogeneous when inspect-
ing the mapping manually; however, a combination of low coverage and low mapping
quality of some reads might have resulted in their exclusion.
Finally, the tumour derived isolates were analysed without subsampling in order to
assess how clonal the viral population in the tumour truly is, as the greater depth allows
calling of even low frequency variants. Variants were called with a minimal coverage
of 80 and a minimal frequency of 5 % in order to fulfil the condition of having at least
2 independent reads per strand supporting the variant. However, even when using the
complete read data, the majority of samples did not show any minority variants at this
low frequency level. Only one silent mutation at a level of 6 % was detected in one sample
(see table 5.3, sample P4-T1*).
Taken together this points towards very low diversity in PTLD patients, both between
compartments as well as over time. Variability in the tumours is except for one position
absent, whereas a few minor variants could be detected in the blood. However, it is fea-
sible that a lot of the variability present in blood remained unobserved, as these isolates
have generally very low read depth. Variants could only be called reliably at a medium
frequency due to this restriction. This was even further limited by some areas not fulfill-
ing the variant calling settings.
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5.2.2 Samples from immunocompromised children with chronically high vi-
ral load
In addition to the seven successfully sequenced samples from chapter 3, further 16 sam-
ples were sequenced. All of these are blood samples from paediatric, solid organ recipi-
ents who are immunosuppressed. They were processed with the 200 ng SureSelect pro-
tocol on the Bravo automation platform and sequenced on an Illumina NextSeq. Reads
were quality checked and genomes de novo assembled with assembly pipeline 2 (chap-
ter 2). Table 5.4 lists the sample and sequencing information for these patients, including
the samples from chapter 3. For six samples, enrichment did not work and OTR were too
low to successfully assemble the genomes (samples ebv18, -20, -24, -26,- 28, -29). Conse-
quently, there are in total 17 EBV genome sequences from immunocompromised children
from the UK. Coverage plots of the succesfully assembled, additional genomes are shown
in supplemental figure C.2.
Sample Viral load Read pairs OTR % Depth Cov
[copies/ml]
ebv6 943,000 4,150,874 1.6 38 95 l
ebv7 445,000 6,208,600 1.4 49 98 l
ebv8 1,200,000 7,277,442 1.8 84 95 l
ebv9 >2,000,000 5,509,174 9.8 450 100 l
ebv13 > 2,000,000 12,110,184 4.1 401 100 l
ebv14 > 2,000,000 18,894,696 24.9 3079 100 l
ebv15 1,295,000 11,715,202 1.4 135 99 l
ebv16 497,000 6,270,139 1.0 6 89 l
ebv17 1,067,000 6,892,091 1.9 14 100 l
ebv18 132,000 6,707,931 0.5 - -
ebv19 714,000 26,727,723 1.4 8 98 l
ebv20 26,000 6,477,110 0.5 - 11
ebv21 2,525,000 5,438,799 2.5 26 100 l
ebv22 4,684,000 10,828,549 2.1 21 100 l
ebv23 1,458,000 6,203,195 1.3 7 93 l
ebv24 7,500 8,136,025 0.5 2 6
ebv25 14,533,000 5,719,107 12.7 49 100 l
ebv26 98,000 5,790,434 0.5 2 8
ebv27 839,000 5,220,880 2.2 34 100 l
ebv28 10,000 5,543,283 1.1 3 6
ebv29 12,000 5,408,600 0.7 8 66
ebv30 473,000 5,019,119 1.2 15 97 l
ebv31 1,131,000 5,460,738 1.2 10 93 l
TABLE 5.4: Sample and sequencing information for samples of paediatric,
solid organ recipients under immunosuppression. OTR: On target reads
in percent. Cov: Percentage of the genome that could be covered (repeats
excluded). Depth: Average read depth after removal of duplicate reads.
All samples that have been included for further analyses are marked by a
l .
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Description of consensus sequences
In the phylogenetic tree with other type 1 EBV genomes in figure 5.1, samples do not
cluster together but are spread across the part of the tree containing the other Non-Asian
genomes (highlighted in orange), although some are very similar to each other.
One of the isolates (ebv16, marked with a * in figure 5.4) has a particularly long final
branch, indicating a large number of changes on that branch in comparison to other se-
quences. Indeed, when typing the genomes, ebv16 is of type 2 given the similarity of the
EBNA2 and -3 genes to type 1 and 2 reference strains, respectively (figure 5.3). All the
other sequences belong to type 1.
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FIGURE 5.3: Genetic distance (K80 model) of EBNA2 and -3 genes of sam-
ples of immunocompromised patients from the UK to type 1 (WT) and
type 2 (AG876) reference sequences.
Intrahost variation
I wanted to investigate the presence of minority variants and possibly multiple infections
in the setting of immunocompromised paediatric patients. In contrast to section 5.2.1,
some isolates had greater read depth due to multiple pooled sequencing runs from the
optimisation experiments (chapter 3), reducing the sampling effect of medium frequency
variants and allowing the detection of potential low frequency variants.
Minor variants were called with different settings depending on the depth of the re-
spective isolate. Settings are summarised in table 5.5. A variant needed further to be
supported by 2 independent reads on each strand.
Table 5.5 also lists the number of minority variants found in the samples and the
fraction of the genome falling over the minimal coverage threshold. Not all samples have
sufficient coverage across the genome to reliably call minority variants (e.g. ebv16, ebv17,
ebv19, ebv23, ebv30, ebv31). However, there are a number of samples with sufficient
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Depth Min cov Min freq frc ≥ Min cov # Min var
ebv6 45 20 0.2 0.761937748 5
ebv7 57 20 0.2 0.804845535 227
ebv8 129 50 0.1 0.758456693 3
ebv9 438 80 0.05 0.83556963 0
ebv13 472 80 0.05 0.818373917 786
ebv14 3650 80 0.05 0.843352524 1
ebv15 154 80 0.05 0.724827839 71
ebv16 6 20 0.2 0.011962488 0
ebv17 14 20 0.2 0.116312643 0
ebv19 8 20 0.2 0.03275568 0
ebv21 26 20 0.2 0.646253791 0
ebv22 21 20 0.2 0.408075116 0
ebv23 7 20 0.2 0.022568646 0
ebv25 49 20 0.2 0.847747501 0
ebv27 34 20 0.2 0.715979673 0
ebv30 15 20 0.2 0.189310018 0
ebv31 10 20 0.2 0.034845477 0
TABLE 5.5: Variant call for the data set of immunocompromised patients
without subsampling. Depth: average depth. Min cov: minimal depth set
during variant calling. Min freq: minimal variant frequency set for variant
calling. frc ≥Min cov: fraction of the genome (without excluding repeats)
with a depth greater or equal than the threshold. # Min var: number of
high quality minority variants.
depth and coverage. In those samples, the diversity is very low with the number of
minority variants ranging from 0− 5 (e.g. ebv6, ebv8, ebv9, ebv14, ebv21, ebv25, ebv27).
There are only three samples with a high number of minority variants (ebv7, ebv13 and
ebv15).
Pos Ref Var Cov Read1 Read2 Freq ORF nonsyn
ebv6 143514 A G 39 29 10 25.64
143552 C T 39 11 28 28.21
143588 C T 33 9 24 27.27
143609 G C 26 7 19 26.92
143642 A C 24 5 19 20.83
ebv8 78258 A C 90 54 33 36.67 BLLF1 I536S
144203 G A 141 111 30 21.28
144257 C T 121 104 17 14.05
ebv14 47246 A G 3800 2166 1622 42.82
TABLE 5.6: Minority variants of samples from immunocompromised chil-
dren. Pos: WT position. Ref: Consensus base. Var: Minor variant base.
Cov: Read depth at this position. Read1/2: Number of reads supporting
the consensus or variant base, respectively. Freq: Minor variant frequency.
ORF: Open reading frame. nonsyn: Amino acid change from consensus to
variant at the respective protein position.
Table 5.6 shows the minority variants for isolates ebv6, ebv8 and ebv14, i.e. those with
only few changes. The changes in ebv6 all occur in a short stretch of around 130 bp up-
stream of the ORF LF3 (figure 5.4), which is associated with the BART cluster. However,
they do not fall within any of the exons of the BART mRNAs nor in any of the BART
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ebv6ebv7ebv8ebv13ebv14ebv15
FIGURE 5.4: Genome map of all minority variants found in the data set of
immunocompromised paediatric patients. Every track represents a sam-
ple, the variants are shown at their genomic position (in relation the the
WT sequence) with the height of the bar indicating the variant frequency
(scaled from 0 to 50 %). Repeat regions are greyed out.
miRNAs. One variant in ebv8 leads to an amino acid change (I536S) in gp350. The mi-
nority variants in these isolates likely reflect changes acquired by the infecting virus, as
depth and coverage are high, but further low frequency variants especially for ebv6 and
-8 cannot be excluded.
Figure 5.5 shows the variant frequency histograms of the other group of isolates with
many changes. Sample ebv7 (figure 5.5a) has a bell shaped histogram, which was cut by
the minimal frequency threshold of 20 %. In total, n = 227 minority variants were called,
the majority in the frequency range of 20-30 %.
Similarly, ebv13 (figure 5.5b) has a bell shaped histogram, with the majority of vari-
ants occurring at 17-30 %. There are a few higher frequency variants between 40-50 %
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and a number of lower frequency variants (< 15 %). The abundance of variants in a lim-
ited frequency range and the high number of variants (n = 786) suggests that these might
represent a multiple infection with another EBV.
ebv7 has compared to ebv13 a much lower average depth (57 compared to 472), and
it is likely more variants could be detected with deeper sequencing of the same sample.
In contrast to that, the majority of variants in ebv15 (figure 5.5c) occur below 10 %
and are fairly few (n = 71), despite high depth (154 on average), suggesting that there
might either be another strain at a lower level that was not fully detected due to the
limited data, or that this virus has acquired a lot of low-level variation in this patient.
The relatively high number of changes compared to other samples of the same data set
with very limited variation (ebv6, ebv8, ebv9, ebv14, ebv21, ebv25, and ebv27) would
point towards a second low frequency strain as being the more likely explanation.
Further evidence supporting multiple infection in ebv13 and ebv7 is the presence of
variants at similar frequencies spread evenly across the genome (figure 5.4).
If the variant data is restricted to those with a frequency between 17 and 32 %, i.e. the
main peak in figure 5.5a and 5.5b, then the minority strain of ebv13 differs at 599 positions
and of ebv7 at 204 positions from the majority strain. The mean number of differences
between type 1 strains is 865 ± 307 (standard deviation). At least ebv13 would therefore
fall within the range of observed differences between strains; for ebv7 too much data is
missing.
Of those sites, 82 and 203 are nonsynonymous in ebv7 and ebv13, respectively. The
majority of minority SNPs for ebv7 affect the EBNA3A, -B and -C genes, both in general
(figure 5.6a) as well as in the case of nonsynonymous SNPs (figure 5.7a).
For ebv13, it is BPLF1 (encoding for large tegument protein deneddylase), the EBNA3s,
LMP1, BLLF1 (encoding gp350) as well as BVRF1 (encoding capsid vertex component 2)
(figure 5.6b for all SNPs and figure 5.7b for nonsynonymous SNPs). Those genes belong
to the most diverse genes in EBV in general, which again supports the notion that this is
a genuine secondary infection with another virus.
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FIGURE 5.5: Variant frequency histogram of samples with greater intrahost
diversity.
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FIGURE 5.6: Number of minority variants per ORF in the minority strain
(17− 32 %) of A) ebv7 and B) ebv13.
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5.2.3 Longitudinal infectious mononucleosis samples from Japanese children
Data set
The data set comprised DNA extracts of PBMCs from 12 Japanese paediatric infectious
mononucleosis patients. For every patient, two extracts were available sampled at two
different time points (table 5.7). The samples were provided by Tetsushi Yoshikawa (De-
partment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan) and
are a subset of the data presented in Nakai et al., 2012.
Patient Sample Age Days after Viral load Read pairs OTR % Depth Cov
onset [copies/µg]
1 P1-812 6 6 114,000 3,803,104 3.2 25 98 l
P1-833 17 240 - - - -
2 P2-1213 7 7 125,000 20,113,834 0.4 37 94 l
P2-1246 19 14,000 5,368,060 0.9 8 85 l
3 P3-2670 7 5 250,000 3,672,286 4.1 81 96 l
P3-2740 28 17,000 7,536,334 1.0 13 92 l
4 P4-2274 6 10 139,000 3,435,030 8.1 16 100 l
P4-2392 59 4,000 5,972,994 1.6 19 97 l
5 P5-1294 15 8 60,000 3,079,348 2.6 62 100 l
P5-1323 15 7,000 1,771,093 0.7 29
6 P6-1751 3 4 50,000 3,832,812 3.8 31 96 l
P6-1789 16 350 1,811,779 0.1 - -
7 P7-2315 11 12 10,000 3,235,942 0.6 7 32
P7-2634 84 24,000 1,138,767 1.8 6 80 l
8 P8-414 7 3 22,000 3,628,334 7.8 76 100 l
P8-516 66 9,000 6,724,909 2.0 23 95 l
9 P9-2631 4 9 63,000 3,262,866 5.5 66 100 l
P9-2645 14 38,000 6,875,569 5.2 97 100 l
10 P10-2187 1 10 4,000 3,425,692 0.1 8 27
P10-2777 211 210 1,299,344 0.1 2 6
11 P11-871 1 7 24,000 1,703,065 14.2 22 100 l
P11-920 30 3,500 - - - -
12 P12-1026 11 15 3,000 2,857,532 0.9 32 90 l
P12-1078 42 1,000 1,743,347 0.1 - -
TABLE 5.7: Sample and sequencing information for longitudinal samples
of infectious mononucleosis samples from Japanese children. OTR: On tar-
get reads in percent. Cov: Percentage of the genome that could be covered.
Depth: Average read depth after removal of duplicate reads. All samples
that have been included for further analyses are marked by a l.
All samples were processed with the 200 ng SureSelect protocol on the Bravo automa-
tion system with a 1:10 dilution of capture baits (0.2 µl) and were sequenced on a MiSeq in
two batches. As the OTR output was still fairly poor for many samples, the library prepa-
ration and hybridisation was repeated on the Bravo automation system and sequenced
on a NextSeq in one run to achieve higher read depth. A few samples were excluded if
there was not enough input material left or if viral loads were so low that the enrichment
success was unlikely (P1-833, P6-1789, P10-2277, P11-920 and P12-1078). Additionally,
the sequence reads from the optimisation experiment in chapter 3 for samples P2-1213
and P2-1246 were included (manual preparation with the 3 µg and 200 ng protocol with
varying bait dilutions). A summary of the sample preparation is given in table C.1.
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Read data for the same samples were pooled after QC and de novo assembled using
the assembly pipeline 2 (see chapter 2).
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FIGURE 5.8: A) Viral load of all twelve IM patients given in copies/µg
DNA. Time points, for which DNA samples are available, are marked with
an open circle; samples for which genomes could be assembled are marked
with a filled circle; time points without any specific symbol only have a VL
measurement, but no DNA sample was available. B) Fold change of viral
load from one time point to the next.
Table 5.7 shows the assembly results and coverage plots are shown in supplemental
figure C.3. For some samples, the second time point did not yield any results as viral
titres were too low (figure 5.8a) and consequently also the number of OTRs (table 5.7, P5-
1323 and P7-2315). In total, 16 samples were retained, with longitudinal, paired samples
for five patients.
Figure 5.8 depicts the viral load (VL) of patients across time, including time points
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for which there was a VL measurement but no DNA sample. The VL drops for many
patients fairly quickly, i.e. the host controlled the EBV infection successfully. This can
be seen more clearly in figure 5.8b by means of the fold change from time point to time
point. A fold change of −1 indicates a nearly complete control of EBV, such as in P1 to
P6. Some patients, however, retain elevated VL (especially P7, but also P8) suggesting
they do not control their EBV infection. But the trajectory of VL for the other samples is
not always clear due to variable number of data points for the VL measurements.
In Nakai et al., 2012, patients have been divided into two groups: slow and fast re-
gression. The former was defined as having >500 copies/µg DNA 21 days after onset of
illness. According to this classification, P1 and P6 belong to the fast regression group and
all other patients belong to the slow regression group. In the same publication, no sta-
tistically significant differences between the groups were found in clinical features, but
during acute phase, the fast regression group showed higher serum concentrations of
interleukin (IL)-1β, IL-12, tumour necrosis factor-α, interferon-inducible protein 10 and
monokine induced by interferon γ (Nakai et al., 2012).
Description of consensus sequences
All patients are infected with EBV type 1 as all samples have smaller distances to type 1
than to type 2 typing genes of the respective reference strains WT and AG876 (figure 5.9).
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FIGURE 5.9: Genetic distance (K80 model) of EBNA2 and -3 genes of infec-
tious mononucleosis samples to type 1 (WT) and type 2 (AG876) reference
sequences.
In a phylogenetic tree with additional type 1 genomes, all samples fall within the pre-
viously determined Asian cluster (figure 5.1, highlighted in blue, IM samples coloured in
red). They also cluster together with the other Asian samples in a split network (supple-
mental figure C.4) and are assigned to the same blue, Asian subpopulation as the other
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Asian derived samples (supplemental figure C.5). Sequences of the same patients usually
cluster together in the tree. The only exceptions are the two samples of P2. They appear
together in a well-supported group of samples that are very similar to each other together
with P3, P8 and a gastric carcinoma-cell line from South Korea (YCCEL1/LN827561).
Short branch length between samples of the same patient indicate only few variations
over time. Table 5.8 lists the consensus level changes found in three patients.
P2 (∆t = 12 d) had four variations, three of them close together in the ORF LF2 that
affect together two amino acid changes (I77S and L78V).
P3 (∆t = 23 d) and P9 (∆t = 5 d) only showed one SNP difference. The one in P3 lies
in the overlapping BARF0 and BALF3 ORFs and leads to an amino acid change in both
gene products (L304P for BARF0, a putative protein, and Q397R for BALF3, the tripartite
terminase subunit 1, respectively), while the one in P9 is not in a coding region. All of
these samples belong to the slow regression group, but P2 and P3 seem to control their
infection (figure 5.8), while the trajectory of P9 is less clear, but the VL is dropping by
0.39-fold within five days.
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TABLE 5.8: SNPs in longitudinal data of IM on consensus level. The iso-
lates are ordered by sample date. Ambiguity codes are R= G/A, S=C/G.
N denotes missing data. Positions are patient WT coordinates.
Description of intrahost variation
In order to study the intrahost variation in primary infection of immunocompetent chil-
dren, variants were called as described with cut-off values for minimal depth set to 20
and minimal frequency to 0.2. Not all samples had sufficient depth to allow variant call-
ing across the majority of the whole genome (table 5.9). The number of variants ranged
between samples from 0 to 60. Some samples (P1, P4 and especially P12) seem to be
fairly diverse even with only a smaller fraction of the genome having sufficient depth. It
is likely a lot of the true diversity is being missed in these samples due to missing data.
All minority variants are shown in the EBV genome map in figure 5.10. The complete list
of variants is given in supplemental table C.2, including the affected ORFs and nonsyn-
onymous changes.
P12-1026 harbours the most minority variants and they mostly fall within the gen-
erally more diverse genes, such as the EBNA3s, LMP2, BRRF2 (encoding a tegument
protein) and BKRF2 (encoding the envelope glycoprotein L). The distribution of variant
frequencies is shown in figure 5.11 and resembles a bell shape (cut off at the lower side
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Depth frc ≥ min cov # Min var
P1-812 25 0.524905843 15
P2-1213 37 0.769889456 6
P4-2274 16 0.241898397 31
P5-1294 62 0.800502948 1
P6-1751 31 0.71997299 21
P8-516 23 0.483983072 0
P9-2631 66 0.841472288 1
P11-871 22 0.505614511 1
P12-1026 32 0.557283147 60
TABLE 5.9: Variant call for the data set of IM patients. Depth: average
depth. frc ≥Min cov: fraction of the genome (without excluding repeats)
with a depth greater or equal than the threshold. # Min var: number of
high quality minority variants.
P1-812P2-1213
P4-2274
P5-1294
P6-1751
P9-2631
P11-871
P12-1026
FIGURE 5.10: Genome map of all minority variants found in the data set
of IM patients. Every track represents a sample, the variants are shown at
their genomic position (in relation the the WT sequence) with the height
of the bar indicating the variant frequency (scaled from 0 to 50%). Repeat
regions are greyed out.
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due to the 20 % cut-off threshold). Only around 55 % of the genome had enough data to
call variants with the chosen thresholds. Of the 60 variant sites, 20 were nonsynonymous
(table C.2). It is hard to asses whether this is truly a mixed infection. The relatively low
number of variant sites (n = 60) and the fact that they mostly cluster in genetically di-
verse areas indicate it could rather be due to infection with an already relatively similar
strain and/or intrahost evolution.
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FIGURE 5.11: Variant frequency histogram of P12-1026.
Interestingly, in five of the eight genomes for which minority variants could be de-
tected, LF2 was affected at in total five loci (marked with an arrow in figure 5.10, and
specifically labelled in table C.2). Two sites (149146 and 149326) were each shared by
two isolates (P4/P12 and P6/P12, respectively). On the consensus level, four of the five
alleles do also occur in other published genomes, whereas one was a singleton. This is
the same ORF for which two longitudinal nonsynonymous consensus level changes in
P2 were detected (but these exact loci were not detected to be heterogeneous at these
frequency/quality cut-offs).
5.2.4 Comparison of intrahost diversity between immunocompetent and im-
munocompromised paediatric patients
While there are six other IM-derived EBV genomes published (the WT strain (NC_007605)
(Baer et al., 1984; de Jesus, 2003) and LN827596, LN827590, LN827567, LN827799 and
LN827583 (Palser et al., 2015)), they are all from LCLs. The IM data set here represents
the first genome set of primary infection derived directly from blood. As such, it allows
the comparison of intrahost diversity of clinical sample-derived sequences between im-
munocompetent (IM) and immunocompromised paediatric (paired tumour and blood
sample (TB) from section 5.2.1 and other immunocompromised (IC) from 5.2.2) patients.
Figure 5.12 shows the intrahost diversity (pii) of the different data sets. The value
represents an average across each sample (see chapter 2). The TB set was split into the
tumour (TB-T) and blood-derived (TB-B) sequences. The tumour data refers to the sub-
sampled data (as described in section 5.2.1). Supplemental figure C.6 shows the same
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data including the complete data set for the tumours (TB-Tall); here, diversity scores
were much higher (pii,TB−Tall = 0.001 vs. pii,TB−T = 0.00013). This is probably due to
not excluding the repeat regions in the calculations, which are based on the whole map-
ping file (reads against consensus). While the diversity is calculated under consideration
of sequencing and PCR errors as well as mapping quality filtering, repeat regions likely
accumulate lots of high quality mapping reads, whose position (which repeat unit) is not
reliable. Moreover, no minority variants were detected (repeat regions were excluded) in
either the subsampled or complete data (with one exception) (see table 5.3). To correct
for this and also to ensure comparability of data in terms of depth, the subsampled data
set was chosen.
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FIGURE 5.12: Intrahost diversity across different data sets. The line in the
box indicates the median, the bottom and top of the box show the 25th and
75th percentile. IM: Infectious mononucleosis; IC: immunocompromised
patients, TB: paired tumour (-T) and blood (-B) data set. The TB-T data
set represents the subsampled data set of comparable depth to its paired
blood samples.
Diversity was higher in the IM data set (pii,IM = 0.00048) compared to the paired tu-
mour and blood samples (TB-B and TB-T, pii,TB−B = 0.00028 and pii,TB−T = 0.00013), but
not the immunocompromised (IC) (pii,IC = 0.00056) samples. This is due to the two out-
liers in IC, as the distribution of the rest of the samples is generally lower. Accordingly,
the median of IC (0.0003) is lower than that of IM (0.00042). Differences were not signif-
icant (IM vs IC: p = 0.35, IM vs TB-B: p = 0.23, Mann-Whitney U test) except between
IM and tumour samples (IM vs TB-T: p = 0.037). There was also no significant difference
between IM and IC even when excluding the two outliers in IC (named hereafter IC*),
which correspond to the multiply infected samples ebv7 and ebv13 (pii,IC∗ = 0.00028,
p = 0.097).
Blood-derived samples (IC and TB-B) were similar (pii,TB−B = 0.00028 and pii,IC∗ =
0.00028), as expected, as both groups are representative of immunocompromised pa-
tients. But the diversity in tumours was much lower (pii,TB−T = 0.00013), and although
differences were not significant, p-values are indicative of a potential difference between
groups (IC vs TB-T: p = 0.05, TB-B vs TB-T: p = 0.063, Mann-Whitney U test).
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FIGURE 5.13: Number of minority variants for different data sets. IM: In-
fectious mononucleosis, IC*: immunocompromised patients without mul-
tiply infected samples (ebv7, ebv13, ebv15), TB: paired tumour and blood
samples (not subsampled).
This is supported by the number of minority variants in the different data sets (fig-
ure 5.13, multiple infected samples in IC excluded), although differences between groups
are not significant (p = 0.1123, Kruskal-Wallis rank sum test). However, it is not clear
within the IM samples, whether the higher diversity results from multiple infection or
within host evolution, as many of the samples with higher number of variants have poor
depth or coverage across the genome.
5.2.5 Comparison between Asian NPC and Non-NPC genomes
The majority of published genome sequences from Asia are isolates from NPC samples
(n = 14). There are six genomes from Non-NPC settings: three sLCL from Hong Kong,
one BL from Japan, one GC from South Korea and one BL from Papua New Guinea (see
table 1.2). The genome from Papua New Guinea is the only type 2 genome in this group.
The IM samples sequenced in this project are therefore the first non-tumour EBV isolates
from an Asian region where NPC is not endemic (Kimura et al., 2011).
Determining whether there are differences between Asian NPC and other Asian Non-
NPC samples might help to disentangle geographic from malignancy-associated varia-
tion. The type 2 genome has been excluded as the EBNA genes would bias the results.
The lower quality sequence of longitudinal pairs from the Japanese IM set have also been
excluded. A split network of these n = 30 Asian NPC (n = 14) and Non-NPC (n = 16)
genomes (figure 5.14) shows that the majority of NPC-derived genomes cluster together.
The reticulations, however, also indicate that recombination between strains has likely
occurred. In order to determine relevant SNPs responsible for this (partial) segregation,
a PCA was performed. Figure 5.15a shows the scatterplot of the PCA and figure 5.15b a
NJ tree of the same genomes as a complementary identification key for the scatter plot.
The first principal component (PC1) explains around 40 % of the variation in the data.
There is a rough separation between NPC and Non-NPC samples with two clusters on
the far left (only NPC samples) and far right (mostly Japanese IM samples, the South
Korean GC samples (LN827561) as well as GD1, a saliva sample from a Chinese NPC
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FIGURE 5.14: Split network of Asian NPC (blue) and Non-NPC (red) de-
rived genome sequences.
patient). The second principal component (PC2) only explains around 11 % of the vari-
ance in the data, but seems to explain the variation within the intermediate samples of
PC1. These intermediate samples comprise the three sLCL from Hong Kong (LN827547,
LN824224, LN824209), the BL from Japan (Akata) as well as some IM samples from Japan
and Southern Chinese NPC samples.
The loadings of the variables from the PCA allow us to determine the variables (SNPs)
with the greatest contribution to PC1 (i.e. these SNPs are responsible for the divide be-
tween the two clusters on axis 1). Figure 5.16 shows the SNP locations in the genome
whose absolute loadings are higher than the third quartile of all absolute loadings. There
are 767 SNPs that fulfil this criterion (red track), the majority of those, 626, lie within cod-
ing regions (blue track). Of these, 271 SNPs lead to a change of amino acid in the encoded
proteins (green track). Figure 5.17 shows the number of nonsynonymous substitutions
for each affected ORF. The largest number of nonsynonymous SNPs lie within the ORFs
BPFL1 and the EBNA3s, followed by the inner tegument protein gene BOLF1, the gp350
gene BLLF1 as well as LMP2 and BZLF1.
Except for BPLF1, all of these ORFs encode antigenic proteins. In fact, 24 of the
nonsynonymous changes lie within experimentally described epitopes (Immune Epitope
Database): six in BZLF1, six in EBNA3A, five in LMP2, four in EBNA3C, and three in
EBNA3B (supplementary table C.3).
In track A of figure 5.16, track A, between 138 kb to 148 kb, there are a number of
SNPs in the noncoding area between BILF2 and LF3 as well as between LF3 and LF2,
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FIGURE 5.15: PCA of whole genomes of Asian NPC and Non-NPC sam-
ples.
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C
FIGURE 5.16: Absolute loadings of the variables that are greater than the
third quartile plotted around the genome map. A: all SNPs, n = 767; B: all
SNPs within coding regions, n = 626; C: nonsynonymous SNPs, n = 271.
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FIGURE 5.17: Number of nonsynonymous substitutions per gene in the
group SNPs that have the highest impact on variation explained by PC1 in
Asian NPC and Non-NPC genomes.
corresponding to the location of the BamHI A rightward fragment (BART) from which
mRNAs and miRNAs are transcribed and which are strongly expressed in NPC and
thought to play a role in pathogenesis (Edwards, Marquitz, and Raab-Traub, 2008; Cai
et al., 2006).
None of the SNPs of interest lie within the miRNAs, which are very conserved. Ten
SNPs however fall into the exons of the BARTs (exon coordinates were given in Ya-
mamoto and Iwatsuki, 2012). These exons are V, VA’ and VB, which are also overlapping
with the ORFs BALF4 and BALF5. In addition, there is a single SNP in the first exon of
RPMS1, a putative ORF also part of the BART family transcripts.
The next question was then if any of the nonsynonymous sites are unique to the clus-
ter of NPC samples (figure 5.15, samples M81, GD2, KF992571, HKNPC1, LN827525,
KF992564, KF992565, KF992570, KF992567, KF992566) when the remaining Non-Asian
type 1 sequences are included. For this, the consensus sequence of this cluster was taken
based on the 271 nonsynonymous sites and compared to all other sequences. Only eight
of these sites were unique to the NPC cluster: 976 and 2086 in BNRF1, 60 and 65 in EBNA-
LP, 1828 in BPLF1, 2087 in EBNA3B, 1279 in BRRF2, and 375 in BGLF1 (CDS positions).
The majority of sites do not lie within any known or in the UniProt database annotated
structural/functional areas. Only the SNP in EBNA3B lies within a proline rich region.
The variant found in the NPC cluster is on the DNA level a T instead of C, and on the
amino acid level isoleucine instead of threonine/alanine (both variants occur in the other
sequences due to additional variations at different codon positions).
Other NPC-associated variations I also looked for other variations that have been de-
scribed in the literature to be potentially associated with NPC.
BZLF1 major switch from latency to lytic. Difference in epitheliotropism might be
related to different expression levels of this gene. Many regulatory elements in the BZLF1
promotor (Zp) have been found in a short stretch ranging from -221 to +12 relative the
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transcription start (WT coordinates 91,126 to 90,893). Four groups of Zp variants have
been described: Zp-P, which is identical to the WT sequence, as well as Zp-V1, Zp-V3
and Zp-V4 based on four positions (-196, -141, -106 and -100) (Lorenzetti et al., 2009).
In the data set here of Asian type 1 sequences, 18/30 were of type Zp-V3 (TGGG) and
12/13 were of type Zp-P (TAAT). Zp-V3 was more often observed in NPC cases (11/14)
than in non-NPC (7/16) cases. Conversely, Zp-P was found more often in non-NPC
(9/16) than NPC (3/14) cases. The null hypothesis that NPC pathology and promotor
variant are independent cannot be rejected, however (p = 0.052, Chi-square test).
Another arguably NPC associated variation is a 30 bp deletion in LMP1. All genomes
except patient 4 of the IM data set exhibited this. Moreover, the XhoI restriction site seems
to be present in all genomes (where data available). Interestingly, there is only one SNP
in the LMP1 ORF, that belongs to the group of sites contributing most to the partitioning
of the two PCA clusters (figure 5.16).
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Akata Non;NPC A A G G C A G
GD1 NPC A A G G A G
LN824209 Non;NPC A A A G G A A G
LN827561 Non;NPC A A G G A A G
P1;812 Non;NPC A A G G A G
P11;871 Non;NPC A A G G A A G
P12;1026 Non;NPC A A G N N A G
P2;1213 Non;NPC A A G G A G
P3;2670 Non;NPC A A G G A G
P4;2274 Non;NPC A A G G A G
P5;1294 Non;NPC A A G G A G
P6;1751 Non;NPC A A G G A G
P7;2634 Non;NPC A N N N A G G A G
P8;414 Non;NPC A A G G A G
P9;2631 Non;NPC A A G G A G
GD2 NPC A A G ; ; ; C G
HKNPC1 NPC A T A G G T C G
M81 NPC A A G G T C G
KF992564 NPC A A G G T C G
KF992565 NPC A A G G T C G
KF992566 NPC A A G G T C G
KF992567 NPC A A G G T C G
KF992568 NPC A A G G T C G
KF992569 NPC A A G G T C G
KF992570 NPC A A G G T C G
KF992571 NPC A A G G T C G
LN824224 Non;NPC A A G G T C G
LN827525 NPC A A G G T C G
LN827547 Non;NPC A A G G T C G
LN827549 NPC A A G G T C G
EBER2intergenicI
EB;8m
EB;6m
FIGURE 5.18: Variations found in the EBER region (genes and intergenic
region). Positions and changes are indicated in relation to WT. N denotes
missing data.
The EBV encoded small RNAs (EBER) EBER1 (167 bp) and EBER2 (173 bp) are the
most abundant viral transcripts (Rymo, 1979). They are expressed in all EBV-associated
tumours. Both EBER genes are highly conserved among the EBV lineages. The majority
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FIGURE 5.19: Midpoint-rooted NJ tree of the EBER region including inter-
genic region of Asian NPC (blue) and Non-NPC (red) samples.
of the variation can be found in the 161 kb spacer region. In the data set here, EBER1
shows no variation. Within the whole EBER region including the spacer, there are 17
polymorphic sites; seven of them lie within EBER2, 10 of them in the spacer region.
Figure 5.18 summarises the SNPs found between the Asian NPC and Non-NPC sam-
ples. A ML tree had too little support due to the lack of variation (except for the two most
basal nodes), but the NJ tree of the whole EBER region (including spacer) in figure 5.19
recapitulates this pattern suitably as well. There are four defined variant types of EBERs,
B95-8 as found in the WT sequence, EB-8m, EB-10m and EB-6m (Wang et al., 2010c). 15
isolates are of type EB-8m and 15 isolates are of type EB-6m (figure 5.18). Type EB-8m
was found most frequently in NPC (13/14) than in Non-NPC samples (2/16), whereas
EB-6m was found most frequently in Non-NPC (14/16) than NPC samples (1/14). This
difference is significant (p = 1.13e−5, Chi-square test).
5.3 Discussion
5.3.1 EBV infection in paediatric immunocompromised patients
Here, I sequenced for the first time paired tumour and longitudinal blood samples from
patients, in this case paediatric PTLD cases. Additionally, a number of EBV genomes
from blood of immunocompromised paediatric patients were sequenced. Whole genome
sequencing of EBV directly from blood is still a greater challenge than from tumours
due to the great difference in viral load. As a consequence, the greatest drawback of the
analyses presented here is the limitation due to the reduced depth achievable from blood
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samples. In the case of immunocompromised patients, this is further hampered by the
administration of Rituximab, a monoclonal antibody against the B cell surface antigen
CD20 that results in B cell depletion, the main site of EBV infection. Rituximab is used
both in prophylaxis and treatment for PTLD after HSCT and SOT (Heslop, 2009; van der
Velden et al., 2013; Blaes et al., 2005; Oertel et al., 2005).
Sequences from paired tumour and blood sample of the same time point from the
same patient resemble each other strongly, suggesting that the majority strain found in
the blood is established in the tumour. This is concordant with the hypothesis that the
progenitor cells of the tumour have already been infected prior to malignant transforma-
tion (Capello, Rossi, and Gaidano, 2005). Moreover, the virus population in the tumour
is extremely homogeneous.
For the two cases where longitudinal data was available, the majority strain in the
blood remains the dominant virus in the blood for many years. While the sample size is
rather small, the results are still indicative that variation of EBV over time without mul-
tiple infection in immunocompromised patients at the consensus level might be rather
limited. However, CTL escape mutants after donor CTL infusion in a case of PTLD have
been described before in one patient (Gottschalk, 2001), but selective pressure might be
low due to EBV’s ability to establish latency in the advent of immune control.
At the minority level, in both data sets (TB and IC), no variation was found in the
majority of samples, though in some cases this might be attributed to insufficient depth
and coverage. Even samples with fair or high depth, however, variable sites were usually
few. Those were mostly synonymous changes; the few nonsynonymous changes were
interestingly mostly observed in genes that encode for structural proteins of the capsid
(BGLF1, BORF1) and glycoproteins (BLLF1, BILF2). These could potentially be related
to immune escape, but in immunocompromised patients, latent replication is usually
the origin of high viral loads. In addition, the lack of CTL immunity should remove any
selective pressure and therefore potential advantage, although treatment such as reduced
immunosuppression or EBV-specific CTL transfusion could re-establish this evolutionary
force. No data on this was available for the PTLD patients in this study.
In two (potentially three) cases of the IC data set, there was clear evidence for co-
infection with another EBV strain. Co-infections can either occur during primary infec-
tion, i.e. due to transmission of multiple strains, or later acquisition of another virus. One
could imagine that new infections might establish themselves easily due to the lack of
immune control in immunocompromised patients.
One risk factor of PTLD is EBV seronegativity pre-transplantation (Gulley and Tang,
2010). This is most likely to be the case in children, which means that the primary in-
fection results from the transplant. In the TB data set consisting of longitudinal blood
samples, co-infection was not detected.
In some cases, it is hard to differentiate between genetic drift and co-infection. On
the one hand, genetic drift would leads to random changes across the genome, while co-
infection likely shows additional variants at sites known to vary between isolates. Addi-
tionally, reconstructing haplotypes could help disentangling this. However, longitudinal
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data is usually necessary for this, as most approaches are cluster-based using frequency
changes of variants over time. A combination of long read sequencing of longitudinal
samples would therefore be the best strategy to resolve questions about genetic-drift ver-
sus co-infection.
Co-infections of EBV, both in terms of co-infections with type 1 and 2, as well as with
different strains of a single type have been described before. Previously, EBV infections
with multiple strains have been analysed using PCR amplification of polymorphic genes
in the setting of HIV-positive, T cell immunocompromised individuals (Yao et al., 1996;
Yao et al., 1998) and in immunocompetent individuals (Srivastava et al., 2000; Sitki-Green,
Covington, and Raab-Traub, 2003). Moreover, heteroduplex tracking assays (HTA) were
being used to describe multiple infection in healthy carriers as well as infectious mono-
nucleosis (Sitki-Green, Covington, and Raab-Traub, 2003; Tierney et al., 2006; Sitki-Green
et al., 2004; Kwok et al., 2015). However, there is very little report on minority variants
detected via NGS in the literature. One study analysed EBNA1 variation in MS patients
(Tschochner et al., 2016), and another study looked broadly at the intrahost nucleotide
diversity in IM patients (Renzette et al., 2014). To our knowledge this is therefore the first
study that looked at intrahost variation on the whole genome level.
5.3.2 Primary EBV infection
Whole genomes from longitudinal blood samples of Japanese paediatric patients with
IM were sequenced. Due to low viral titres after the onset of immune control, genomes
could rarely be recovered from the second time point. For three patients, however, it
was possible to obtain longitudinal genomic data. In these patients, the two time points
were only a few days apart, yet a few consensus level changes could be observed. Ad-
ditionally, a number of minority variants was found in most samples where depth was
high enough. One patient sample, P12-1026, displayed a higher number of those. But
it is not possible to determine, from these data, whether this is due to accumulation of
variation of the infecting strain, or whether it might be co-infection with another strain
due to missing data (especially depth to reliably call minority variants) and only a single
time point. Intrahost nucleotide diversity and the fairly low number of variants, would
argue against a different distinct virus. On the other hand, most variants fall within re-
gions that are highly diverse between strains. The sample was taken at a relatively early
time point after infection (15 days after onset of disease), suggesting either a surprisingly
high mutation rate within this patient or primary transmission of an already more poly-
morphic pool of virus. As mentioned earlier, an approach to differentiate between drift
and co-infection would be long-read data in combination with high depth sequencing of
longitudinal data, as this would enable the reconstruction of haplotypes. Moreover, one
can consider whether minor variants occur at sites, that show lineages (in other words
often differ between viruses). This might be confounded, however, by a sampling effect
if coverage and depth are as low as in this case.
One patient displayed three longitudinal consensus level polymorphisms located in
the ORF LF2. Additionally, five genomes out of eight, for which minority variants could
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be detected, had polymorphic sites in the same ORF. Protein LF2 binds Rta (encoded by
BRLF1), one of the two viral transactivators responsible for the switch to lytic replication.
LF2 inhibits Rta pomotor activation and alters it subcellular localisation, thereby block-
ing EBV replication in cells (Heilmann, Calderwood, and Johannsen, 2010). The ORF was
affected in both fast (P1, P6) and slow regressing patients (P4, P11, P12), but none was
nonsynonymous. No sites under positive selection were detected in LF2 in the data set
of section 4.2.3, but this did not include the new Japanese IM sequences presented here.
However, there is only little variation present on the nucleotide consensus level, and
barely any on the amino acid consensus level, even with these genomes included. Con-
sequently, a ML tree was very poorly supported. Why there is variation on this locus in
particular in IM patients remains therefore elusive. Its regulatory role in virus replication
makes it interesting, though, as this might participate in disease progression.
It is possible, that the diversity found within the patients is underestimated by study-
ing the virus population solely in the blood. One study analysed the intrahost nucleotide
diversity in IM patients in both oral washes and blood at acute phase and convalescence
(Renzette et al., 2014). They found that the diversity during AIM is lower than during
convalescence due to a relatively homogeneous founder virus. Interestingly, diversity
was generally higher in oral washes than in blood. Moreover, the diversity increases
during convalescence in the oral washes, but remains low in B cells.
Another study described virus strain variation within different compartments (saliva,
PBMCs and plasma) in children with IM and asymptomatic primary infection based on
HTA (Kwok et al., 2015). They found that there is a constant interchange of viruses
between circulating B cells and epithelial cells, but that there is a discordance between
plasma and saliva/PBMCs. This would suggest another undefined reservoir of EBV
(Kwok et al., 2015).
Kwok’s implication of a unknown EBV reservoir shedding into the plasma is also
very interesting. In the context of this study, the plasma compartment would also be
included, as DNA has been isolated from whole blood, i.e. both the PBMC and plasma
fraction, and therefore also whatever might be shed into the plasma. This reservoir could
be, for example, B cells residing in lymphoid organs or peripheral tissue.
5.3.3 Comparison of diversity of EBV infection in immunocomporomised and
immunocompetent patients
The data sets presented here include blood-derived sequences from paediatric patients
from both immunocompromised (data sets TB and IC) and immunocompetent (data set
IM) patients. In both sets, there is an additional (even if limited) longitudinal component.
This allows a comparison of diversity found between the two cohorts.
In both data sets, the observed variability over time was very low (tables 5.2 and 5.8).
However, the time difference between sample points varied greatly between the data sets
(days in the IM data set, years in the immunocompromised data set, see tables 5.1 and
5.7). The sample size is extremely small to draw any strong conclusions, but one could
argue that the variability over time might be greater in the IM data set, as a few variants
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on the consensus level could already be observed within days compared to a similar
number after years in the immunocompromised patients. But more samples are needed
for a reasonable estimation of the substitution rate during acute infection (Fu, 2001).
This observation of higher variability is supported by the intrahost diversity and by
the number of minority variants in those two groups (figure 5.12 and 5.13). Immunocom-
promised patients showed a lower nucleotide diversity and lower number of minority
variants (when excluding mixed infections), even though results were not statistically
significant.
A possible explanation for these varying degrees of diversity could be differences in
the mutation rate. Depending on the responsible process of virus replication, the muta-
tion rate can vary. In latency, the high fidelity host polymerase is being used for viral
DNA replication in the normal process of cell division. This also means the genome is
only replicated once during S phase (Adams, 1987). In contrast to that, the viral poly-
merase is being used during lytic cycle and replication is initiated more than once (Ham-
merschmidt and Sugden, 1988). While the polymerase does have proof reading function
(Tsurumi et al., 1993; Tsurumi, Daikoku, and Nishiyama, 1994), its mutation rate is not
known and it might be possible that higher lytic replication leads to greater changes in
the viral population than clonal expansion of infected B cells.
Traditionally, IM is associated with latent infection (Niedobitek et al., 1997; Kenney,
2007), with its clinical symptoms being a result of the strong immune response against
EBV-infected B cells. But the relatively long incubation period of one month suggests
that lytic replication precedes the onset of clinical symptoms (Kenney, 2007). Moreover,
during acute infection in IM patients, EBV has been found to lytically replicate in B cells
in the blood (Prang et al., 1997).
In immunocompromised/PTLD patients, the reason for the high viral load in blood,
i.e. whether it is lytic or latent replication, is controversial, and both explanations are not
mutually exclusive. Additionally, the number of genomes per cell could be a factor. In
paediatric SOT patients, a group with particularly high viral loads have been found to
carry two populations of infected B cells: one infected with 1-2 genomes per cell, and
another one infected with 20-30 genomes per cell (Rose et al., 2002). Carriers with lower
(but still elevated) VL usually only had 1-2 genomes per cell.
Gärtner et al., 2002 argue that the main mode of replication in immunocompromised
patients is latent rather than lytic. Similarly, another group finds no evidence of viral
DNA in the plasma nor lytic replication gene expression with a restriction of the high
viral load to the memory B cell compartment (Qu et al., 2000; Rose et al., 2001). This is
supported by a literature study that has found that circulating EBV levels in transplant
recipients have an EBV DNA doubling time which corresponds to the doubling time of
lymphocytes undergoing cell division (Funk, Gosert, and Hirsch, 2007; Gulley and Tang,
2010).
In contrast to that, another study found that EBV DNA, which normally resides in
B lymphocytes, can be detected in plasma in patients with active EBV infection or EBV-
related PTLD, both in encapsidated form as well as naked DNA, indicating both virus
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production as well as originating partially degraded DNA from dying cells (Gulley and
Tang, 2010). There have also been reports of variable BZLF1 expression in PTLD cases
(Vakiani et al., 2008). One study found a higher ratio of EBV lytic replication in PTLD
patients compared to immuncompetent hosts and transplant patients without PTLD, but
sample sizes for the PTLD group was very low compared to the other groups (Kroll et al.,
2011). In fact, a picture seems to emerge where oncogenicity of EBV is primarily related
to latent infection, but that lytic replication can play a role in cancer development. In a
humanised mouse model, Zta (BZLF1)-knockout infected mice develop tumours less fre-
quently than wild-type infected mice, although both viruses establish long-term latency
(Ma et al., 2011). In tumours of human adult PTLD patients, latency II and III were de-
tected in 79 % of cases, and lytic replication in 60 % of cases. The subgroup of patients
expressing latency III as well as lytic EBV replication displayed a shorter survival and
early-onset PTLD (Gonzalez-Farre et al., 2014).
If lytic replication has a higher mutation rate, it would also explain the emergence
of consensus level changes after days as well as the higher number of minority variants
in the blood of IM patients, In particular also in P12-1026. The patient is part of slow
regression group, perhaps due to a particularly high rate of EBV replication, which in
turn would lead to a higher number of minority variants found in the blood.
The notion of lytically replicating virus (especially in epithelial cells in the early phase
of IM) playing a role and generating more diversity is supported by the studies discussed
earlier, which looked at intrahost variation in different compartments in IM patients
(Renzette et al., 2014; Kwok et al., 2015). Especially the findings by Renzette et al., 2014
showed a generally higher diversity in oral washes, in particular during acute phase,
suggesting a process which introduces more diversity.
Another factor to be considered in this comparison might be the lack of selection
pressure from the immune system in immunocompromised patients. This, however, is
also dependent on treatments that reinstate a immune response, such as decreasing the
immunosuppressive dose and infusion of EBV-specific CTLs (Heslop, 2009) – information
that the data sets presented here are lacking.
5.3.4 Comparison Asian NPC and non-NPC isolates
A whole genome comparison of Asian NPC and Non-NPC samples using PCA showed
that the first principal component divides roughly between some NPC and Non-NPC
samples, excluding a few intermediate samples of both groups (figure 5.15). The SNPs
with the largest contribution are distributed across the genome and lie mostly within cod-
ing regions (figure 5.16). Of those SNPs, 271 are nonsynonymous and are also distributed
equally across the genome.
The majority of the most affected ORFs are very polymorphic genes encoding anti-
genic proteins. A number of the nonsynonymous SNPs also affect experimentally de-
scribed epitopes, indicating that these sites might be important adaptations for immune
escape. However, IEDB does not provide information about the HLA allele for which
these epitopes have been described (in particular whether they might be presented by
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HLA alleles common in China or other Asian countries) which restricts a deeper inter-
pretation.
There is a large number of the NPC/Non-NPC discriminating SNPs falling into the
BART region of the genome, from which mRNAs as well as miRNAs are transcribed.
The BART miRNAs are highly expressed in latently infected epithelial cells, such as NPC
(Cai et al., 2006), which usually display latency II. Another miRNA cluster located in the
BHRF1 locus is expressed in particular in cells of expressing latency III. However, none
of the SNPs fall within the miRNAs. This is not overly surprising as miRNAs are usually
very evolutionary conserved. They play an important role in the viral life cycle by post-
transcriptionally regulating gene expression of various targets involved in regulation of
apoptosis, immune evasion and the establishment of latency (Kuzembayeva, Hayes, and
Sugden, 2014; Vereide et al., 2014; Kang, Skalsky, and Cullen, 2015; Lin et al., 2015).
The differential expression in different tissues rather than sequence variation is likely the
more important factor in maintaining the balance between virus and host (Cai et al., 2006;
Lin et al., 2015).
It has been shown that there exist at least six different splicing forms of BART mRNAs,
and they are assumed to have each an ORF, but native proteins have rarely been shown
conclusively in vivo (Yamamoto and Iwatsuki, 2012). Ten NPC/Non-NPC discriminating
SNPs fall into three exons of the BART mRNAs (V, VA’, VB). VA’ is part of a minor-
splicing form RK-BARF0, which is only rarely detected. On the other hand, VB is part of
the BARF0 and RPMS1A splicing form and V part of the RPMS1 and A73 splicing form,
all of which have been deteted in various EBV-infected cells (BL, pyothorax-associated
lymphoma, LCL, T/NK cell lines) (Yamamoto and Iwatsuki, 2012).
The existence of BARF0 and RK-BARF0 proteins have not been unquestionably shown
(Thornburg, Kusano, and Raab-Traub, 2004), but proteins produced from constructs showed
the localisation in the nucleus (Kienzle et al., 1999). Additionally, RK-BARF0 could lead
to increased levels of LMP1 through sequestering Notch (Kusano and Raab-Traub, 2001;
Thornburg, Kusano, and Raab-Traub, 2004). In turn, LMP1 as one of EBV’s major onco-
genes might contribute to NPC pathogenesis through introduction of morphological and
phenotypic changes in epithelial cells (Dawson, Port, and Young, 2012).
RPMS1 is another transcript of potential interest. Two SNPs fall into the exons affect-
ing the RPMS1 transcript, and an additional SNPs is within the RPMS1 reading frame
(G155391A, leading to an amino acid change from Asp to Asn). This specific polymor-
phism has previously been described as being strongly associated with NPC in southern
China (Li et al., 2005; Feng et al., 2015; Cui et al., 2016) and has been proposed to be used
in a risk prediction model (Cui et al., 2016). RPMS1 mRNA is transcribed at high levels
in epithelial carcinoma cells (Li et al., 2005; Yamamoto and Iwatsuki, 2012), but could
not be detected yet on the protein level in cultured NPC cells or NPC tumour biopsies
(Al-Mozaini et al., 2009). However, the SNP has been in vitro functionally characterised
to decrease RPMS1 protein stability in the NPC-associated variant. In addition, a study
found the RPMS1 mRNA expression is upregulated in association with BZLF1 mRNA,
in Akata and P3HR1 cells (two BL cell lines) when stimulated with PMA, suggesting that
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induction of lytic infection might play a role (Yamamoto and Iwatsuki, 2012).
While LMP1 is often seen as an important contributor to NPC pathogenesis and is a
very polymorphic protein (Dawson, Port, and Young, 2012), only a single SNP (G335D)
affecting LMP1 is contained in the list of NPC/Non-NPC discriminating SNPs. This
SNP is located within the cytoplasmic domain, but does not affect any of the C-terminal
activating regions or the TRAF protein interaction motif. A clear functional association
can therefore not be made in this context. However, this finding also suggests that most
variation found in Asian LMP1 could rather be due to geography/population structure
than disease association.
One key protein is Zta (encoded by BZLF1), the major switch from latency to lytic
replication and changes here, either in sequence or expression, might contribute to dif-
ferences in tropism. Among the discriminating, nonsynonymous sites, 17 affect Zta, two
of them (195 and 205) in the DNA-interacting bZIP domain (Chen, Reinke, and Keating,
2011).
Increased lytic replication might also be due to the regulation of gene expression. In
the data here, the BZLF1 Zp-V3 promotor variant is most often observed in NPC cases,
compared to the Zp-P variant, but differences were not significant. Zp-V3 was first only
associated with type 2 sequences. Later it was also frequently found in Asian samples
(Jin et al., 2010) and this variant was most often found in NPC cases here. It was first
only found in malignant samples (Gutiérrez et al., 2002), but later also in healthy carriers
and IM patients (Tong et al., 2003; Martini et al., 2007). Additionally, a study found it
might correlate with severe diseases such as CAEBV (Jin et al., 2010). The other promotor
variant found in the data here is Zp-P. It was found to be the dominant variant in non-
malignant EBV associated diseases in Chinese children (Jin et al., 2010). The comparison
done here is rather small in sample size and does unfortunately not elucidate further
whether the potential association between Zp and disease might be real.
Another variation that is arguably associated with NPC development are a 30 bp
deletion in LMP1. The deletion leads to the loss of ten residues in the transformation
effector site 2 (TES2) of LMP1. Some studies have suggested a higher oncogenicity of this
variant (Ai et al., 2012; Chang et al., 2009; Tao et al., 1998), while others did not show
a difference (Fielding et al., 2001; Yeh et al., 1997). The variant seems to be distributed
world-wide. While a recent meta study showed an association with NPC development
restricted to Asian populations, other studies showed it is frequently occurring in healthy
carriers in various populations. Here, all Asian genomes except for one Japanese IM
isolate exhibited the deletion, strengthening no specific association with NPC.
Apart from the miRNAs, another group of noncoding RNAs expressed by EBV are the
EBERs. There is a significantly different occurance of EBER variants between Asian NPC
and Non-NPC samples. These results confirm the association of EB-8m with enedemic
NPC cases (Shen et al., 2015).
In general, this PCA-based approach allowed us to generate a list of Asian NPC/Non-
NPC discriminating SNPs. It is a step further towards differentiating between geographic
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variation and disease associated variation, as it enables to filter out Asian-specific vari-
ation also found in NPC-nonendemic regions. A comparison of NPC-endemic strains
between samples of NPC patients and healthy controls would obviously be important
to further remove more local geographic signatures leading to false positives. However,
this approach bears the disadvantage that a healthy control might already be infected
with a possibly more oncogenic strain, without having developed NPC yet, calling for
appropriate control selection (e.g. healthy elderly).
PCA also has some problematic properties intrinsic to the method. Here, we are inter-
ested in identifying variables that differentiate between two groups of sequences. PCA,
however, aims to describe the overall variability among individuals. In other words,
this variability is comprised of both, within-group as well as between-group variation.
A method suggested to overcome this is Discriminant Analysis of Discriminant Compo-
nents (DAPC). It combines PCA and disriminant analysis (DA), with the latter aiming
to summarise the genetic differentiation between groups (Jombart, Devillard, and Bal-
loux, 2010). Moreover, another source of false positives are sites identified due to genetic
linkage.
To properly assess the significance of the polymorphisms found independent of the
method used, functional studies are needed. While we can data mine the variation data to
narrow down on potentially interesting study targets, proper functional characterisation
is necessary.
In conclusion, I could not find correlation between previously suggested NPC-asso-
ciated variations. There are many previous studies which focussed on very specific vari-
ations in various populations and clinical settings and associations to pathogenesis seem
to be controversial. It is not surprising that data set here cannot contribute significantly
to this issue. However, our approach has the advantage of allowing a whole genome
comparison approach.
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Chapter 6
Conclusion & Future work
The advances in EBV WGS demonstrated here, as well as those shown by other groups,
now enables the study of a new range of pathologies associated with EBV. Moreover, pre-
vious studies can be reevaluated and repeated without gaps in experimental designs to
fully uncover the genomic diversity of EBV while minimising the introduction of bias. By
using target enrichment strategies it is possible, given sufficient viral load, to sequence
directly from blood, saliva and tumour tissue while retaining minority variant alleles at
original frequencies. Consequently, this method can now be applied to virus genomics of
acute infection such as IM and CAEBV. However, potential malignancy-associated virus
variants may be better identified by sequencing both tumour tissue and the geographic
"backdrop" (healthy carriers or primary infection). Sequencing from conditions of low
VL titre is still problematic and sequencing from spontaneous LCLs is still the only op-
tion in some cases (e.g. MS, where EBV load is not always elevated (Pender and Burrows,
2014) or healthy, asymptomatic carriers).
Comparative genomics and evolutionary analysis are a useful tool to explore a path-
ogen’s vulnerabilities. For example, here we identified potential novel epitopes based on
the identification of sites under selection. In the future, it would be important to test the
presence of these experimentally and to confirm the use of these tools to predict immune
selected sites, as this would help in vaccine design, not just for EBV but also other path-
ogens.
Many questions regarding EBV genomic diversity remain unanswered. This work
and others, most notably Chiara et al., 2016, have elucidated more details about the pop-
ulation structure of EBV, albeit with partly divergent results. While the population struc-
ture observed here was best explained with two subpopulations, Chiara et al., 2016 report
ten subpopulations. Differences in methods and data sets are likely responsible for this
and it is therefore important to undertake an extended, comprehensive analysis a) with
the same data as used in Chiara et al., 2016, which incorporated further geographic re-
gions, and b) with additional, carefully selected samples of different ethnicities and geo-
graphic regions, ideally with good meta-information of the donors.
For example, intra-subpopulation recombinants from the UK and Australia were de-
scribed in this work. In Chiara et al., 2016, however, these sequences were assigned to a
separate subpopulation, which in a tree of non-admixed representatives clustered more
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closely to the Asian subpopulation as defined in their study. Second, within the West-
ern/African subpopulation identified in this work, isolates are in a complex relationship
with each other. Chiara et al., 2016 observed that Africa appears to carry the largest
number of subpopulations. This was not picked up here as the analysis was restricted to
type 1 genomes which had a strong bias for sequences from Kenya. Strategic sampling
of more regions and ethnicities would be of great interest. Similarly, there is a bias in
available sequences from Asia towards NPC samples from Southern China. While we
extended the available genome sequences with genomes of non-malignant background
from Japan by eleven unique novel genomes, China and Japan have a partly overlap-
ping culture and history, and more samples from other regions of Asia would be of great
interest to elucidate a potential finer population structure on the Asian continent.
EBV’s population structure is of interest for several reasons:
First, humans and EBV have a long, shared history. The distinct allele frequencies
presented by EBV might reflect distinct strains carried by the human ancestors which col-
onized the world. They could also be the result of genetic drift and coevolution between
virus and host. In this data set, it was observed that the signal of subpopulation was
strongest in the set of nonsynonymous sites in LD, i.e. a subset of sites on which selection
can act. We therefore propose the hypothesis that EBV’s allele frequencies are the result of
co-evolutionary adaptations to HLA and recent migration of previously non-overlapping
human cultures/populations has led to recombinants between distant genotypes. In fu-
ture work, this needs to be thoroughly tested. For this, additional information on samples
and donor are indispensable, due to recent global migrations and multi-cultural societies
in many parts of the world.
Second, it is important to incorporate data on population level allele frequencies to
exclude geographic biases in association studies. There is a huge interest in identify-
ing disease-associated alleles in EBV, as these would help to assess patient risk for onset
or severity of disease. In order to truly assess the effect of variation, functional studies
are necessary. However, effects of population structure (i.e. linkage of non-associated
variants) need to be accounted for and previous studies have failed to truly disentangle
the relative contribution of geographic variation and disease-association, in particular
in pathologies that have geographically divergent incidence rates such as NPC. Further-
more, other factors need to be taken into account to choose appropriate controls. Many
studies choose asymptomatic carriers of a similar age distribution. However, given EBV’s
nature of lifelong latent infection, it is impossible to exclude the development of disease
later in life for some of the donors. An alternative option would therefore be the choice
of asymptomatic, elderly carriers.
The number of East Asian genomes was expanded by eleven unique novel genomes
from Japan. A comparison of Asian EBV genomes derived from NPC and non-NPC led
to the identification of a number of sites differentiating between the two groups. In the
future, one needs to more accurately distinguish between sites relating to pathogenesis of
NPC, and those sites that are simply linked or related to a finer geographic signature. The
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analysis illustrates the potential WGS can bring to the field of EBV association studies.
Again, more isolates to account for geographic divergence and/or choosing appropriate
controls will facilitate this.
Another area of interest regarding EBV’s genomics is within host diversity. Studying
intra-host diversity could illuminate the diversity in different compartments and the rel-
ative contribution of lytic and latent replication. It further allows the understanding of
the evolutionary dynamics over time in different clinical settings of EBV infection.
A few studies have aimed to study within host diversity using single gene sequencing
or HTA with varying results. Kwok et al., 2015 described the persistence and interchange
of viral strains based on LMP1 variation using HTA and made the interesting obser-
vation of a potential hidden reservoir of EBV interchanging with plasma but not with
PBMCs/saliva. Within-host recombination, however, is a likely scenario and could bias
studies such as this, which WGS could overcome.
Here, intra-host diversity on the whole genome level of EBV has been described for
the first time. Secondary EBV infections were detected in the case of some immunosup-
pressed children. In paired tumour- and blood samples of PTLD patients, tumours were
found to be completely monoclonal, while blood samples contained a few minor vari-
ants. A comparison of paediatric immunosuppressed and immunocompetent patients
revealed a slightly higher diversity in immunocompetent children with primary infec-
tion, but differences were not significant. It is unclear, however, whether this is due to
secondary infections or within host evolution, as this approach was limited by the depth
achieved by sequencing EBV from blood. Improvements in EBV sequencing will over-
come this.
Lastly, EBV genome sequencing, in this work as well as in other published studies,
has been hampered by short read length of the most common NGS platforms such as Illu-
mina, which affected in particular the numerous repeat regions of the genome. However,
repeat regions can be functionally important and to date, we are missing all the diver-
sity found there. The application of novel long read sequencers such as the Nanopore
MinION will help tackling this issue.
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FIGURE A.1: PCA of whole genome sequences for type 1. This is the same
plot as in 3.11, but samples are labelled based on their geographic origin.
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FIGURE B.1: Split network of all sites in LD.
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FIGURE B.3: Split network of all synonymous pairs of sites in LD.
Appendix B. Appendix for Chapter 4 145
WT
LN827555
LN827559
ebv8
LN824207
LN827568
K4123-Mi
LN827551
LN824203
ebv13
LN827562
LN827596
LN824204
LN827578
LN827586
LN827799
LN827561
GD1
LN827549
KF992569
LN824142
LN824209
HKNPC1
KF992570
KF992571 KF992565
Akata
LN824226
LN824205
LN827527
ebv6
LN827588
LN827567
LN827576
LN827582
LN827573
LN827552
Mutu
LN827585
LN827577
ebv7
LN827545
LN827584
ebv15
LN827524
LN827592
LN827569
LN827523
LN824225
LN827597
LN827572
LN827565, LN827566
GD2 LN827564
LN827550
LN827558
LN827595
M81
LN827571
LN827594
LN827579
KF992566
KF992567
LN827575
LN827570
LN827574
LN827581
LN827522
LN827590
KF992568
LN824224
LN827547
LN827525
KF992564
ebv14
LN827526
LN827593, K4423-Mi
LN827583
ebv9
LN827553
LN827546
0.1
FIGURE B.4: Split network of biallelic sites in LD with a threshold of p <
0.001.
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FIGURE B.5: Split network of biallelic sites in LD with a threshold of p <
0.002.
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FIGURE B.6: Split network of biallelic sites in LD with a threshold of p <
5E − 05.
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FIGURE B.7: Histograms of sites in LD across genome in 1 kb bins. Grey
areas mark the repeat regions.
2 3 4 5 6 7 8 9
K
0
1000
2000
3000
4000
5000
6000
7000
De
lta
 K
DeltaK = mean(|L''(K)|) / sd(L(K))
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Regnaut, and Goudet, 2005).
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into distance classes of 1 kb size.
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FIGURE B.11: Results of different graph clustering algorithms.
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(A) PPI between closest linked nodes according to hierarchical clus-
tering of the gene network (grey shaded box in figure 4.10).
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(B) PPI between top 25 Eigenvector centrality ranked nodes of the
gene network.
FIGURE B.12: Protein-protein interactions (PPI) between top ranked nodes
of the gene network according to different approaches where data is avail-
able. Interaction data is from Calderwood et al., 2007 and Fossum et al.,
2009 based on Yeast two hybrid screenings. Low confidence interactions
(Calderwood et al., 2007) are shown as dashed lines.
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pos pos pos residue substi- M1a-M2a M7-M8
aa nt genome tution
BALF2 1065 3195 161117 E G ** **
1093 3279 161033 S G *
BALF3 5 15 160893 V I ** **
62 186 160722 Q R ** **
127 381 160527 T A ** **
BBRF3 15 45 106894 V F *
BLLF1 71 213 79652 H Y/R ** **
72 216 79649 T M * **
201 603 79262 E Q ** **
755 2265 77600 Q K *
BNLF2B 6 18 166818 P K/S ** **
72 216 166620 Q K ** **
BNRF1 459 1377 3113 G R * **
500 1500 3236 S G/N * *
552 1656 3392 G S * *
739 2217 3953 C F * *
BOLF1 492 1476 61475 A V/T *
1179 3537 59414 R H *
BPLF1 12 36 59203 T P ** **
625 1881 57358 P S *
636 1914 57325 P S/L * *
648 1950 57289 D E/Y ** **
654 1968 57271 S A * *
76 2394 56845 S A ** **
1528 4584 54655 A V * *
1535 4605 54634 D E **
1808 5424 53815 A S *
1879 5637 53602 V F *
2087 6261 52978 R K *
2246 6738 52501 N D **
2616 7848 51391 K E **
2657 7971 51268 V A **
2696 8088 51151 S T/R **
2736 8208 51031 H N **
2765 8295 50944 P S/L *
2869 8607 50632 F L *
2895 8685 50554 R S **
2897 8691 50548 Q K *
3000 9000 50239 R Q **
BRLF1 290 870 92025 A S/D **
377 1131 91764 A E ** **
479 1437 91458 V I *
489 1467 91428 Q R/K ** **
542 1626 91269 S N *
BRRF2 184 552 94566 L P ** **
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pos pos pos residue substi- M1a-M2a M7-M8
aa nt genome tution
260 780 94794 R Q * *
285 855 94869 Q K ** **
313 939 94953 H R ** **
323 969 94983 R Q ** **
325 975 94989 S L ** **
BSLF1 293 879 73714 M V 8 * *
404 1212 73381 R Q ** **
BVRF2 482 1446 137084 S P * **
540 1620 137258 A T/V *
BZLF1 146 438 90429 V A *
205 615 90042 A S ** **
206 618 90039 A S/T ** **
BcRF1 738 2214 127391 K R * **
745 2235 127412 C R/H ** **
BdRF1 222 666 137084 S P * **
EBNA1 411 1233 96895 E D/Q/G 8 ** **
429 1287 96949 V M * *
487 1461 97123 A T/L/V ** **
499 1497 97159 D E ** **
500 1500 97162 E D *
502 1506 97168 T N * *
524 1572 97234 T I * *
582 1746 97408 L F ** **
584 1752 97414 M L ** **
585 1755 97417 T P/I ** **
588 1764 97426 A P *
594 1782 97444 R K ** **
595 1785 97447 V A * *
EBNA2 23 69 36285 L V/R ** **
42 126 36342 D G/E *
163 489 36705 R M/V *
187 561 36777 R S/K *
194 582 36798 L F/P ** **
195 585 36801 M T/I *
315 945 37161 L S *
475 1425 37641 Y F/H ** **
477 1431 37647 E G/V *
EBNA3A 189 567 80611 T M/L ** **
190 570 80614 T A/N * *
219 657 80701 L P * *
293 879 80923 S N/G ** **
333 999 81043 I L/Q * *
459 1377 81421 P T/S/R * *
561 1683 81727 I F ** **
620 1860 81904 P T ** **
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pos pos pos residue substi- M1a-M2a M7-M8
aa nt genome tution
647 1941 81985 F S/E ** **
648 1944 81988 S Q * *
655 1965 82009 R H/Q ** **
656 1968 82012 A T * *
675 2025 82069 I T *
681 2043 82087 V A/M ** **
733 2199 82243 Q R ** **
764 2292 82336 N T ** **
807 2421 82465 A V/D ** **
814 2442 82486 G A/V/T/D ** **
EBNA3B 33 99 83164 T K/Q ** **
173 519 83663 C H/Y * *
212 636 83780 T M/L/P/R ** **
462 1386 84530 Q H ** **
489 1467 84611 A T ** **
556 1668 84812 S L * *
611 1833 84977 T M * *
615 1845 84989 R Q/W * *
848 2544 85688 A E * *
900 2700 85844 G S ** **
901 2703 85847 Q R/K ** **
EBNA3C 21 63 86146 N D *
44 132 86215 R G * *
51 153 86236 Y D * *
104 312 86395 T A/P * *
107 321 86404 T V/I ** **
141 423 86581 I V * *
162 486 86644 A V * *
215 645 86803 A G/E * *
277 831 86989 L M * *
357 1071 87229 G V/I ** **
821 2463 88621 T A * *
978 2934 89092 A V/S ** **
LF1 8 24 151670 Q H ** **
234 702 150992 G E ** **
LMP1 2 6 169010 E D 8 * *
3 9 169007 H L/R ** **
18 54 168962 G R/Q ** **
25 75 168941 L I/R/S ** **
26 78 168938 G R/L/V/A ** **
43 129 168887 V I/T/L ** **
46 138 168878 D N ** **
63 189 168827 I L/V/M ** **
84 252 168764 C G/A *
101 303 168634 H Q/R/N/S ** **
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pos pos pos residue substi- M1a-M2a M7-M8
aa nt genome tution
115 345 168490 G A ** **
210 630 168205 D A/N/Y *
212 636 168199 G S/T/R/A/C ** **
214 642 168193 E Q/D/H ** **
229 687 168148 S T ** **
318 954 167881 G K * **
322 966 167869 Q N/E/T/D/K ** **
331 993 167842 G Q/R *
RPMS1 3 9 150332 G E *
18 54 155296 Y C *
20 60 155302 A V *
24 72 155314 P H *
29 87 155329 G E *
49 147 155389 P L *
50 150 155392 P L *
51 153 155395 D N *
55 165 155407 R Q *
91 273 155515 G C *
98 294 155536 S N *
99 297 155539 C Y *
103 309 155551 R K *
TABLE B.1: Positively selected sites. Protein, gene and genomic positions
refer to the WT genome. *: 95 %; **: 99 % BEB posterior probabilities for
codeml (Yang, 2007) analysis.
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pi D p
A73 0.002329303 -1.360452592 0.162943913
BALF1 0.002172382 -2.156903008 0.010255326
BALF2 0.003958144 -1.166916023 0.245112234
BALF3 0.005440788 -0.282738891 0.822481383
-1.283155305 0.193592065
-0.554614361 0.619247514
BALF4 0.003982123 -1.620375316 0.083352211
-0.757734698 0.478639791
BALF5 0.003862471 -1.387852965 0.152929779
-1.091755985 0.281884668
BaRF1 0.004159379 -0.852229463 0.418068776
BBLF1 0.005395712 0.529843774 0.585831948
BBLF2-BBLF3 0.007003594 -1.54457441 0.103142588
0.12412682 0.867043136
BBLF4 0.006308038 -1.134572916 0.260438429
-1.552405138 0.100908706
BBRF1 0.005088512 -1.034516774 0.31197938
BBRF2 0.003982382 -1.187865443 0.235047079
BBRF3 0.003989965 0.011574032 0.951476534
-1.057628583 0.299634165
BcLF1 0.004800532 -0.707323303 0.512328142
-0.148401478 0.925960444
BcRF1 0.006336994 -0.908039043 0.384078966
BCRF1 0.001504379 -1.569045988 0.096537261
BDLF1 0.004525912 -0.585375845 0.597228165
BDLF2 0.003547349 -1.44050082 0.134853182
-1.210385825 0.224822587
BDLF3 0.01107506 -0.699332021 0.517747888
BDLF4 0.006214425 -0.515552792 0.647738847
BdRF1 0.004537489 -1.782476748 0.050035382
BFLF1 0.005050547 -0.160185248 0.916977791
-1.242733317 0.210437066
BFLF2 0.005799323 -0.840069657 0.425664063
-0.417356135 0.720552785
BFRF1 0.005059306 -1.406697385 0.146269462
BFRF1A 0.006959805 -0.617655365 0.574333688
BFRF2 0.005654338 -0.905986569 0.385307256
-1.24488196 0.209641178
BFRF3 0.004651978 -1.585799533 0.092270581
BGLF1 0.006025708 -0.827731189 0.433432771
BGLF2 0.002436647 -1.07447274 0.290801598
BGLF3.5 0.000483985 -1.6546416 0.075331389
BGLF3 0.004181198 -0.950732022 0.358870787
BGLF4 0.003144808 -0.695256273 0.520519161
BGLF5 0.003934926 -0.334107171 0.783520763
-0.684071939 0.52815753
BGRF1-BDRF1 0.002682059 -1.612866189 0.085247037
BHRF1 0.004126864 -1.662678669 0.073528615
BILF1 0.003533138 -0.960223079 0.353394413
BILF2 0.001504564 -1.885021802 0.034580557
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pi D p
BKRF2 0.004988368 -0.681321908 0.530041978
BKRF3 0.003856782 -0.308373351 0.803150941
BKRF4 0.004251064 -0.616579383 0.575092715
BLLF1 0.008725829 -1.449624963 0.131783289
-1.783247008 0.049903997
BLLF2 0.008901829 -1.124798555 0.265252778
BLLF3 0.002298161 -1.758036707 0.054330444
BLRF1 0.001450522 -1.874863541 0.0359353
BLRF2 0.005975062 -1.3362279 0.172124051
BMLF1 0.004512425 -1.470424818 0.12510468
BMRF1 0.002441708 -1.713699721 0.062762682
BMRF2 0.004995081 -0.804638253 0.44813712
BNLF2A 0.006826267 -0.750155686 0.483646036
BNLF2B 0.006191014 -0.702023451 0.515917736
BNRF1 0.004680507 -1.694207087 0.066738981
-1.43763078 0.135735207
BOLF1 0.006275237 -1.554532805 0.100808086
-1.745616232 0.057001133
BORF1 0.005132135 -1.592501182 0.090414133
BORF2 0.004475411 -0.880043076 0.400927619
-1.22445008 0.218463817
BPLF1 0.005954189 -2.921785888 6.09e−7
-1.177893155 0.240083623
-0.973586625 0.346029218
BRLF1 0.00668177 0.185353287 0.82184647
-0.485429273 0.669873692
BRRF1 0.002789568 -1.748626298 0.056050325
BRRF2 0.013771688 -0.430661888 0.710581847
BSLF1 0.004557408 -0.914783957 0.380018659
-1.382876701 0.15479013
BSLF2-BMLF1 0.004196182 -1.504846625 0.114535161
BSRF1 0.002817085 -1.598448962 0.088773523
BTRF1 0.004190326 -0.811231796 0.443937791
BVLF1 0.005363463 -0.892004329 0.39365711
BVRF1 0.004989001 -1.918619795 0.030359291
-1.055924908 0.300535287
BVRF2 0.003985609 -1.719471316 0.061617257
BXLF1 0.003299354 -0.747446779 0.485440465
-1.038743364 0.309702329
BXLF2 0.004038546 -0.820018042 0.43834254
-0.914154299 0.380393498
BXRF1 0.005800498 0.315203327 0.728974821
BZLF1 0.013921389 0.299317891 0.740110857
BZLF2 0.005882372 -0.470317951 0.681048832
EBNA1 0.014437942 -0.525660585 0.640356452
0.546393416 0.57541632
EBNA2 0.008714703 -1.152551535 0.252817253
EBNA3A 0.009894401 -1.451741547 0.132070918
-0.985932461 0.339424787
EBNA3B 0.011302704 -1.180669454 0.239295401
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pi D p
-1.42880094 0.13967507
EBNA3C 0.009958089 -0.757928833 0.478704815
LF1 0.007702755 -1.21345248 0.22344184
-1.091858747 0.281889084
LF2 0.003140119 -1.465896288 0.126539932
LMP1 0.030201344 -0.636759965 0.560913111
-2.574544895 0.000466718
LMP2 0.010775619 -1.322469248 0.177474791
-1.104772201 0.275267523
RPMS1 0.004129052 -1.567006855 0.096948967
TABLE B.2: Nucleotide diversity for whole ORFs and Tajima’s D values
with respective p value for ORFs or ORF fragments if recombination break-
points have been detected as depicted in figure 4.12.
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FIGURE B.13: Density of biallelic SNPs across the genome. Note that ex-
tremely low values are due to missing data in the repeat regions.
159
Appendix C
Appendix for Chapter 5
0 50000 100000 150000
0
20
00
60
00
P1−T1
position
co
ve
ra
ge
avg cov = 4891.8
(A) Patient 1, tumour
0 50000 100000 150000
0
20
00
60
00
P2−T1
position
co
ve
ra
ge
avg cov = 4508
(B) Patient 2, tumour
0 50000 100000 150000
0
10
0
20
0
30
0
P2−B1
position
co
ve
ra
ge
avg cov = 26.1
(C) Patient 2, blood 1
0 50000 100000 150000
0
50
15
0
25
0
P2−B2
position
co
ve
ra
ge
avg cov = 29.6
(D) Patient 2, blood 2
0 50000 100000 150000
0
50
10
0
20
0
P2−B3
position
co
ve
ra
ge
avg cov = 29.8
(E) Patient 2, blood 3
0 50000 100000 150000
0
20
00
60
00
P3−T1
position
co
ve
ra
ge
avg cov = 2004.4
(F) Patient 3, tumour
0 50000 100000 150000
0
20
0
40
0
60
0
P3−B1
position
co
ve
ra
ge
avg cov = 44.8
(G) Patient 3, blood 1
0 20000 40000 60000 80000 100000 120000 140000
0
20
60
10
0
P3−B2
position
co
ve
ra
ge
avg cov = 15.8
(H) Patient 3, blood 2
Appendix C. Appendix for Chapter 5 160
0 50000 100000 150000
0
20
00
60
00
P4−T1
position
co
ve
ra
ge
avg cov = 5884.8
(I) Patient 4, tumour
FIGURE C.1: Coverage plots of paired tumour and blood samples after du-
plicate removal. Mapping is done against the sample consensus sequence
directly after assembly (i.e. repeat regions are not masked or considered
specifically).
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FIGURE C.2: Coverage plots of immunocompromised patient samples af-
ter duplicate removal. Mapping is done against the sample consensus se-
quence directly after assembly (i.e. repeat regions are not masked or con-
sidered specifically).
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Patient Sample Protocol Sequencing
3 µg 200 ng 200 ng MiSeq NextSeq
manual manual automated
1 P1-812 5 5 5
P1-833 5 5
2 P2-1213 5 5 5 5 5
P2-1246 5 5 5 5 5
3 P3-2670 5 5 5
P3-2740 5 5 5
4 P4-2274 5 5 5
P4-2392 5 5 5
5 P5-1294 5 5 5
P5-1323 5 5 5
6 P6-1751 5 5 5
P6-1789 5 5
7 P7-2315 5 5 5
P7-2634 5 5 5
8 P8-414 5 5 5
P8-516 5 5 5
9 P9-2631 5 5 5
P9-2645 5 5 5
10 P10-2187 5 5 5
P10-2777 5 5
11 P11-871 5 5 5
P11-920 5 5
12 P12-1026 5 5 5
P12-1078 5 5
TABLE C.1: Processing of IM samples.
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FIGURE C.3: Coverage plots of IM samples after duplicate removal. Map-
ping is done against the sample consensus sequence directly after assem-
bly (i.e. repeat regions are not masked or considered specifically).
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FIGURE C.4: Split network of whole genome alignment including the
Japanese IM samples from chapter 5 as further representatives of Asian
non-NPC genomes. The IM isolates from Japan are coloured in red, the
remaining Asian isolates are coloured in blue.
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FIGURE C.5: Structure analysis of EBV type 1 genomes including the
Japanese IM samples. All Japanese samples were completely or to a large
proportion assigned to the blue (Asian) cluster.
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Pos Ref Var Cov Read1 Read2 Freq ORF nonsyn
P1-812 37856 T C 28 22 6 21.43
80710 C G 20 16 4 20
81070 C T 30 22 8 26.67
81110 G A 34 26 8 23.53 EBNA3A A357T
84503 C A 20 16 4 20
99057 C T 20 14 6 30
107643 A C 20 14 6 30 BBRF3 M266L
114682 T G 20 16 4 20
140600 T G 21 15 6 28.57 LF3 K915T
140688 G A 23 17 6 26.09 LF3 H886Y
149989 G A 30 24 6 20 LF2
152710 T C 20 16 4 20
152854 T C 20 16 4 20
162132 A G 26 18 8 30.77
165354 T C 20 16 4 20
P2-1213 48433 C T 20 16 4 20
60525 C A 20 16 4 20 BOLF1 R809M
60860 A C 28 20 8 28.57 BOLF1 D697E
60872 A G 26 20 6 23.08
71085 C A 20 16 4 20 BMLF1 R229M
BSLF2/BMLF1 R270M
86576 A G 34 26 8 23.53 EBNA3C I141V
P4-2274 9593 C T 20 16 4 20
79739 G A 20 16 4 20
81722 A T 20 16 4 20
86232 T G 35 26 9 25.71 EBNA3C Y51D
90389 G T 20 15 5 25
90412 A G 23 18 5 21.74
91046 T C 20 16 4 20
108600 T A 20 16 4 20 BBLF1 Y29F
116286 C A 20 16 4 20
117231 C T 34 26 8 23.53
117291 A T 28 22 6 21.43
117303 A G 28 22 6 21.43
118210 G C 32 24 8 25
133947 C T 20 16 4 20
134064 T C 20 12 8 40
140688 G A 26 20 6 23.08
145934 A G 20 16 4 20
146055 A G 24 16 8 33.33
146075 G A 26 16 10 38.46
146110 T C 28 16 12 42.86
146273 A G 22 14 8 36.36
146706 T C 20 16 4 20
146760 C G 20 16 4 20
146772 A G 20 16 4 20
146780 T C 20 16 4 20
148623 A G 24 18 6 25
148652 T G 24 16 8 33.33
149146 T G 20 16 4 20 LF2
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Pos Ref Var Cov Read1 Read2 Freq ORF nonsyn
157839 T C 20 16 4 20
168346 T G 20 16 4 20
168845 T G 24 16 8 33.33
P5-1294 96720 C T 20 16 4 20 EBNA1 R354W
P6-1751 37856 T C 32 24 8 25
63911 C T 20 16 4 20
67621 A T 26 20 6 23.08
78005 T A 26 20 6 23.08
79649 C T 26 20 6 23.08
81984 C G 25 20 5 20
84257 A G 30 24 6 20
84524 A T 30 24 6 20 EBNA3B Q461H
86779 T C 20 16 4 20
87256 G A 30 22 8 26.67
87265 C T 28 22 6 21.43
89920 G A 20 16 4 20
99285 A C 20 12 8 40
106006 A G 21 14 7 33.33
118210 C G 28 22 6 21.43 BDLF3 V190L
123264 A C 20 16 4 20
140001 T G 40 32 8 20
147747 G C 28 20 8 28.57
149017 T A 26 18 8 30.77
149326 C T 20 12 8 40 LF2
149370 T C 22 14 8 36.36 LF2
P9-2631 88491 C A 80 52 28 35
P11-871 149055 A G 35 27 8 22.86 LF2
P12-1026 80349 G C 46 36 10 21.74
81070 C T 50 40 10 20
81212 T C 38 30 8 21.05
81682 A G 32 24 8 25
81722 T A 24 18 6 25 EBNA3A F561I
82201 C A 38 30 8 21.05
82239 G A 44 32 12 27.27 EBNA3A R733Q
83092 A G 36 28 8 22.22 EBNA3B Q10R
83186 G A 34 22 12 35.29
83192 A G 34 22 12 35.29
83237 A G 30 18 12 40
83283 G C 37 24 13 35.14 EBNA3B E74Q
84653 G A 20 16 4 20
86779 T C 26 20 6 23.08
88752 T C 28 22 6 21.43 EBNA3C L866S
89081 A G 42 30 12 28.57 EBNA3C K976E
89920 A G 30 14 16 46.67
90046 A C 46 32 14 30.43 BZLF1 S205A
90107 A G 52 40 12 23.08
91005 C A 44 34 10 22.73
91011 C T 40 28 12 30
93087 A G 41 31 10 24.39
93194 A C 64 48 16 25 BRRF1 D101A
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Pos Ref Var Cov Read1 Read2 Freq ORF nonsyn
93225 A G 64 48 16 25
93294 T C 44 34 10 22.73
94840 A G 30 22 8 26.67
94900 G T 20 12 8 40
94950 G A 20 12 8 40 BRRF2 R313H
97848 C T 42 32 10 23.81
97951 A C 26 16 10 38.46
97972 G A 26 16 10 38.46 BKRF2 G102S
98005 A T 20 14 6 30 BKRF2 T113S
102988 G A 22 16 6 27.27
104549 C A 20 16 4 20 BBLF2-BBLF3 M705I
104635 G A 20 16 4 20 BBLF2-BBLF3 H677Y
108561 A G 26 20 6 23.08 BBLF1 V42A
112914 T G 38 28 10 26.32 BGRF1-BDRF1 I89S
116501 C A 20 16 4 20 BDLF4 D78Y
116664 G A 20 16 4 20
117030 C T 28 16 12 42.86
117093 C G 22 12 10 45.45
117231 T C 30 24 6 20
117291 T A 34 26 8 23.53
117303 G A 40 30 10 25
117360 A G 26 20 6 23.08
118202 G T 30 24 6 20
118372 C A 20 16 4 20 BDLF3 A136S
130603 T C 33 22 11 33.33
148447 C T 31 22 9 29.03
149146 G T 28 22 6 21.43 LF2
149326 C T 46 36 10 21.74 LF2
152260 G T 34 24 10 29.41
164292 T G 25 20 5 20
164633 T G 20 12 8 40
166230 C A 30 22 8 26.67 LMP2 S38Y
166353 C A 20 16 4 20 LMP2 T79N
166362 A C 20 14 6 30 LMP2 Q82P
166367 C T 24 16 8 33.33
167172 C T 40 32 8 20
169090 C A 28 20 8 28.57
TABLE C.2: Minority variants of IM samples. Pos: WT position. Ref: Con-
sensus base. Var: Minor variant base. Cov: Read depth at this position.
Read1/2: Number of reads supporting the consensus or variant base, re-
spectively. Freq: Minor variant frequency. ORF: Open reading frame. non-
syn: Amino acid change from consensus to variant at the respective protein
position.
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FIGURE C.6: Intrahost diversity for the paired tumour and blood samples.
The line in the box indicates the median, the bottom and top of the box
show the 25th and 75th percentile. TB-B: blood samples, TB-T: subsampled
tumour samples, TB-Tall: complete tumour sample.
ORF pos WT pos aa Epitope ID Peptide
LMP2 207 169 20892 GLGTLGAAL
LMP2 410 208 60930 SSCSSCPLSK
LMP2 410 208 60931 SSCSSCPLSKI
LMP2 613 248 105557 TVCGGIMFL
LMP2 1068 348 6808 CPLSKILL
LMP2 1075 350 6808 CPLSKILL
EBNA3A 79975 8 5679 AWNAGFLRGRAYGLD
EBNA3A 79976 8 5679 AWNAGFLRGRAYGLD
EBNA3A 80609 190 63546 TETAQAWNAGFLRGRAYGIDLLRTE
EBNA3A 80626 195 63546 TETAQAWNAGFLRGRAYGIDLLRTE
EBNA3A 81416 459 75356 YPLHEQHGM
EBNA3A 81432 464 75356 YPLHEQHGM
EBNA3B 84345 402 5316 AVFDRKSDAK
EBNA3B 84413 424 27375 ILTDFSVIK
EBNA3B 84413 424 29466 IVTDFSVIK
EBNA3B 85116 659 68229 VEITPYKPTW
EBNA3C 86391 104 47807 PHDITPYTARNIRDAACRAV
EBNA3C 86400 107 47807 PHDITPYTARNIRDAACRAV
EBNA3C 86576 141 26981 ILCFVMAARQRLQDI
EBNA3C 87163 336 30430 KEHVIQNAF
BZLF1 90158 195 53128 RAKFKQLL
BZLF1 90158 195 53129 RAKFKQLLQ
BZLF1 90379 163 23103 GVPQPAPVAAPARRTRKPQQPE
BZLF1 90412 152 23103 GVPQPAPVAAPARRTRKPQQPE
BZLF1 90430 146 23103 GVPQPAPVAAPARRTRKPQQPE
BZLF1 90665 68 149830 LTAYHVSTAPTGSWF
BZLF1 90684 61 13701 EPLPQGQLTAY
BZLF1 90684 61 38458 LPEPLPQGQLTAY
BZLF1 90684 61 149830 LTAYHVSTAPTGSWF
TABLE C.3: Experimentally described epitopes that are affected by the
nonsynonymous SNPs found to differentiate between Asian NPC and
Non-NPC genomes. ORF: open reading frame. pos WT: position in WT
genome. pos aa: position in protein. Epitope ID: epitope identifier from
IEDB database. Peptide: epitope sequence in IEDB, the affected site is bold.
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